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Abstract 
Aerosols are an effective method to deliver therapeutic agents to the respiratory tract. Among 
aerosol generation systems, dry powder inhalers have been an attractive area of research for 
both local and systemic delivery of drugs. The challenge of any inhalation delivery system is to 
generate particles with an adequate range of particle sizes. In order to advance powder aerosol 
technologies, researchers have recognized the importance of investigating determinants 
affecting powder dispersion. The effect of particles’ surface characteristics, inhalation airflow 
rate, inhalation device, and development of an effective drug-carrier system are some of the 
fundamental areas that have been under investigation.  
The aim of this thesis is to study parameters that govern the aerosolization characteristics of 
inhalation drug particles. In order to improve the therapeutic bioavailability of drugs, the 
current work demonstrates several techniques to manipulate the surface characteristics micro- 
and nanoparticles of two model drugs, namely; progesterone and 5-fluorouracil. With the 
recent interest in the development of targeted therapy, the present study introduces novel 
carriers for controlled delivery of magnetic nanoparticles to the respiratory tract. Management 
of nanoparticles physical characteristics as well as drug encapsulation efficiency was achieved 
via controlling variable formulation parameters.  
The findings presented in this dissertation suggest a significant dependence of the aerosol 
characteristics on the characteristics of both drug and drug-carrier system. In this sense, with an 
increasing development of potent drug molecules for potential drug delivery via inhalation, it 
becomes quite pivotal to first accurately assess the determinant factors for lung deposition and 
dispersion behavior of dry powders. In this context, we proposed a novel setup for assessment 
of in-vitro aerosol deposition under the effect of an external magnetic field. The results suggest 
significant dependence of the particles dispersion behavior and deposition profile on their 
physical properties as well as the presence of magnetic field for their guidance to the required 
lung site. Encapsulating the drug in the proposed carrier system offered the advantage of 
controlled drug delivery; which is beneficial for therapeutic delivery of chemotherapeutic 
agents. Enhanced in-vitro cytotoxicity was achieved via controlling the formulation parameters 
in the engineered magnetic nanoparticles. Finally, this work presents alternative techniques of 
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designing micro- and nano-vehicles for pulmonary drug delivery, with a localized deposition in 
the diseased area and the potential to reduce dose-related adverse effects.  
Keywords: Dry powders inhalers, Crystallization, Controlled drug delivery, In-vitro aerosol 
deposition, Progesterone, 5-Fluorouracil.  
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Chapter 1 
1 INTRODUCTION 
 Background 1.1
Drug delivery to the respiratory tract is a rapidly growing field of research 
1
. With the 
recent advances in synthesis and manipulation of micro- and nanoparticles, drug delivery has 
shown great potential for pulmonary application, not only for local therapy but for systemic 
therapy as well. This is primarily because of the several advantages offered by the pulmonary 
route as compared to the other routes of administration. The pulmonary route is an ideal route 
of administration, especially for drugs that undergo extensive first-pass metabolism. Several 
categories of drugs (such as hormones, peptides and proteins) exhibit an improved therapeutic 
efficacy following their pulmonary administration 
2
. Besides, the pulmonary route offers more 
advantages, i.e., decreased invasiveness; which leads to an improved patient compliance. For 
localized pulmonary therapy, a reduced incidence of side effects is usually detected due to the 
reduced systemic distribution of drugs.  
Targeted drug delivery to the respiratory tract has progressed to be one of the most recently 
investigated approaches for both local and systemic therapy. For local therapy, pulmonary 
administration offers greater site-specific deposition within the lung; thus lowering the drug 
dose due to the reduction in first-pass effect.  
Drug delivery systems to the respiratory tract can be classified into two broad categories: (1) 
immediate release systems, which consist of the pure drug in a physical form suitable for dry 
powder inhaler administration, (2) controlled release systems, which include micro- and 
nanoparticles based on polymeric matrix.  
Polymeric micro- and nanoparticles for pulmonary drug administration have been applied to 
improve the therapeutic index of drug. This can be achieved by modifying the drug 
bioavailability; that is a function of enhancement in the drug absorption and reduction in the 
drug metabolism. In addition, drug encapsulation in micro- and nanoparticles leads to the 
reduction of drug toxicity and prolonging the biological half-life. 
In the case of immediate release dry powders for inhalation, the deposition of particles in the 
respiratory tract is governed by the physico-chemical characteristics of drugs. However, the 
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deposition of micro- and nanoparticles in the lung is controlled by the properties of the carrier 
rather than the drug itself. Designing a successful system for drug delivery to the respiratory 
tract requires a comprehensive understanding of the disease condition, lung anatomy and 
physiology, physico-chemical properties of pure drug and polymeric matrix combined with its 
production process, In addition to an optimized selection of dry powder inhaler devices.   
 Dry powder inhalation as a method of drug delivery 1.2
The drug delivery to the respiratory tract has attracted significant attention as a non-invasive 
systemic route of administration 
3
. As opposed to other routes of drug administration, the 
pulmonary route is accompanied by several unique challenges. The first major challenge is the 
generation of aerosol particles in a physical form suitable for inhalation. It is generally 
accepted that aerosol particles of 1-5 µm are required for deposition at the site for systemic 
absorption, namely the pulmonary alveoli 
4
.  
Formulating drug in the form of inhalable particles can provide an effective targeting of the 
respiratory epithelium 
5
. Drugs with a molecular weight below 30 kDa can easily penetrate the 
alveolar membrane to the blood circulation. This can be obtained without the need of 
absorption enhancers; which are necessary for other non-invasive routes 
6
. A dry powder 
formulation for pulmonary administration is an attractive route; many solubility and stability 
issues can be avoided 
7
.  
 Clinical efficacy of inhalation dry powders 1.3
Dry powder inhalation is an attractive method to deliver therapeutic agents to the respiratory 
tract. Dry powder inhalers are commonly used for both local and systemic purposes. Local 
delivery is highly recommended for patients with cystic fibrosis 
8
, asthma 
9
, chronic obstructive 
pulmonary disease 
10
 and lung cancer 
2,11
. Local delivery to the respiratory system is highly 
beneficial in this case due to significant reduction of systemic side effects, in addition to the 
localized concentration of medication at the site of drug action 
11-14
. Therefore, hormones and 
toxic chemotherapeutic agents are ideal drug candidates for local pulmonary administration 
15
.  
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Dry powder inhalers have been certainly seen as a promising approach for treatment of lung 
cancer 
2,16
. Given the advantages of dry powder inhalation, it is foreseeable that cancer 
treatment via pulmonary administration will be developed further 
12,13
.  
 Objectives 1.4
The main objectives of this thesis work are: 
1) To develop and characterize microcrystals of progesterone for dry powder inhalation.  
2) To optimize the synthetic crystallization parameters to achieve a high respirable 
fraction of inhaled progesterone microcrystals.  
3) To develop a controlled pulmonary drug delivery system, that is suitable for 
encapsulating both hydrophilic and hydrophobic drugs.   
4) To investigate the release kinetics of drugs from the proposed magnetic nano-carrier 
system with an understanding of the underlying release mechanism.  
5) To examine the deposition and possible localization of nanoparticles designed for 
pulmonary drug delivery.  
6) To examine the in vitro aerosol performance of magnetic nanoparticles by designing a 
modified setup for the next generation impinger; which incorporate the effect of 
magnetic field on the deposition of particles. 
 Motivation and significance of the research study 1.5
The therapeutic delivery to the respiratory system suffers from several limitations; which can 
be all linked to the presence of drugs in intimate contact with the internal surface of the lungs. 
The two major pathways of removing deposited particles from the lungs are the mucociliary 
and alveolar clearance. The mucociliary clearance occurs in the pharynx and trachea, while the 
alveolar clearance is a part of the function of the terminal airways.  In a healthy trachea, the 
speed of mucus clearance is estimated to be 10 mm/min 
17
. This means that more frequent drug 
administration is required to get the aimed therapeutic efficacy; which results in an increased 
incidence of systemic side effects. In this context, nanomedicine represents a valuable drug 
delivery platform for respiratory drug delivery 
18
. Polymeric nanoparticles are attractive area of 
research among the numerous potential carrier systems. They enable a controlled drug release 
4 
 
 
 
and targeting properties and thus, optimize the pharmacokinetic and the pharmacodynamic 
profile of the encapsulated drug within the respiratory tract 
19,20
. Nevertheless, the safety 
assessment of polymeric nano-carriers is currently the subject of intense research 
21,22
. An 
important physiological aspect of pulmonary polymeric nano-carriers arises from their direct 
interactions with the pulmonary surfactant system 
23
.  
Pulmonary surfactants are composed of a mixture of phospholipids and proteins. Pulmonary 
surfactants are located in the internal wall of the alveolar region and their main function is to 
prevent the collapse of the alveoli by a drastic reduction in the surface tension and the 
concurrent gaseous exchange 
24
. The complex interaction between phospholipids and surface 
associated proteins enables the formation of a phospholipid-enriched film at the air-water 
interface 
25
. During the expiration process, the phospholipid film is compressed; leading to 
clearance of the less surface active component to the bulk phase 
26
. Upon inspiration, the 
phospholipids facilitate the rapid re-entry of surfactants compounds located in the bulk phase. 
Therefore, factors affecting lung surfactant biophysical characteristics might have severe 
outcome. Particulate inhalation can have a dramatic influence on the function of pulmonary 
surfactants 
27
. However, it is challenging to provide definitive conclusions on the extent of 
surfactant inhibition following pulmonary administration of nanoparticles. Therefore, several 
studies have aimed to examine the extent of biophysical inhibition of pulmonary surfactant by 
polymeric nanoparticles 
28,29
.  
Alveolar macrophages can also play a significant role in particles’ clearance from the 
respiratory system 
30
. These cells can be attached to an inhaled particle through electrostatic or 
receptor-mediated mechanisms. Adhesion to the macrophage cells is usually followed by 
ingestion of particles and thereafter, migration to the bronchioles for mucociliary clearance. 
Pure drug designed for pulmonary administration should be engineered in the particle size 
range from 1 to 5 µm, in order to escape clearance by the alveolar macrophage. On the other 
hand, cellular uptake by the macrophages should be taken into consideration in designing 
micro- and nanoparticles for pulmonary administration.  
Drugs administered to the lung encounter hydrolytic enzymes at every region. Therefore, drug 
encapsulation in micro- and nanoparticles vehicle assists in reducing enzymatic degradation in 
the lung.  
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With this aim, a systemic approach is presented to overcome the above mentioned limitations 
by employing particulates delivery systems composed of micro- or nanoparticles. These 
polymeric carriers are clearly beneficial for systemic pulmonary drug delivery 
31,32
.  
 Thesis outline 1.6
This thesis presents an investigation on the possible approaches for development of particles 
suitable for pulmonary inhalation. The current work focuses on two modeled therapeutic 
agents; progesterone and 5-fluorouracil.  
Chapter one presents the general considerations in pulmonary drug delivery, Limitations of 
pulmonary drug delivery and approaches to overcome current challenges.   
Chapter two presents a literature review on the recent approaches in the area of particle 
engineering for pulmonary drug delivery. This chapter is primarily divided into two parts: (1) 
the first part covers recent studies to identify determinants that influence particle formation via 
crystallization; (2) The second part explains how the selection of a nano-carrier system in 
combination with the synthetic variables affects the drug-encapsulating criterion of engineered 
nanoparticles.   
Chapter three demonstrates the influence of crystallization technique, as well as, the operating 
conditions on the physical properties of progesterone microcrystals. Chapters four, five and six 
introduce novel nano-carriers for dual controlled drug release and targeted respiratory 
deposition functions.  
The focus of chapter four is to maximize the drug loading and drug encapsulation efficiency of 
both progesterone and 5-fluorouracil in the proposed nano-vehicle. The drug release kinetics is 
analyzed in details in a trial to understand the mechanism of drug release through the polymeric 
matrix.  
Chapter five describes the in-vitro aerosol deposition of magnetic aggregates of nanoparticles 
as a proposed carrier for pulmonary drug delivery. The aerosolization performance of these 
particles was investigated with an insight on their deaggregation performance. The aggregates 
dispersion was studied with an exposure to an external magnetic field in a novel magnetic next 
generation setup (mNGI).  
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Chapter six was designed to prepare magnetic Fe3O4 nanorods for controlled delivery of 
progesterone. Progesterone release from magnetic nanorods was investigated and 
mathematically modelled, in order to determine the drug release mechanism. A relationship 
between the chemical composition of CS-MIAA and physical properties of the composite, such 
as viscosity and swelling was established, with an insight in the thermodynamics of the system.   
Finally, chapter seven presents the overall conclusions and recommendations of the presented 
work with a tip-off on the possible future directions of this research.  
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CHAPTER 2 
2 LITERATURE REVIEW: PARTICLE ENEGINEERING 
STRATEGIES FOR PULMONARY DRUG DELIVERY 
Abstract 
Because of limitations associated with the conventional routes of treatment, a growing attention 
has been given to the development of targeted drug delivery systems. Pulmonary route has 
gaining much interest as it enables site-specific drug delivery for both local and systemic 
treatments. The pulmonary route has demonstrated great potential for the systemic absorption 
of a broad range of therapeutics. This chapter aims to discuss the technical, physiological and 
efficacy aspects of pulmonary drug delivery. The different techniques employed for production 
of pulmonary particulate formulations, together with the effect of inhaler device are also 
discussed. The better understanding of the complex challenges facing the delivery of 
pulmonary formulations offers an opportunity to minimize the clinical and technical gaps.  
Keywords: Pulmonary drug delivery, Microcrystals, Nanoparticles, Polymorphism, Inhaler 
devices.  
 Pulmonary drug delivery for systemic therapy 2.1
Drug delivery to the respiratory tract is an interesting alternative to other routes of 
administration; that generated an increasing consideration over the past decade 
1
. Many drugs 
exhibited an enhanced bioavailability following their pulmonary administration (2). This can 
be attributed to: (1) the tremendous surface area of the alveoli (100 m
2
), (2) a relatively low 
metabolic activity and (3) an elevated blood flow; which means rapid distribution of drugs 
throughout the body 
2
.  
Drug delivery to the lungs can combine the advantages of both local and systemic delivery 
systems. Localized pulmonary administration can be favorable for treatment of various lung 
disorders, i.e., asthma and chronic obstructive pulmonary diseases. However for systemic 
therapy, the natural permeability of the lung can be utilized to transfer molecules to the blood 
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stream. Most of the marketed dry powder inhalation therapeutics is for localized treatment of 
lung disorders.  With the approval of Pfizer’s Exubera®, recombinant human insulin for dry 
powder inhalation, many possible candidates for systemic pulmonary administration are 
currently under development and being clinically tested. Nevertheless, the same rationale of 
improving patient compliance through switching to needle-free delivery encouraged research 
for inhalation therapy of other active pharmaceutical ingredients (APIs) that are currently 
administered only via injection. These compounds include morphine and fentanyl as 
analgesics, di-hydro-ergotamine for migraine, interferon b for multiple sclerosis, leuprolide 
acetate for prostate cancer and growth hormone releasing factor to treat pituitary dwarfism
3
.  
 Dry powder inhalation devices 2.2
Within the pharmaceutical manufacturing, selection of the appropriate inhalation delivery 
system is a pivotal decision. This is dependent on different aspects such as the clinical 
objective (acute or chronic treatment) and target patient features (infant, elderly or 
ambulatory). Different dry powder inhalation devices are available in the market, yet no single 
inhaler device possesses all the properties of an ideal inhaler 
4
.  
Dry powder inhalers are devices which store the medication as fine particle aggregates, either 
as a pure drug substance or encapsulated in a nano- or micro-particulate formulation. These 
inhaler devices have the option of regulating the dose. The dry powdered drug is stored at the 
bottom of inhaler in the powder reservoir compartment 
5
. In some multi-dose inhalers, the drug 
is separately sealed in individual storage compartments. Figure 2-1 shows photographs for 
some currently available dry powder inhalers 
6
.   The patient inspiration comprises the main 
force that initiate actuation of the inhalation device. As compared to metered dose inhalers, the 
need for good coordination between the patient’s inspiration and inhaler device actuation is 
eliminated. The inspiratory airflow rate is a critical factor for delivery of medication. However, 
some dry powder inhaler devices appear to be relatively independent on the patient’s 
inspiratory rate 
7
. For evaluating all inhalation drug delivery systems, the fractional deposition 
of drug and its depth of penetration have to be accurately assessed.  
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Figure 2-1 Images of some currently available dry powder inhaler devices: (a) Aerolizer
®
, 
(b) Easyhaler
®
, (c) Turbohaler
®
, (d) Diskhaler
®
, (e) Novolizer
®
, (f) Clickhaler
®
, (g) 
MAGhaler
®
, (h) Spinhaler
®
 and (i) Handihaler
®
. 
 
 Fundamental aspects of aerosol inhalation from dry powder 2.3
inhalers 
The deposition profile of inhalation dry powders is affected by two major independent factors: 
(1) patient-related factors; which can be cited as the anatomical and physiological aspects of 
the respiratory system as well as the inhalation airflow rate, (2) physical properties of dry 
powders; which can be subdivided into (i) properties of pure drug, and (ii) properties of nano-
carrier systems (in case of controlled release particulate systems).  
2.3.1 Patient-related factors 
2.3.1.1 Anatomy and physiology of the respiratory tract 
The function of the respiratory system is to deliver oxygen from the lungs to the cells. This 
process is followed by the removal of carbon dioxide; which can be exhaled from the lungs. 
The respiratory tract is composed of two major compartments:  the upper respiratory tract, 
which composed of the nose, nasal cavity and pharynx; the lower respiratory tract, including 
the larynx, trachea, bronchi and the lungs (Figure 2-2). The trachea constitutes the main 
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pathway connecting the larynx to the bronchi and then to the lungs.  The alveoli constitute the 
terminal part of the alveoli; which represent the functional part for gas exchange 
8
. The 
branching airways of the respiratory system demonstrate a progressive decrease in diameter 
towards the alveolar region. It is generally assumed that the alveolar deposition is 
therapeutically important. This can be attributed to the large surface area of the alveoli; which 
facilitates the rapid absorption of drugs. For pulmonary drug delivery, the site of particle’s 
deposition is significantly affected by the geometry of the respiratory system. Deposition in the 
respiratory tract takes place by a combination of inertial impaction and gravitational 
sedimentation. For enhancing the pulmonary deposition, it is necessary to decrease the 
impaction loss in the upper respiratory tract. The fraction of particles deposited by inertial 
impaction is exponentially correlated to the particle diameter and airflow rate. One of the major 
challenges of drug delivery to the respiratory system is dependence of dry powder deposition 
characteristics on the inhalation airflow rate. A low airflow rate enhances deposition of 
particles in the terminal parts of the lungs. However, the airflow rate should be high enough to 
create turbulence in the dry powder inhaler device for dispersion of aggregated particles. 
Therefore, achieving an appropriate particles’ deaggregation at relatively low airflow rate is an 
important prerequisite for inhalable powders. This can be accessible by manipulating the 
deaggregation profile of drug or drug-nano-carrier particulate systems.  
2.3.1.2  Inhalation mode 
The site of particles’ deposition in the respiratory tract is affected by the mode of aerosol 
inhalation. The mode of inhalation comprises the airflow rate, volume of air inhaled, and the 
period of breath holding. Deposition by gravitational sedimentation is decreased as the airflow 
rate decreases. Therefore, the deposition of particles in the respiratory system can be enhanced 
by forceful expiration prior to inhalation and deep inhalation followed by a period of breath 
holding.  
2.3.1.3  Inhalation airflow rate 
The driving force for deposition in the respiratory airways is the patient’s inspiration effort. 
The inhalation airflow rate is important to achieve an acceptable deaggregation of particles. 
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Figure 2-2 Different regions of the respiratory tract. 
 
However, the patient’s inhalation rate is difficult to control. Pitchard et al. 9 reported the 
dependence of the regional aerosol deposition of inhaled particles on the patient’s sex. In 
general, the total pulmonary deposition in both male and female patients is similar. However, 
female patients demonstrated higher aerosol deposition in the upper respiratory tract and 
trachea-bronchial region. This effect may be referred to the differences in airway 
10
caliber 
between male and female patients 
9
. Similarly, several studies pointed out to the effect of 
inhalation airflow rate on the pulmonary deposition of dry powders 
11,12
. This, in turn, depends 
on the patient’s disease state, age, sex and height.  
Generally, the mean peak inspiration airflow rate in healthy human was found to be 300 L/min 
13
.  However, in asthmatic patients, this value is changed to be as high as 200 L/min 
12
. Many 
recent studies focus on understanding the nature of airflow (laminar or turbulent) created inside 
the inhaler device. It has been demonstrated that turbulent airflow is more effective for 
dispersing the dry powder mixture  
2.3.2 Formulation-related properties 
2.3.2.1 The particle size of inhaled particles 
The formulation technique applied for manufacturing inhalation dry powder plays a prominent 
in determining the aerosolization behavior of particles. It is theoretically assumed that aerosol 
particles can be targeted to a specific lung site through manipulating the particle size. However, 
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the complexity of the respiratory tract and the patient’s respiratory dynamics cannot be 
ignored. Yet, several studies demonstrated the importance of particle size on the deposition and 
clinical efficacy of inhaled dry powder therapeutics 
14-18
. The aerosolization performance of 
inhaled particles is also affected by the particle morphology, density and their aggregation 
profile. Therefore, it is commonly accepted to propose the aerodynamic diameter as a 
parameter to describe the diameter of particles moving in an air stream.  
The deposition profile of inhaled particles is a function of several interactive factors, such as 
the hygroscopic growth, particle agglomeration and particle charge. Therefore, it is difficult to 
specify a particle size range for an optimum aerosol deposition 
18
. However, most researchers 
that aerosol particles in aerodynamic diameter range 1-5µm are most effective. Particles with 
an aerodynamic diameter greater than 10 µm are generally deposited in the upper respiratory 
tract or retained in the dry powder inhaler device. On the other hand, particles with an 
aerodynamic diameter less than 0.5 µm are rapidly exhaled from the respiratory system 
19
. For 
these reasons, controlling the particle diameter is one of the major challenges in formulating 
dry powders for inhalation.  
2.3.2.2  Presence of a carrier (formulation of particles’ aggregates) 
The flow of powders in the respiratory tract is also dependent on particle size distribution. 
Generally, coarse particles exhibit better flow performance than particles with a small 
diameter. One of the basic requirements in manufacturing dry powder for inhalation is the 
capability to dispense the particles from a bulk reservoir in an adequately reproducible dose. 
The encapsulation of drug in a suitable carrier can fulfill the two mutual contradictory 
requirements for smooth flow properties and minimal pharyngeal deposition.  
Conventionally, this problem can be resolved through inclusion of lactose carrier particles (30-
90 µm) in the formulation of an inhalation dry powder 
18
. However, the incorporation of large 
carrier particles may cause irritation, coughing and even bronchial constriction. Aggregates of 
nanoparticles can be suggested as an alternative approach that can accomplish the enhanced 
flow characteristics of particles as well as improving the emptying from the gelatin capsule 
during the patient’s inspiration. In such a case, the aggregate diameter should not exceed the 
recommended diameter range for deposition in the respiratory tract (1-5 µm). More 
importantly, selection of the polymers involved in formulating aggregates of nanoparticles can 
16 
 
 
 
play a crucial role in enhancing the penetration of fine drug particles through the pulmonary 
epithelium. It is worth mentioning that, the proposed formulation of particles’ aggregates can 
be advantageous as compared to the traditional involvement of lactose carrier in terms of 
lowering the cohesive forces between drug particles and adhesive forces between drug and 
carrier particles. Thus, significant enhancement in the dispersion of particles from the inhaler 
device and, consequently, better availability of medicament to the lungs is expected.  
In this thesis we are proposing beta cyclodextrin, chitosan and poloxamer
 
as a vehicle for 
formulating nanoparticles for pulmonary drug delivery. Beta cyclodextrin is widely used as an 
excipient in pharmaceutical manufacturing. In addition, the Food and Drug Administration 
(FDA) approved it as an excipient for inhalation purposes.   
2.3.2.3 Design of dry powder inhaler device 
The drug deposition profile in the respiratory system is significantly affected by the design of 
dry powder inhaler device. A comparison between the deposition profiles of sodium 
cromoglycate emitted from two different inhaler devices, namely Inhalator Ingelheim
®
 and 
Rotahaler
®
, indicated the dependence of aerosolization performance on the design of dry 
powder inhaler device 
20
. Another study pointed to the influence of inhaler design on the 
amount of particles retained in the gelatin capsule and adhered to the walls of dry powder 
device 
21
.   
 Mechanisms of intra-pulmonary particle deposition 2.4
Inhaled particles are carried by the flowing air through the respiratory tract. However, the 
deposited particles’ trajectories are usually opposite to the direction of inspiratory air; because 
of the forces acting on the particles. The most important mechanical forces influencing 
particles’ deposition are gravity, inertia and collision with gas molecules.  
 Particle engineering strategies for pulmonary drug delivery 2.5
The following section covers the recent developments applied for the development of particles 
suitable for pulmonary drug delivery. The focus of this literature review is to highlight two 
different strategies for the development of inhalation dry powders. The first strategy is the 
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production of microcrystals; which contributes to the stability and efficacy of inhalation dosage 
forms. While the second approach is the production of nanoparticles for the aim of controlled 
and localized drug delivery to the respiratory tract. The present review provides basic concepts 
and theoretical backgrounds involved in particle design for inhalation. It offers a 
comprehensive explanation of how formulations as well as process variables affect the 
morphology of engineered particles. A wide range of particulate systems are proposed, with a 
specific emphasis on the underlying mechanism of micro- and nanoparticle formation.  
2.5.1 Terminology used to define particulate systems 
This section aims to define the common terms needed for a discussion of engineering 
particulate systems suitable for delivery to the respiratory tract. It also explains the important 
mathematical correlations describing particle characteristics, inter-particulate interactions, 
surface energies and particle dispersion profile. 
2.5.1.1 Particle morphology 
The particle shape, internal structure and surface properties can be collectively described as 
particle morphology. 
2.5.1.2 Particle aerodynamic diameter (da) 
 The term aerodynamic describes the physical behavior of a particle in a fluid; such as an air 
stream. Generally, measurements of particle’s diameter is a challenging issue; especially in 
case of irregular shape particles. Therefore, the aerodynamic diameter can be described as the 
diameter of a spherical particle with a unit density and has the same settling velocity as the 
original irregular particle. This diameter is commonly applied to describe the aerodynamic 
behavior of particles as well as the deposition mechanism in the respiratory system. Neglecting 
the slip correction factor, the aerodynamic diameter is proportional to the square root of the 
terminal settling velocity, VTS: 
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Equation 2-1 
 
 
where, ρ0 is a unit density (1000 kg/m
3
), da is the aerodynamic diameter, η is the gas viscosity 
and g is the acceleration due to gravity. The aerodynamic behavior of particle is strongly 
dependent on its shape, density, in addition to its diameter. The aerodynamic diameter can be 
numerically calculated based on the following equation: 
 
 
 
 
where, de is the estimated particle’s geometric diameter and ρp is the density of particle, The 
dynamic shape factor, x can be defined as the drag force acting on the particle relative to that 
acting on the spherical-equivalent particle at the same velocity. Thus, the aerosol deposition in 
the respiratory system is dependent on one or combination of the following parameters; the 
estimated geometric diameter, the particle’s density and the shape factor.  
2.5.1.3 Mass median aerodynamic diameter (MMAD) 
Several methods can be applied for the measurements of in-vitro aerosol deposition; such as 
twin stage impinger (TSI), Anderson cascade impactor (ACI) and next generation impinger 
(NGI). The basic idea of all these equipment is the fractional distribution of powdered drug 
based on the cut-off diameter on each collection stage. It is a kind of sieve analysis; in which 
the cumulative mass of powder less than the stated size of each impinge stage is calculated as 
percent of the total mass recovered in the impinger. The percentage cumulative mass of 
powders is plotted versus the effective cut-off diameter on a logarithmic scale. Inhaled aerosols 
are typically described by a logarithmic size distribution function because most aerosols exhibit 
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𝜌0𝑑𝑎
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Equation 2-2 
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a skewed distribution function with a long tail. The mass median aerodynamic diameter 
(MMAD) and the geometric standard deviation (GSD) represent two statistical properties of 
inhaled drug particles. The MMAD can be directly calculated as the size associated with a 
cumulative count of 50 %, while the GSD is calculated as: 
 
Equation 2-3 
 
where, X and Y are the diameter of particles associated with 84% and 16% cumulative mass 
deposition, respectively 
22
. 
2.5.1.4 Fine particle dose (FPD) 
The fine particle dose can be defined as the fraction of the loaded dose that can be aerosolized 
in the respirable range. The fine particle dose can be estimated directly from the in-vitro 
aerosol deposition testing assuming that the experiment is performed with a high and 
reproducible drug recovery.  
2.5.1.5 Inter-particle interactions 
The site of deposition of particles in the respiratory system is strongly dependent on the inter-
particle interactions, surface energies and the degree of powder dispersibility 
23-27
. It is worth 
mentioning that, the dispersion profile of aerosolized particles is not just a function of the 
magnitude of inter-particle forces. This is because the aggregate structure exhibited significant 
effect on the aerodynamic forces generated. The aerodynamic forces can be described as the 
force exerted on a particle moving in an air stream and it originates from the relative motion 
between the particles and the moving air. The dispersion of powders in an air stream is a 
function of the balance between the aerodynamic forces and the aggregate strength. Deep lung 
deposition can be achieved when the aerodynamic forces exceeds the aggregate strength; thus 
the primary particles can simultaneously disperse in an air stream. For uniform primary 
particles, the aggregate strength (δ, N/m2) can be calculated as: 
 
𝐺𝑆𝐷 =   
𝑋
𝑌
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Equation 2-4 
 
where, ϕ is the ratio between the powder bulk density and the true particle density; which can 
be ascribed as the packing fraction. W (J/m
2
) denotes the work of adhesion and dv refers to the 
spherical equivalent diameter. The work of adhesion can affect the strength of aggregates to 
some extent. Nevertheless, it is highly affected by the powder packing fraction. In addition, it 
can be assumed that aggregates of non-spherical particles can perform better dispersion profile 
than spherical particles. This is because of the reduction in the mean curvature of non-spherical 
particles; which is proportional to the spherical equivalent diameter (dv) 
24
.  
2.5.1.6 Van der Waals forces 
The deposition of particles in the respiratory system together with its dispersion profile is 
affected by the nature of inter-particle forces. These forces are complex in their nature and can 
include electrostatic, van der Waals, capillary-viscous forces. Van der Waals forces represent 
the major component of forces acting on an aerosol particle and it can be considered as the 
most effective force on the particle deposition as well as its dispersion behavior. This is due to 
the fact that all aerosol particles experience van der Waals forces arising from the induced 
dipole-dipole interactions among the molecules making up the particles 
28
.  
2.5.1.7 Work of adhesion/cohesion 
In addition to the induced dipole-dipole interactions, the aggregate strength is dependent on the 
work of cohesion (arising from the drug-drug interactions) or the work of adhesion (due to the 
drug-excipient interactions). Because of the difference in diameters between the drug and 
excipient particles, the effective interaction diameter (dv) can be calculated as the arithmetic 
mean of the drug and excipient diameters (d1 and d2, respectively) 
29
: 
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2.5.1.8 Electrostatic Interactions 
The electrostatic forces and the associated coulombian forces can also affect the dispersion of 
particles. These interactions exhibited comparable effects to the van der Waals forces 
30
.  The 
amount of aerosol particles exiting the capsule and inhaler device as well as the amount of 
particles deposited in the mouthpiece is significantly affected by the electrostatic interactions 
between particles. The agglomerate formation results from the incorporation of differently 
charged particles in the dry powder formulation.  
2.5.1.9 Estimation of the aggregate strength 
Several theoretical approaches have been developed for estimation of the aggregate strength 
because of the difficulty of its experimental determination. These approaches are based mainly 
on the estimation of particle’s surface energy. Nevertheless, it is necessary to take into account 
the total energy of interactions between drug particles. This energy arises from the atomic 
dispersion force, molecular dipole-dipole forces and the molecular hydrogen bonding; which is 
dependent on the Hildebrand solubility parameters δA and δC. The mathematical expression for 
the relationship between the solubility parameters and the strength of cohesive (σC) and 
adhesive (σA) interactions is: 
 
Equation 2-6 
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Equation 2-7 
 
where θ is the interaction parameter between drug molecules; which can be determined using 
inverse gas chromatography (IGC) 
31,32
. Therefore, we can assume that the work of cohesion 
and adhesion are directly proportional to the strength of drug-drug as well as the drug-excipient 
interactions.  
Based on the above theoretical analysis, the following conclusions can be drawn: 
1) The increase in the particle diameter, dv, results in reduction aggregate strength. 
2) Powders with low bulk density promote loose and weak aggregate structure. 
3) The enhancement in the powder dispersion behavior is correlated to the reduction in the 
particle surface energy. Therefore, a coated dry powder formulation is strongly 
recommended for controlled σA and σC parameters.  
4) Smooth spherical particles demonstrated higher aggregate strength than particles with 
an irregular shape; this is because of the reduced contact area between neighboring 
particles and reduced inter-particles forces. 
The first approach can be achieved through the formulation of hollow porous microparticles. 
These porous structures have a relatively high geometric volume diameters compared to their 
aerodynamic diameters. Low-density large particles can be produced by spray freeze-drying; 
which demonstrate an enhanced deposition profile in the cascade impactor experiments 
33
.  
2.5.2  Principal requirements for deep pulmonary deposition 
The pulmonary efficiency of dry powder formulation is dependent on both the fraction of the 
drug-emitted dose deposited in the lung (fine particle fraction, FPF) and the rate of elimination 
of drug particles through the epithelial clearance mechanism. The emitted dose (ED) can be 
expressed as the fraction of drug leaves the dry powder inhaler device in the form of aerosol 
particles. The FPF is the percentage of emitted dose that has an aerodynamic particle diameter 
in the range of 1-5 µm; which allows its lung deposition.  
The FPF is usually determined via in-vitro aerosol deposition equipment, such as, twin stage 
liquid impinger, Andersen cascade impactor, multistage liquid impinge and next generation 
 𝜎𝐴 = 0.25 𝜃𝛿𝑐  𝛿𝐴  
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impinger 
34
. The aerosolization criterion calculated via these testing is usually dependent on the 
particulate properties and inhaler device.  
The FPF is calculated as the percentage of particles (measured as with reference to the fraction 
of particles exiting the inhaler device) below a cut-off diameter of 4.7 µm; which is below 
stage 2 in Andersen cascade impactor.  
Coming to the in vivo point, the bioavailability of drug is influenced by the molecular 
permeability of drug as well as its metabolism. In addition, the dissolution rate and rate of 
epithelial clearance through phagocytosis also have their effects on the pulmonary deposition 
35
.  
Depending on the method of engineering particles for pulmonary delivery, different 
aerosolization parameters can be attained. The desirable product criteria include high FPF and 
ED in addition to the independence on the type of inhaler device and the inhalation flow rate. 
In terms of the particle size, the ideal particles for inhalation should have a narrow size 
distribution and readily dispersible at relatively low aerodynamic forces 
24,25
.  
In other words, the desired requirement for an inhalation dry powder is a relatively low span 
index. The span index is a parameter that indicates the width of particle size distribution 
relative to the median diameter (D50) and is calculated as follows: 
 
Equation 2-8 
 
where, D10, D50 and D90 are the diameters corresponding to 10%, 50% and 90% cumulative 
under size. A narrow size distribution is indicated by a small span index 
26
. The polydispersity 
of particles affects its impaction loss; which is defined as the fraction of particles deposited in 
the mouth and throat. In comparison to the smaller span index powder, the impaction loss for 
larger span index powders is much higher. The impaction loss is proportional to the airflow 
rate and the square of particle diameter.  
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2.5.3  Investigation of different techniques involved in 
micronization of particles 
2.5.3.1 Spray freeze-drying 
One of the conventional methods for the production of uniform micro-particles is spray-drying. 
However, an important stability issue is associated with the production of spray-dried particles; 
this is because of the production of thermodynamically active amorphous particles. These 
particles tend to re-crystallize; which leads to alteration of drug characteristics. Therefore, 
spray freeze-drying technique is favorable for thermo labile drugs. A spray freeze-drying 
procedure combines both the atomization step from the spray-drying technique and freezing 
step involved in the freeze-drying. Typically, the drug solution or suspension is atomized into a 
spraying chamber filled with a cryogenic liquid 
36
. Different particles characteristics can be 
obtained based on of the location of the atomization nozzle. The spraying step can be 
performed either on the surface or beneath the cryogenic liquid 
37
. In the process of spray 
freeze-drying; the surface area available for heat transfer is much larger than the conventional 
freeze-drying 
38
. Therefore, spray freeze-dried product can be formulated in the size range less 
than 5 µm 
39,40
, in addition to the nano-scale 
41-44
. The diameter of particles can be manipulated 
via control of the mass flow rate of the liquid feed 
45
. A decrease in particle size can be 
achieved by an increase in mass flow ratio 
45,46
, while the addition of excipients (e.g., trehalose, 
ammonium sulfate) may lead to an increase in particle size 
47
. Further modification of the 
spray-freezing process has been proposed; instead of spraying the drug solution into the 
cryogenic medium, the drug solution is atomized and frozen simultaneously by mixing with a 
liquefied gas or supercritical fluid, such as supercritical CO2 
25,41,48
.  
2.5.3.2 Jet-Milling 
Jet-milling has been used as a successful tool for producing very fine particles. The main 
drawback of jet milling is that the fluidized particles might suffer from a considerable degree of 
breakage; which resulted from the intense inter-particle collisions. The particle size, shape, 
morphology could be hardly controlled by jet-milling. In addition, it provides limited control of 
the surface properties and electrostatic charges 
49
. The micronized powders produced by jet-
milling always demonstrate a broad size distribution. The formed powders are not naturally 
grown because of the mechanical forces applied for micronization; which leads to breakage of 
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the crystals at the cleavage plane with the lowest attachment energy 
50
. The inefficiency of the 
jet-milling process comes from the reduction in powder crystallinity in addition to the 
enhanced chemical degradation 
51,52
. The alteration in the surface properties of drug substance 
could be related to the creation of thermodynamically-activated surfaces 
53,54
. Jet-milling also 
leads to reduction in therapeutic bioavailability, because of the conversion of crystalline 
surfaces into partially amorphous solids 
55
. Therefore, the production of disordered structures 
in the therapeutic substance affects the processing properties of the formulations, such as 
powder flow and cohesion. Jet-milling produces micronized particles with poor flow 
properties, due to the increased surface energies 
56,57
. Because the powders produced by 
mechanical micronization demonstrated decreased powder dispersibility, the drug delivery 
from dry powder inhalers may be less effective
58
. The association between the active sites of 
the carriers and the micronized drug substance results in reduction of the powder dispersibility. 
Generally, milling techniques show several drawbacks. However, the main research effort in 
the pulmonary drug delivery area is focused on the development of dry powder inhaler devices 
59
. New techniques for the direct production of micronized particles are desirable. Therefore, 
micro-crystallization is a technique with high potential for production of particles for 
pulmonary purposes.   
 Crystallization as a tool for preparation of inhalable drug 2.6
particles 
2.6.1  Micro-crystallization of Proteins using pH Controlled 
Method 
Production of crystalline protein powders has been found to be more favorable than their 
amorphous counterparts 
60,61
. This is because of the higher stability observed for the crystalline 
materials, which results from organized arrangement of molecules, in addition to the presence 
of distinguishable crystal lattice 
62
. Thermodynamically, the lower stability associated with the 
amorphous state resulted from the lack of crystallinity; which increases the energy content of 
molecules 
62
. Due to their high reactivity, amorphous protein particles are rapidly cleared from 
systemic circulation. Therefore, they are more susceptible to hydrolytic and enzymatic 
degradation because of their higher reactivity 
63
. Due to their advantages, crystalline protein 
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powders are desirable as a fine pharmaceutical ingredient. They possess the advantages of high 
purity and better handling during processing, storage and delivery. It can also provide the 
possibility of sustained drug release as a result of controlling the dissolution characteristics 
64
. 
However, apart from insulin, limited numbers of crystalline protein are commercially marketed 
as APIs. This is because of the fact of high degree of oriental freedom resulted from their sheer 
sizes 
63
. In addition, crystallization of proteins can lead to particles with wide size distribution. 
Micronization by milling has been applied for producing microcrystals of proteins. 
Nevertheless, due to the high energy input, the produced protein microcrystals was 
characterized by reduced crystallinity, stability and the presence of regions with disordered 
atoms or molecules 
65
.  
The concept of micro-crystallization has been introduced to overcome milling-induced disorder 
in the crystalline powders. Microcrystals of α-lactalbumin, a 16 kDa glycoprotein, have been 
produced through crystallization from acetic acid aqueous solution containing PEG-8000 as a 
stabilizer. The produced microcrystals showed a controlled diameter between 1 and 2 µm and 
have a roughly spherical morphology. An enhanced pulmonary delivery was observed for the 
particles produced by this method 
66
. 
2.6.2  Crystallization of Proteins Using a Seed Zone Method 
For successful systemic pulmonary drug delivery, the APIs have to be delivered to the alveolar 
region. Generally, the bioavailability of therapeutic agents administered through the lung do 
not exceed 10%; indicating the high clearance mechanism within the respiratory tissue. On this 
basis, many methods have been developed to decrease the exposure time to degradation 
processes. The use of low molecular weight amino acid analogues has been developed as a 
recent strategy for delivery of proteins within the respiratory tissue. The production of partially 
unfolded structures resulted in a facilitated transport across the pulmonary epithelia
67
. The 
production of microcrystals of insulin using a seed zone method was developed by Known et 
al. 
66
. In this method, crystallization of insulin was performed at pH 10.5 ± 0.5. Upon reaching 
supersaturation conditions, the seeds grow into microcrystals suitable for pulmonary inhalation. 
The commercially available insulin zinc crystals, used as long-acting formulations for control 
of diabetes, were characterized by large diameters (up to 20 µm). Smaller microcrystals of 
insulin zinc were produced by a seed zone method (approximately 3 µm) could be considered 
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as a better model to test the long-acting anti-diabetic activity of insulin microcrystals 
administered via pulmonary inhalation.  
Figure 2-3 demonstrates the insulin microcrystals produced by the seed zone method. The 
produced microcrystals showed homogeneous rhombohedral structures without the presence of 
significant aggregation. 
 
 
 
 
Following the intra-tracheal instillation of insulin microcrystals, the blood glucose level were 
reduced and therapeutic action was prolonged over 13 h as compared to normal insulin solution 
66
. The sustained drug release effect resulted from the controlled solubility of insulin 
microcrystals. In contrast to spray-dried amorphous insulin, crystalline insulin produced by the 
seed zone method gave a persistently enhanced hypoglycemic effect 
66
.  
2.6.3  Production of Inhalable Microcrystals by Direct Controlled 
Crystallization 
The antisolvent crystallization technique in the presence of a growth retarding agent can be 
also applied as an alternative strategy for producing inhalable particles of hydrophobic 
drugs
68,69
. Hydroxypropyl methyl cellulose (HPMC) is a common example of stabilizing agents 
applied for direct controlled crystallization technique. The process of crystallization, in this 
case, was carried out through the instantaneous change in solvent composition in the presence 
of stabilizing agent 
70
. Microcrystals with smaller diameters could be attained at higher additive 
concentrations. This procedure has been investigated for several APIs, such as budesonide, 
prednisolone, fluticasone and disodium cromoglycate 
68,70,71
. As compared to jet milled 
powders, the produced microcrystals exhibited an enhanced inhalation characteristic, 
 
 Figure 2-3 The shape of microcrystals obtained by the seed zone method. Light 
microscope analysis: (a) 100× and (b) 400×. Scanning electron microscope analysis: (c) 
8000×. 
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represented by the higher FPFs.  Such particles demonstrated better stability, due to the lower 
amorphous content than the conventional mechanically micronized materials. Figure 2-4 shows 
the SEM micrographs of jet-milled and in-situ-micronized disodium cromoglycate 
71
. 
Disodium cromoglycate produced by jet-milling shows non-homogeneous microcrystals with a 
wide size distribution. Oppositely, direct controlled crystallization produces more uniform 
particles smaller than 1 µm. Production of zinc-free insulin microcrystals (0.2-5 µm) can be 
also attained by the antisolvent controlled crystallization method 
67
. Better stability was also 
shown for the precipitated insulin microcrystals, which were essentially of the same 
composition and prepared by spray-drying, freeze-drying, vacuum-drying or oven-drying.   
Direct crystallization of spherical agglomerates has also been applied for producing pulmonary 
formulations. This technique involves antisolvent of drug solution in a water-miscible organic 
solvent, followed by addition of a bridging solvent, which is immiscible or partially miscible 
with water. For example, spherically agglomerated inhalable microcrystals can be produced 
through the addition of ethyl acetate into a water/acetone crystallization medium 
72,73
. The 
produced agglomerates showed diameters between 200 and 300 µm and composed of primary 
crystals in the respirable range (d50 = 1.3-2.7 µm). Production of primary particles from 
agglomerated crystals could be attained upon mixing with lactose carrier for 2 min. The 
adhered microcrystals can be easily detached from the lactose surface during inhalation with a 
considerable enhancement in inhalation efficiency 
72-75
.  
 
Figure 2-4 SEM photographs of (a) jet-milled and (b,c) in-situ-micronized disodium 
cromoglycate. 
Quenching of a hot organic or aqueous organic solution of the drug with a cold organic or 
aqueous organic solvent can be successfully applied for producing spherical microcrystals. The 
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quench solvent should be miscible with the drug solvent. Salmeterol xinafoate could be easily 
formulated as spherical microcrystals by adding a hot solution of the drug (in 2-propanol) into 
a chilled quench solvent 
76
. The resulting agglomerates are free-flowing and readily 
micronizable to a material suitable for inhalation delivery. 
2.6.4  Reactive Crystallization/Reactive Precipitation 
Reactive crystallization can be defined as the reaction between two homogeneous liquid 
reactants, producing a sparingly soluble crystalline product. This kind of crystallization 
involves the creation of a high degree of supersaturation; which results in a partially 
amorphous product. This is because of a shortage of sufficient time for the molecules to 
arrange themselves in a crystalline form. Reactive precipitation can also occur in the absence of 
chemical reaction, such as, addition of antisolvent or a change of the pH 
77,78
. For instance, 
nanoparticles of sumatriptan succinate (diameter between 630 and 679 nm) could be also 
prepared by additive-free reactive crystallization followed by spray-drying. The technique used 
for producing sumatriptan succinate nanoparticles has been recognized as a promising 
approach for pulmonary formulations, since the FPF value was as high as 50.6%± 8.2% 
78
. 
 Challenges in using crystallization for preparation of 2.7
microparticles 
The main challenge in all crystallization methods is the increased tendency for the formation of 
relatively larger crystals. The crystallization process usually yields particles within the 10-100 
µm size range, which results from the competition between the nucleation and growth 
mechanisms. Therefore, there is a necessity to optimize the process of mixing between the drug 
solution and antisolvent. In order to optimize the obtained particles’ diameters, various types of 
agitation techniques could be applied, such as fast agitation 
79
, high-velocity mixing jets in 
coaxial or impinging configurations, which is a natural choice for particle production in a 
continuous manner 
80
, and also precipitation with ultrasound 
81
. A high gravity rotating packed 
bed could be also applied as an efficient method for smaller and more uniform microcrystals 
82
. 
The particle size can be decreased as well as the size distribution by using an ultrasound 
crystallization method. This happens due to the effect of sonic-induced mixing in addition to the 
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influence of cavitation on supersaturation and nucleation processes. For producing smaller 
particles with a more uniform size distribution, high concentrations of stabilizing agents are 
usually needed. These stabilizing or growth retarding agents are compound-specific, in terms of 
their interaction with the crystal surfaces. For example, polysorbate 80, polysorbate 20, hydroxyl-
propyl methyl cellulose, gelatin, poloxamer 188, sodium alginate and L-leucine have been 
applied as growth inhibitors.  
Although controlled crystallization can be applied as a feasible method for producing well-
defined crystalline particles, removal of the residual solvent can be considered as a major 
drawback of such a process. Powder packing and reduce powder dispersibility are usually the 
results of post-processing drying steps.  
 Polymorphism  2.8
Polymorphism is the tendency of solid material to exist in multiple crystal structures, known as 
polymorphs 
62
. The polymorphic transformation of biopharmaceuticals is a potential problem, as 
regulatory bodies, such as FDA only approve a specific crystal structure or polymorph 
83
. 
Formation of different polymorphs may occur during the crystallization process 
62
. Successful 
control of crystalline solids requires control over molecular packing. The more stable polymorph 
has the higher molecular packing density. From the thermodynamic point of view, APIs 
exhibiting polymorphism should possess different thermodynamic activities. The more stable 
polymorph typically displays the lower values of Gibb’s free energy, vapor pressure, and thus 
lower dissolution rate in any solvent 
62
.  Most commonly, the less stable polymorph has the 
tendency to convert to the more stable one. From the practical pharmaceutical standpoint, the 
existence of polymorphism may lead to good or bad consequences. The utilization of the less 
stable polymorph may provide higher therapeutic bioavailability. Nevertheless, the existence of 
unrecognized polymorphs may result in a wide range dose-to-dose therapeutic efficiency.  
Different mechanisms might be involved in polymorphic transformation, such as solid–solid 
transition, melting, and solution mediated 
84
. The kinetics of transformation to the more stable 
form can be affected by temperature, pressure, relative humidity, presence of impurities and 
mechanical stress 
62
. Therefore, regulatory authorities have restricted the limit of impurities in 
pharmaceutical materials. 
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Characteristic morphologies associated with different crystalline polymorphs have also been 
exploited in improving deep lung delivery. Polymorphic transformation from one form to 
another can be induced by agitated powdered material in a liquid medium. Phase transition of 
the α form (mean diameter = 2.2 µm) of the steroid KSR-592 to the acicular β-form (1.8 x 41 
µm) can be induced by means of agitation in hexane/ethanol (95:5) mixture
85
. The resulting 
powders demonstrated enhanced aerosolization characteristics because of the increased shape 
factor. Furthermore, the β-form exhibited an improved respirable fraction and FPF values due 
to more efficient detachment from lactose carrier. The above inhalation performance of β-form 
crystals depended on their particle size in DPI formulation (i.e., finer crystals decreased the 
FPF value owing to their increased adhesion to the carrier lactose particles) 
73
. 
 Polymorph selection 2.9
The identification of stable polymorphs with desired physical properties is very important for 
product development. Before a drug is submitted for review to the regulatory authorities, it is 
important to identify the most stable polymorph of the drug. The solid phase must be 
monitored, via x-ray diffraction, especially after processes that may cause modification in the 
solid-state properties of the components 
62
. For instance, during micronization processes such 
as milling, spray-drying and spray freeze-drying, the substance is usually exposed to 
mechanical stress, contact with solvents, heating–cooling cycles that can often lead to 
alteration of the solid phase, such as new  polymorph formation, dehydration or melting 
mechanism 
62
. The supercritical fluid process has proved to be an effective technique in 
obtaining pure polymorphs of different drugs based on different operating conditions and 
crystallization kinetics 
86
. The rapid drying and cooling experienced in the process of solution 
enhanced dispersion of supercritical fluids (SEDSF) resulted exclusively in a polymorph of a 
drug 
62
. 
 Nano- strategies for pulmonary drug delivery 2.10
Recently, pulmonary delivery of nanoparticles dry powder formulations has gained great 
attention. Apart from the large surface area of the alveoli, there are other important 
characteristics that can make the pulmonary route an ideal route for the delivery of therapeutic 
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agents. These characteristics are namely, the decreased thickness of the epithelial cells lining 
the lower part of the respiratory tract and the enhanced blood supply at this region 
87
. 
Nanoparticles offer an ideal size range required for pulmonary drug delivery. Nevertheless, 
designing the appropriate carrier remains the major challenge in respiratory drug delivery of 
nanoparticles 
88
. Several carrier systems have been investigated in order to improve the 
delivery of nanoparticles to the lower part of the respiratory tract (alveolar region). 
Enhancement in the aerosolization performance has been recently reported following the 
fabrication of ultrafine nanoparticles of hydroxypropyl methyl cellulose phthalate (HPMCP) 
89
. 
Encapsulation of the hydrophobic drug pranlukast into HPMCP nanoparticles has been 
associated with a significant enhancement in the FPF. In this study the aerosolization behavior 
for the synthesized nanoparticles is first monitored using an in-vitro inhalation test (twin stage 
impinger). A decreased FPF has been reported for the as-synthesized nanoparticles. The 
nanoparticles are then subjected to post-synthetic surface modification through mixing with 
lactose followed by spray freeze-drying. The inhalation performance for the surface modified 
nanoparticles is significantly improved due to the enhancement of the surface properties. The 
fraction of particles deposited in the lower part of the impinger has been recorded to increase 3 
fold compared to the original unmodified particles. The authors referred the observed 
enhancement to the increased surface roughness and hydrophilicity of the surface modified 
nanoparticles.  
The pulmonary delivery of encapsulated insulin into poly lactic -co- glycolic acid nanoparticles 
has also been investigated with the same research group 
90
. The synthesized nanoparticles have 
exhibited an improved hypoglycemic effect which was sustained over a period of 48 hours.  
On the other hand, the concept of producing hollow porous particles for pulmonary drug 
delivery has been investigated by Tsapis et al. 
91
. Spay drying technology has been applied for 
the production of large porous thin walled nanoparticles. The nanoparticles formulations 
studied involves, two different surfactants [1, 2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC) and 1,2-dimyristoyl-sn-glycero-3-phophoethanolamine (DMPE)]. The idea of 
administration of nanoparticles incorporated with carrier system was first introduced in 2004 
88
. 
It should be noted that the particle size before and after spray- or freeze-drying might change 
significantly. This can be attributed to the heat exchange involved in the drying process. The 
authors reported their nanoparticles as good candidates for pulmonary drug delivery for 
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systemic applications. The application of these nanoparticles can be extrapolated to treatment 
of lung cancer, asthma and cystic fibrosis. 
Interestingly, Ely et al. 
92
 has recently introduced the model of active release mechanism of 
nanoparticles following pulmonary administration.  The authors presented a novel method for 
the preparation of effervescent inhalable nanoparticles by spray-drying. They claimed that the 
synthesized effervescent nanoparticles were able to release 56 % of therapeutic agent 
(ciprofloxacin) into simulated body fluid compared to 32 % for conventional formulation 
mixed with lactose carrier. It has been clearly shown that the active release formulations 
provided an enhanced respirable performance due to the decreased agglomeration of drug 
particles following the dissolution of the carrier matrix. 
Based on the previously mentioned investigations, it should be noted that the nanoparticles for 
pulmonary drug delivery have been distinguished as a promising tool for treatment of localized 
lung diseases and potentially for systemic delivery of drug particles. 
2.10.1 Magnetic nanoparticles for drug targeting and pulmonary 
drug delivery 
Magnetic nanoparticles have been extensively investigated in the last few years. Magnetic 
nanoparticles have been distinguished for diversity of biomedical applications, i.e., diagnostic 
and treatment applications. The pharmacokinetics of magnetic nanoparticles encapsulating the 
anticancer drug, doxorubicin, has been investigated in an animal model 
93
. In this research, the 
nanoparticles formulation was applied to the animal model. The magnetic nanoparticles have 
been targeted by the effect of magnet employed over the left lung. The animal model 
experiment has been compared to a reference one without the application of a magnetic field. 
Magnetic targeting of doxorubicin has been achieved following an intra-arterial infusion into 
the pulmonary artery 
93
. Wu et al. 
94
 investigated the effect of magnetic accumulation in the 
lung following intravenous injection of Fe3O4 magnetic nanoparticles.  
As a general statement, magnetic nanoparticles have been investigated for their potential 
pulmonary application. Engineering magnetic nanoparticles for respiratory drug delivery 
deserve more detailed research as it has been proven to be a safe tool for diagnostic and 
treatment purposes. In the next section, various applications of nanoparticles will be briefly 
discussed. 
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2.10.2 Pulmonary delivery of nanoparticles for diagnostic      
purposes 
Nanoparticles have been recently applied for several diagnostic purposes, such as cancer 
diagnosis 
95
. There are limited numbers of publications focusing on the pulmonary instillation 
of nanoparticles for diagnostic purposes. Ketai et al. 
96
 have conducted one of these studies. In 
this research, the authors investigated the applicability of nanoparticles encapsulating a contrast 
material [(1-ethoxycarbonyl) pentyl bis ((3, 5- acetylamino)-2, 4, 6-triiodobenzoate] for 
diagnostic purposes following the pulmonary instillation into dogs as animal model. An 
enhancement in contrast has been shown following the pulmonary administration of 
nanoparticles. Inhaled nanoparticles have exhibited considerable potential for lung imaging 
97
. 
2.10.3 Pulmonary delivery of nanoparticles for treatment 
purposes 
The pulmonary route can be distinguished as a promising approach for treatment of bacterial 
infections invading the lung, i.e, tuberculosis. Mycobacterium tuberculosis starts its bacterial 
replication in the deep region of the respiratory tract (within the alveolar macrophage). 
Therefore, pulmonary administration of magnetic nanoparticles can be described as a 
promising strategy for the treatment of tuberculosis. Macrophage targeted drug delivery 
systems was first introduced by Löbenberg and Kreuter 
98
.  
In another study, an enhancement in the pulmonary deposition of calcitonin has been observed 
following the pulmonary administration of chitosan coated poly lactic -co- glycolic acid 
(PLGA) nanoparticles
99
. Pulmonary administration of surface modified PLGA nanoparticles 
encapsulating calcitonin resulted in 80% reduction in the blood calcium level. Treatment 
utilizing pulmonary nanoparticles has shown a sustained drug release (up to 24 hours). 
Prolonged release of calcitonin can be attributed to the adherence of nanoparticles to the 
bronchial mucosa.  
McConville et al. 
100
 have investigated the improvement of the anti-fungal activity of 
itraconazol (anti-fungal poorly water soluble drug). Nanoparticles of itraconazole can be 
formulated by either spray-freeze drying into liquid or evaporative precipitation into aqueous 
medium. The results of this study have shown that the pulmonary inhalation of itraconazole can 
be applied as a promising alternative for the oral or intravenous route. 
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2.10.4 Anti-body conjugated nanoparticles for magnetic targeting 
and pulmonary drug delivery 
The concept of monoclonal anti-bodies can be employed for the process of active targeting 
101
. 
The drug delivery can be improved by either conjugation of monoclonal anti-body to drug 
molecule or to drug delivery systems 
102,103
. Anti-body conjugated nanoparticles can be utilized 
to target lung cancer. Nanoparticles conjugated with specific lung monoclonal anti-body have 
been explored in an attempt to target lung tumors 
104
. Significant enhancement in the 
localization of nanoparticles in the cancerous lung tissue has been observed for the anti-body 
conjugated nanoparticles. Even though the previously mentioned study has shown an 
improvement in the field of cancer targeting, there is still room for further enhancements. 
Anti-body conjugated nanoparticles can also be applied for endothelial cell targeting 
105
 or even 
specific receptor targeting. The nanoparticles diameter and size distribution can be 
distinguished as a key parameter for controlling the endothelial cell uptake of nanoparticles. 
The endothelial cell membrane can only allow the permeation of nanoparticles with diameters 
from 100 -300 nm. On the other hand, the larger nanoparticles (500 nm - 1 µm) can only be 
attached to the cell surface
106
. Nanoparticles specifically conjugated to monoclonal anti-bodies 
can be a promising approach for targeting cancerous cells. 
 Challenges and possible solutions on stabilization of 2.11
inhalable particles 
Formulating protein powders for inhalation for aerosol delivery requires not only flowability 
and dispersibility of the powders but also biochemical stability of the protein molecules.  
Proteins have secondary and higher order structures. During powder production, removal of 
water from the proteins can cause significant molecular conformational damage, which can 
lead to further protein degradation such as aggregation, deamination and oxidation during 
storage. Amorphous glassy excipients, mainly carbohydrates, have been widely employed to 
stabilize proteins for inhalation, e.g., lactose for recombinant human deoxyribonuclease 
(rhDNase) 
107
, trehalose, lactose and mannitol for recombinant humanized anti-IgE monoclonal 
antibody (rhuMAbE25) 
108
. 
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To satisfy better protein dispersibility, proteins are usually formulated in amorphous glasses, 
which, are physically unstable and tend to crystallize with inter-particulate bond formation and 
loss of powder dispersibility. The choice of the excipients is thus critical. Sodium chloride is 
co-spray dried with rhDNase to increase the dispersibility. In this particular case, the FPF of 
rhDNase increased linearly with the sodium chloride content and powder crystallinity. 
Scanning electron microscope revealed the presence of sodium chloride crystals on the surface 
of the protein particles 
109
. The dispersibility enhancement can be attributed to decreased 
cohesion as a result of changes in surface energy and morphology of crystalline particles when 
the protein-salt composition changes.  On the other hand, inhalable protein particles can be also 
obtained by precipitation from aqueous solution using non-solvents. In recent years, 
supercritical fluids (SCFs) are increasingly used for this application. For example, insulin 
precipitated from dimethyl sulfoxide (DMSO) has been structurally stable for two years 
110
. 
However, the residual solvent of DMSO can be a major concern. To overcome this limitation, 
water-based protein solutions can be used. Special coaxial nozzle has been used to enhance 
mixing of water-based protein solution with supercritical CO2 
111
. More recently, Foster and 
co-workers developed another approach by using high pressure CO2 modified with ethanol, 
which has successfully been employed as an antisolvent to precipitate rhDNase and insulin 
from aqueous solutions 
112
. A potential problem of using CO2 is its acidic nature, but solution 
pH can be adjusted to minimize protein degradation.  
From the pulmonary clearance perspective, alveolar macrophages comprise a major barrier for 
the systemic absorption of macromolecules. For example, significant enhancement in 
pulmonary absorption of IgG (150 kDa) was observed for liposome-encapsulated 
dichloromethylene diphosphonate following depletion of the rat alveolar macrophages. 
Conjugating peptides and proteins with polyethylene glycol (PEG) can protect macromolecules 
from the clearance mechanisms, and thereby increase bioavailability following inhalation. 
However, attachment of larger PEGs (5-12 kDa) hinders transport across pulmonary epithelia, 
emphasizing the importance of optimizing PEG size 
66
.  
Microencapsulation using a biodegradable polymer has been also proposed for prolonging 
insulin absorption in the lung, but the problem is perceived with the accumulation of these 
polymers in the lung and loss of the insulin activity during the preparation of microspheres 
113
. 
Recently, a unique insulin micro-crystallization process using a seed zone method was 
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developed 
66. Insulin microcrystals with a mean diameter of 3 μm were prepared using this 
seed zone method. 
 Conclusions 2.12
The better understanding of the basic nature of therapeutic agents, properties of delivery 
system, aerosol administration mechanism, lung deposition patterns and types of inhaler 
devices plays a significant role in the successful manufacturing of pulmonary formulations. 
The emergence of advanced particle engineering techniques coupled with the modification of 
the traditional methods such as milling has contributed to the increased possibility of 
formulating biopharmaceuticals for pulmonary delivery. Particles with aerosol properties suited 
for deep lung delivery have been engineered without destroying the biological activity of these 
sensitive molecules. The wide range of techniques currently available or being developed 
coupled with the increasing knowledge of excipients used for the protection of 
biopharmaceuticals, allow a diverse range of biopharmaceuticals to be processed for use in 
inhalation delivery devices. Micro-crystallization offers a viable technique for the preparation 
of respiratory drugs.  Other techniques such as spray-drying, spray-freeze drying and jet-
milling have certain disadvantages.  Micron-sized particles can also be produced by 
precipitating the drug in supercritical gas phases as shown for steroids and proteins. These 
techniques require specialized equipment and scale-up into the kg-scale. Developing a site-
specific controlled release formulation presents a solid basis for future advancement in 
nanomedicine strategies for pulmonary drug delivery.  
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CHAPTER 3 
3 CRYSTALLIZATION OF PROGESTERONE FOR 
PULONARY DRUG DELIVERY 
 
Abstract 
 The purpose of this study is to investigate the suitability of the crystallization process to 
produce microcrystals of progesterone for respiratory drug delivery. Crystallization of 
progesterone was carried out from water-isopropanol (IPA) mixture. The antisolvent (water) 
was added at two different addition rates (10 and 100 ml/min). The mass percentage of 
antisolvent was varied between (50 and 75 %), and the initial drug concentration was adjusted 
at (0.5 and 1 g / L).  The effect of the crystallization method (antisolvent precipitation or 
combined cooling and antisolvent) was also examined. These operating conditions were 
investigated in a 2
4
 factorial design in an effort to optimize the process. Different solid-state 
and surface characterization techniques were applied in conjunction with measurements of 
powder flow properties using aerodynamic particle sizer (APS). Powder dispersibility and 
aerosol performance were analyzed using Anderson Cascade Impactor (ACI). Antisolvent 
addition rate, initial drug concentration and dynamic solvent composition are shown to have a 
significant effect on the aerosol characteristics of progesterone microcrystals. An increase of 
38.73% in the fine particle fraction (FPF) was demonstrated for some powders produced by 
combined cooling and antisolvent crystallization. In conclusion, it was possible to control 
particle size and hence, pulmonary deposition using process parameters alone, and produce 
particles with a narrow particle size distribution and a mean particle size of 5 µm with nearly 
no particles larger than 10 µm by direct crystallization. The suitability of deep pulmonary 
deposition was proved by the platelet – like morphology of processed microcrystals and greater 
surface-to-volume ratio than spherical particles. 
Keywords: Respiratory drug delivery, Progesterone, Crystallization, Microcrystals, Cooling, 
Antisolvent, Isopropanol, Aerodynamic particle sizer, Anderson Cascade Impactor. 
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 Introduction 3.1
Micronized drugs are required for different pharmaceutical dosage forms. The 
bioavailability of poorly water soluble drug substances like many newly developed 
pharmaceutically active molecules is a well-known limitation of some drugs. For class II drugs 
and class IV drugs, according to the bio-pharmaceutics classification system 
1
, the dissolution 
rate is the limiting factor for the drug absorption rate in the human body. In order to achieve a 
higher solubility or a higher dissolution rate of a drug, several methods are available. A 
common method for increasing the dissolution rate is to ensure a high specific surface area by 
micronization 
2,3
. Furthermore, micronized drug powders are required for pulmonary drug 
delivery. For pulmonary drug delivery, the drug powder should have a narrow particle size 
distribution and a mean particle size of 5 µm with nearly no particles larger than 10 µm. 
Besides the particle size of the single particles, the pulmonary available fraction is determined 
by the aerodynamic behavior of the drug powder. For a good dry powder inhaler (DPI) 
formulation, drug particles with low agglomeration tendency, sufficient flow properties 
(expressed by Carr’s index, which is the difference between the true and bulk powder density 
divided by the true density) and good batch-to-batch conformity are required 
4
. The common 
way for micronization by jet-milling provides only limited opportunity for the control of 
important product characteristics such as size, shape, morphology, surface properties, and 
electrostatic charge 
5
. Surfaces in mechanically micronized powders are not naturally grown as 
the crystal cleaves at the crystal face with the smallest attachment energy 
6
. The micronization 
process using mills is extremely inefficient 
7
. Due to the high-energy input, crystallinity is 
decreased 
8
 and chemical degradation is enhanced 
9,10
. As a thermodynamically activated 
surface 
11,12
 is created, the surface properties and thus the drug substance properties are altered. 
The conversion of crystalline solid surfaces to partially amorphous solid surfaces leads to a 
physical and chemical instability of the micronized drug 
13
 and its reduced shelf life. 
Disordered structures in the material influence the processing properties and the performance 
in formulations 
14-17
. 
In spite of the development of new processes capable of generating powders for inhalation 
18,
 
crystallization followed by drying and comminution are the established and most extensively 
used techniques for their manufacture. The popularity of this approach has been attributed to 
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the relative simplicity and ease of scale-up of such methods 
19
. Precipitation by antisolvent 
crystallization represents an attractive approach for the production of respirable particles.  
Precipitation is a rapid crystallization process characterized by high levels of solute 
supersaturation, generated by the homogeneous mixing of a solution of an active 
pharmaceutical ingredient (API) with an appropriate antisolvent. Generating a molecularly 
homogeneous solution composition throughout the crystallizer prior to nucleation is difficult at 
high supersaturation 
20
 resulting in disperse crystal nucleation and growth rates throughout the 
crystallizer 
21
. Agglomeration and ageing of precipitates may broaden the particle size 
distribution (PSD) further 
22
. Strategies to control the PSD by limiting crystal growth and 
agglomeration during precipitation include the use of crystal growth inhibiting polymers 
23-25
; 
the use of controlled mixing technologies 
26,27
; the application of ultrasound to accelerate 
diffusion and nucleation 
28,29
; and the use of supercritical fluid antisolvent technologies 
18
. 
These approaches, however, demonstrate several major deficiencies. First, the presence of 
polymeric stabilizing excipients in the final API-containing particles is undesirable. Second, 
the presence of polymeric stabilizers on the surface of the particles contributes to amorphous 
content 
24
, although crystallization techniques are intended to avoid the generation of 
amorphous regions. Third, the use of growth inhibitors is highly specific for the molecule being 
crystallized and is also concentration dependent. All these factors result in further 
complications when developing an appropriate crystallization process.  
Crystallization method in combination with process variables can affect both the nucleation 
and growth phases of crystallization 
30-32
. Hence optimization of the process variables used in 
the crystallization of an API affect the polymorphic form, crystal size and crystal habit (macro-
morphology) of the final crystal.  
Progesterone is a naturally occurring chiral steroid (Scheme 3-1) secreted by the ovary as part 
of the menstrual cycle. It belongs to the broad category of substances called progestins and is 
used in birth control pills and in menopausal hormone replacement therapies. The important 
pharmacological use of estrogens and progestins is as oral contraceptives.  
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Scheme  3-1 Molecular structure of progesterone showing the four chiral atoms (C21, 
C20, C17 and C13). 
 
Progesterone is a poorly water-soluble drug. Oral progesterone is almost completely 
inactivated in the liver and, therefore, it is a good candidate for pulmonary drug delivery. 
Progesterone can be also given by parenteral injection; however, it has an elimination half-life 
of only a few minutes. It is converted in the liver to pregnanediol and conjugated with 
glucuronic acid at the C3 position, and the conjugate is excreted mainly in urine. 
Administration of progesterone via inhalation overcomes the hepatic first pass metabolism and 
therefore increases its elimination half-life. Early studies report two forms of nat-progesterone 
that co-existed (form 1 melts at 129-131°C and form 2 at 121-123°C) as well as the observation 
of three high temperature, low melting phases (111°C, 106°C and 100°C) by hot-stage 
microscopy 
33
. Recent thermal analysis work 
34
 involving heating glassy progesterone suggests 
that a polymorph exists with a melting point of 104°C, well below that for form 1 or 2. To date 
only the orthorhombic polymorphs 1 and 2 have been structurally characterized at room 
temperature and can be found in the Cambridge Structural Database 
35-37
 (CSD references 
PROGST10 and PROGST01) (Scheme 3-2). 
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Scheme  3-2 The crystal structure of progesterone form I and form II 
 
The present work is based on a comparative study of progesterone powders produced by 
antisolvent or combined cooling and antisolvent crystallization. The main aim is to investigate 
the effect of four operating conditions, namely, antisolvent addition rate, cooling rate, drug 
concentration and mass percentage of the antisolvent on the PSD of the microcrystals and 
hence aerosolization performance of the product. 
 Materials and methods 3.2
3.2.1 Materials 
Progesterone was purchased from Calbiochem Company [EMD Biosciences, CA] and 
isopropyl alcohol (IPA) was purchased from VWR Company [VWR International Ltd, CA]. 
3.2.2  Determination of the equilibrium solubility of progesterone 
The solubility of progesterone in water-isopropanol solvent was measured in the range of 0-
40˚C.  Water (antisolvent) was added to the drug to produce a series of solutions with 
compositions ranging 0–100% w/w water in water-IPA. To measure the saturation 
concentration of progesterone in each solvent mixture individually, 20g of the solvent mixture 
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and an excess amount of solids were added to a flask at a given temperature and mixed using a 
magnetic stirrer plate [AGE Magnetic Stirrer, Newtec Inc., U.S.A.]. These suspensions were 
then placed on a multiple vortex control unit [ChemSpeed Technologies, Swizerland], and 
were left to equilibrate for 72 h in a temperature controlled water bath. Samples were filtered 
through 0.45 µm cellulose acetate syringe filters into volumetric flasks. Supernatant were then 
diluted appropriately with IPA, and analyzed for drug content by UV spectrophotometric 
analysis at λ max 290 nm [Cary 100 Bio UV visible Spectrophotometer, USA] 38. 
3.2.3 Crystallization of progesterone 
3.2.3.1 Preparation of progesterone in IPA solution  
Solutions of progesterone were prepared by weighing appropriate amount of progesterone into 
a glass beaker and adding sufficient IPA to achieve the required concentration (% w/w). The 
beakers were covered with sealing film, and the solution was mixed using a magnetic stirrer 
(1000 rpm) at 20 ˚C. The solutions were then filtered to remove excess crystals using a 0.45 
µm cellulose acetate syringe filter into glass vials and sealed.   
3.2.3.2 Crystallization by antisolvent addition 
Progesterone / IPA solution was weighed into a standard 150 ml glass beaker (diameter = 50 
mm). The beaker was placed on a laboratory elevator platform, under a controlled overhead 
magnetic stirrer. Water was added as the antisolvent at a controlled rate using a Master Flex 
pump [Masterflex Console Drive, Barnant Co., Barrington, U.S.A.] equipped with 6 mm 
internal diameter silicon tubing, which had a 2 mm thick wall. A 1 mL plastic pipette tip fixed 
to the end of the silicon tubing was used to direct the water flow. The pump was calibrated for 
each desired flow rate, the time for the addition of water differed randomly from batch to 
batch, depending upon the mass percentage of water added. The crystals were harvested by 
vacuum filtration using a 0.45 µm membrane filter (47 mm diameter) housed in a glass filter 
unit [VWR International Ltd., CA]. The wet cake was washed with 200 mL volumes of water. 
The washed filter cakes were transferred to Petri dishes, covered, and vacuum dried at 50 ˚C 
overnight [NAPCO Vacuum Oven, Krackeler Scientific, Inc., U.S.A.]. The dry cake was 
transferred to sealed glass vials and stored at room temperature over dried silica gel in a glass 
desiccator. 
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3.2.3.3 Crystallization by combined cooling and antisolvent method 
In the case of combined cooling and antisolvent crystallization, the reaction flask temperature 
(0˚C) was controlled by a Thermo Scientific cooling bath [Thermo NESLAB RTE 740, 
Newington, U.S.A.]. A Pt resistance temperature detector was used to measure the temperature 
inside the crystallizer and to control the temperature of the cooling bath with accuracy of ±0.01 
˚K. The temperature of antisolvent in a jacketed flask was also controlled by the same cooling 
bath. The system was sealed completely to minimize the evaporation of IPA. Linear cooling 
and antisolvent were performed in all experiments. 
Crystallization was terminated 20 min after the addition of the antisolvent was complete, and 
percentage theoretical yields were calculated.  
3.2.3.4 Experimental design for screening the effects of crystallization 
conditions 
A 2
4
 (two-level four factor) full-factorial experiment was designed using Design-Expert 7.0 
software (StatEase, QD Consulting, Penzance, UK). Progesterone was crystallized from IPA 
solutions according to the general method presented above. The final weight of the 
crystallization solutions was approximately 100 g and the mass percent of water varied from 50 
to 75 %. The factors considered were progesterone concentration, mass percent of antisolvent 
and the addition rate of the antisolvent. Influence of the crystallization method whether 
antisolvent or combined cooling and antisolvent was also investigated. The details of the factor 
levels employed for the crystallization experiments are presented in Table 3-1. The responses 
examined were the geometric median diameter (D0.5), of the resultant crystallized progesterone 
as measured by laser diffraction, aerodynamic diameter (Da), percentage of theoretical yield, 
mass median aerodynamic diameter (MMAD), fine particle fraction (FPF) and aggregation 
index (AI) (Table 3-2 and 3-3).   
3.2.4  Particle size determination 
Particle size distribution of progesterone powder was measured by laser diffraction dispersing 
system (Mastersizer S, Malvern Instrument, Malvern, UK). The instrument consisted of a laser 
sensor and a dry powder air dispersion system. Different measurement ranges of the laser 
sensor were provided by interchangeable objectives R1 (0.1 - 35µm) and R2 (0.25 - 87.5µm). 
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Adjusting the pressure of the compressed air flow controlled the rate of powder dispersion. A 
pressure of 2 bar was sufficient to achieve deagglomeration of primary particles without 
attrition. Samples were analyzed in triplicates and averages of three measurements are 
presented in Table 3-2. The size distribution was expressed by the median diameter and span 
index. Span index is a measure of the polydispersity of the PSD, defined as the difference in 
the particle diameters at 10% and 90% cumulative volume, divided by the volume median 
diameter 
39
. 
3.2.5  Particle morphology 
Particle morphology was examined by high resolution scanning electron microscopy (SEM, 
JSM 6000F, Joel, Japan) operating at 15 keV. Samples were mounted on metal plates by 
carbon tape and sputter coated with platinum. 
3.2.6  Powder Crystallinity 
Structural analysis of the samples was performed using an X-ray powder diffractometer 
[Rigaku Miniflex XRD, Texas, U.S.A.], fitted with a rotating sample holder, a scintillation 
counter detector and a divergent beam utilizing a Cu Kα source of X-rays (λ = 1.5418 Å). Each 
sample was placed in the cavity of an aluminium sample holder flattened with a glass slide to 
present a good surface texture and inserted into the sample holder. In order to measure the 
powder pattern, the sample holder and detector were moved in a circular path to determine the 
angles of scattered radiation and to reduce preferred sample orientation. All samples were 
measured in the 2θ angle range between 1.5◦ and 40◦ with a scan rate of 5 s per step and a step 
size of 0.05
◦
. Samples were analysed in duplicate.  
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Table 3-1 Operational variables investigated in the antisolvent (AS) and combined 
cooling and antisolvent crystallization (C / AS) of progesterone from IPA / water 
mixtures.  C: cooling, AS: antisolvent 
 
 
Experiment 
 
 
Standard 
 
 
Addition 
rate Crystallization 
method 
 
 
Mass 
percentage 
 
 
Initial drug 
concentration 
number 
order 
number 
(mL/min) 
of 
antisolvent 
(g/L) 
      (%)   
1 8 10 C/AS 75 1 
2 15 100 C/AS 50 1 
3 5 10 C/AS 50 0.5 
4 12 100 AS 75 1 
5 10 100 AS 75 0.5 
6 7 10 C/AS 50 1 
7 4 10 AS 75 1 
8 1 10 AS 50 0.5 
9 14 100 C/AS 75 0.5 
10 6 10 C/AS 75 0.5 
11 3 10 AS 50 1 
12 9 100 AS 50 0.5 
13 11 100 AS 50 1 
14 16 100 C/AS 75 1 
15 13 100 C/AS 50 0.5 
16 2 10 AS 75 0.5 
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Table 3-2 Geometric diameters, polydispersity, aerodynamic diameter and percentage 
theoretical yield of progesterone microcrystals. 
 
 
Experiment 
 
 
Standard 
 
 
D50 
(µm) 
 
 
 
D10 
(µm) 
 
 
D90 
(µm) 
 
Span 
index 
 
 
Aerodynamic 
Percentage 
theoretical 
yield 
number 
order 
number 
diameter (µm) (%) 
1 8 2.9 1.89 7.9 2.07 3.25 70.9 
2 15 1.65 1.18 3.22 1.24 2.28 75.51 
3 5 4.05 2.48 10.31 1.94 7.92 60 
4 12 1.62 1.16 5.97 2.97 3.71 48.61 
5 10 3.76 2.79 8.83 1.61 7.15 38.15 
6 7 3.9 2.15 8.16 1.54 5.09 67.49 
7 4 2.94 2.12 5.73 1.23 5.3 44 
8 1 9.59 6.32 17.88 1.21 14.01 53.57 
9 14 1.64 1.03 4.09 1.87 3.16 73.85 
10 6 2.96 1.79 10.35 2.89 5.94 64.03 
11 3 7.25 5.23 12.32 0.98 10.28 40.24 
12 9 5.73 3.65 10.65 1.22 9.94 72.62 
13 11 1.56 0.86 5.68 3.09 4.49 46.93 
14 16 1.52 1.14 3.33 1.44 2.06 79.45 
15 13 1.81 1.33 3.82 1.37 2.28 73.51 
16 2 8.41 5.2 17.15 1.42 16.68 30 
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Table 3-3 Influence of the process parameters on progesterone dry powder aerosolization 
properties. 
 
 
Experiment 
 
 
Standard 
 
 
Percentage 
 
 
Mass 
median 
 
 
Aggregation 
index 
number 
order 
number 
fine 
particle 
aerodynamic 
diameter 
(AI) 
  
fraction (µm) 
 
    (%)     
1 8 38.4 5.64 0.58 
2 15 50 4.52 0.5 
3 5 30.12 5.7 1.39 
4 12 44.62 5.36 0.69 
5 10 33.5 6.12 1.17 
6 7 35.74 5.99 0.85 
7 4 36.25 6.15 0.86 
8 1 29.5 6.93 2.02 
9 14 39.5 5.78 0.55 
10 6 33.1 6.57 0.9 
11 3 20.2 7.58 1.36 
12 9 22.1 7.32 1.36 
13 11 36.04 6.08 0.74 
14 16 49.22 4.99 0.41 
15 13 45.67 4.75 0.48 
16 2 20.95 7.57 2.2 
 
3.2.7  Dynamic vapor sorption (DVS) 
The physical stability of progesterone samples was examined by Dynamic Vapour Sorption 
[DVS-1000, Surface Measurement Systems Ltd., U.S.A.]. This instrument gravimetrically 
measures the uptake and loss of water vapor on a substrate by means of a recording 
microbalance with a resolution of ±0.1µg. In the first step of the experimental run, the sample 
was dried at 25 
◦
C and 0% relative humidity (RH) for at least 600 min in order to bring the 
sample to constant weight. Then, the instrument was programmed to increase the RH in steps 
of 5% RH from 0 to 90% RH and decrease the RH in steps of 10% RH from 90 to 0% RH. A 
criterion of dm/dt = 0.005%/min was chosen for the system to hold at each RH step before 
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proceeding to the next RH step. Sample masses between 30 and 100 mg were used in this 
study. The change in mass (%) is expressed in terms of g H2O per 100 g of dry substance.  
3.2.8  Powder dispersion by cascade impaction 
An Anderson Cascade Impactor (Eight Stage Non-Viable Andersen Cascade Impactor, Copley 
Ltd., Nottingham, UK) was used to determine the dispersibility and fine particle fraction (FPF) 
of each powder through a dry powder inhaler device (Turbuhaler
®
 Biomed, St. Albans, UK).  
The Turbuhaler
®
 is a dry powder inhaler that delivers multiple doses from a drug reservoir. In 
addition to the advantage of requiring no coordination between actuation and inhalation, the 
Turbuhaler
® 
offers other design advantages including a metering system that prevents 
accidental multiple dosing, a dose counter, an end of life lock-out system, different metering 
cones to provide a range of doses, and conventional inhaler appearance 
40
. To prevent particles 
from bouncing off the plates and becoming re-entrained in the air stream prior to each analysis, 
the eight metal plates of the impactor were coated with thin layer of silicone spray and left to 
dry for 30 min. A pre-separator was attached to the top of the impactor to prevent large 
particles or aggregates from reaching the stages. The airflow through the apparatus, measured 
at the inlet to the throat, was adjusted to generate a pressure drop of 4 k Pa over the inhaler 
device under test. The duration is consistent with the flow of 4 L min
−1
 in accordance to 
pharmacopeia guidelines 
41
. These conditions are consistent with a flow rate of 49 L min
−1
 and 
4.9 s duration. Ten doses were discharged into the apparatus and each determination was 
carried out at least twice. After each determination, rinsing with IPA collected the powder on 
each impaction stage and the resulting solutions were analyzed by UV spectrophotometry. The 
amount of drug deposited in the throat piece and the pre-separator was also determined. The 
percentage of the total dose collected on the stages 3 through 5 represented particles with the 
aerodynamic diameters less than 4.36 µm, and was considered as the fine particle fraction 
(FPF). 
3.2.9  Aerodynamic particle sizer (APS) 
The particle size distributions of the product, in an accelerated air stream, were measured by 
APS [TSI model 3321, TSI Inc., U.S.A.], which operates on time-of-flight and light-scattering 
intensity principles. A small amount of particles were loaded into a dry powder inhaler (DPI), 
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(Turbuhaler
®
 DPI), to generate the drug aerosols. The APS connected with the Turbuhaler
®
 
DPI was operated at an inhalation flow rate of 30 L/min chosen to simulate the actual patient 
use. The APS renders measurements of particle concentrations in the aerodynamic diameters 
(Da) range of 0.57-20 μm. Each test by the APS was performed in triplicate and averaged. The 
theoretical aerodynamic diameter of a particle, Da, is defined as the diameter of an equivalent 
spherical particle with a density of 1 g/cm
3
 that has the same settling velocity as the particle of 
interest. It is the key particle property for characterizing respiratory deposition 
42
. Inhaled 
aerosols are typically described by the logarithm of the size distributions rather than the size 
itself because most aerosols exhibit a skewed distribution function with a long tail. Two 
important statistical properties of inhaled drug particles are the mass median aerodynamic 
diameter (MMAD) and the geometric standard deviation (GSD). The MMAD can be directly 
calculated from the mass-based particle size distribution provided by the APS. The GSD is 
obtained as:                                     
     (  ⁄ )
   
 
Equation 3-1 
                                                             
where X is the size associated with a cumulative count of 84% and Y is the size associated with 
a cumulative count of 16% of the particles. 
The aggregation index was calculated by dividing the experimental aerodynamic diameter 
measured using the aerodynamic particle sizer (Da) on the computed MMAD calculated from 
cascade impaction experiment, which is, the aerodynamic diameter of particle aggregates 
divided by the calculated aerodynamic diameter of the individual particles.  
 Results and discussion 3.3
3.3.1 Solubility of progesterone in IPA/water mixtures 
The addition of water (antisolvent) to progesterone / IPA solution resulted in a decrease in the 
solubility of progesterone in the crystallization liquor. The solubility of progesterone in a series 
of solutions (ranging 0–100% w/w water in water-IPA mixture) is presented in Figure 3-1. IPA 
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has a high solubilization capacity for progesterone. The measured solubility of progesterone in 
IPA/water mixtures in the temperature range of 0 - 40˚C is presented in Equation 3-2.  
S = 4.68 + 0.23 T – 0.09 D – 1.48 T * D -1.98 T2 + 4.02 D2 
Equation 3-2 
where S is the solubility of progesterone (g/100 ml), T is the temperature (˚C) and D is the 
mass percent of water.  
3.3.2  Particle size 
The average geometric particle size (D50) was between 1.52 and 9.59 µm, while the 
aerodynamic diameter ranged from 2.06 to 16.68 µm (Table 3-2). This difference in the 
measured size suggests that the particles had a relatively small aspect ratio.  The data obtained 
at high dispersion using the aerodynamic particle sizer (APS) indicate a significantly smaller 
aerodynamic diameter for progesterone powders prepared using combined cooling and 
 
Figure 3-1  Solubility of progesterone in a series of IPA/water mixtures at 0, 15, 25 and 
40 ºC. 
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antisolvent crystallization. Analysis of particle size distribution indicates that there is a 
significant fraction of sub-micron particles in both antisolvent and combined cooling and 
antisolvent crystallization. The polydispersity, viz., the width of the particle size distribution of 
the powders was expressed by the span index. A small span index indicates a narrow size 
distribution (Table 3-2). The span index of progesterone powders ranged between 0.98 and 
3.09. The largest span index values were observed for runs 13 and 4 that could be attributed to 
the high addition rate of antisolvent (100 mL / min) and / or the high mass percentage of 
antisolvent (75%). Polydispersity is likely to be the result of two competing factors: adding 
more antisolvent which will result in a greater mass of crystals, but will also cause more 
primary nucleation compared to the crystallization by cooling alone. The crystal yield increases 
at higher mass of antisolvent addition due to the change in solvent composition over time. 
Solvent composition can affect the predominating mechanisms determining the metastable 
zone width (nucleation and crystal growth) due to a reduction in the solid-liquid interfacial 
energy. The polydispersity of the primary powder affected the impaction loss, which is defined 
as the mass fraction of particles collected in the throat and pre-separator of the impactor. There 
were a greater proportion of larger particles present in the larger span index powder, and the 
particles had the potential to impact at the throat. Larger particles could also act as carriers with 
"binding sites" onto which the smaller particles adhere, forming agglomerates for impaction. In 
comparison with the smaller span index powder, the impaction loss for larger span index 
powders was much higher and was flow dependent, as impaction loss is proportional to the air 
flow and square of particle or agglomerate size 
43
. 
3.3.3  Powder Crystallinity  
The X-ray powder diffraction of micronized and progesterone samples processed by both 
crystallization methods was examined. After collecting the spectra, the data was processed 
using the MDI-Jade version 7.5 software [Materials Data Inc., Livermore, CA].  Figure 3-2 
shows a typical X-ray diffraction profile of progesterone. Combined cooling and antisolvent 
microcrystals showed higher degree of crystallinity (94.48%) as compared to both antisolvent 
crystallized (81.74%) and micronized (68.96%) samples. The degree of Crystallinity was 
determined by the software by dividing the major peaks in the XRD patterns by their 
67 
 
 
 
corresponding of standard progesterone sample (Calbiochem Company, EMD Biosciences, 
CA) 
44
. 
 
Figure 3-2 X-ray diffraction profile of progesterone prepared using combined 
cooling/antisolvent crystallization. 
3.3.4  Hygroscopicity and stability of progesterone microcrystals 
Dynamic vapor sorption measurements were performed to determine the thermal effects of 
water adsorption for materials of different physical stability at increased %RH levels. Figure 3-
3 shows the sorption isotherms of micronized and two progesterone samples (runs 4 and14) 
formed by both crystallization methods (antisolvent addition and antisolvent with cooling). The 
sorption isotherms were measured at 25 ˚C, the equilibrium moisture content “moisture 
uptake” of all samples in this study was very low (<0.04 wt. %) at all RH levels. Interestingly, 
run 4 (prepared by antisolvent precipitation) adsorbs additional moisture at relative humidity 
higher than 80% RH compared with the other samples. Under these conditions, the sample may 
be deliquescing at high RH. 
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Figure 3-3 Comparison of moisture sorption isotherms (25 ºC) of micronized and 
processed progesterone samples. 
3.3.5  Aerosol performance of microcrystals processed by 
antisolvent versus combined cooling and antisolvent 
crystallization 
Figure 3-4 compares the in-vitro performance of micronized and progesterone processed 
powders dispersed form Turbuhaler
®
 DPI device and analyzed using an Andersen Cascade 
Impactor (ACI). The ACI measurements demonstrate that the progesterone batches prepared 
using combined cooling and antisolvent crystallization produced a significantly higher FPF in 
comparison to both micronized and antisolvent precipitation processed powders. The product 
of antisolvent and cooling crystallization showed a high proportion of fine particle mass with a 
narrow distribution was collected on stage 1–3 in contrast to the broad distribution across 
stages 3–5 for the micronized material.  In addition, an increased fine particle fraction (FPF) 
was observed.   
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Figure 3-4 Deposition profiles of micronized and processed progesterone crystals through 
Anderson cascade impactor. 
Results of FPF for the 16 runs are presented in Table 3-3. Progesterone powders had a FPF 
ranging between 20.2% and 50%, with aggregation index values between 0.41 and 2.2. The 
enhanced FPF observed for runs 2 and 14 could be attributed to increased dispersion between 
drug particles, and this could be directly related to the reduction of cohesive (drug-drug) 
interaction forces. The de-aggregation and dispersion properties of the respirable particles upon 
activation (driven by the patient’s inspirational energy) are, on a microscopic scale, governed 
by the resulting cohesive interaction force within the formulation. Excessive strong cohesive 
forces may enhance agglomerate formation, which could directly affect the fluidization and 
dispersion characteristics of the formulation. This fact can be clearly illustrated by the 
aggregation index values (Table 3-3) and the morphological properties examined using 
scanning electron microscopy (Figure 3-5).  Progesterone powder with good aerosolization 
properties (FPF = 44.62%) can also be prepared using antisolvent precipitation (run 4). 
Furthermore, reducing the drug concentration from 10 to 5 g/100 mL or changing the 
antisolvent addition rate from 100 to 10 mL/min dramatically reduce the FPF as seen in batches 
11 and 12, and this could be attributed to increased particle aggregation (Figure 3-5). 
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3.3.6  Screening factorial experimental design 
A 2
4
 full-factorial design was used to screen the effects of four key crystallization conditions 
on the suitability of the produced microparticles of progesterone for inhaled delivery. Tables 3-
1 and 3-2 present the input conditions of crystallization, percentage crystal yield and particle 
size distribution of progesterone microparticles. There is a significant difference between the 
mean cumulative 10% undersize (D(v,0.1)) or median diameter (D(v,0.5)) values (p < 0.05). This 
demonstrated a greater degree of variance arising from the determination of median particle 
size (the primary response for the factorial study) than that which arose from the yield of the 
crystallization process. The F-value of 15.3 implies the model is significant. A significant 
difference was observed for the aerodynamic particle size (Da) for the three replicates (p < 
0.05). It was clear from the particle size data in Table 3-2 that the crystallization process was 
successful in producing crystals in the low micron size range, which would be suitable for 
pulmonary drug delivery. The range of median diameter values was 1.52 to 9.59 µm while the 
cumulative 90% undersize values ranged from 3.22 to 17.88 µm. The median diameter data 
 
Figure 3-5 Effect of crystallization method on the morphological properties of 
progesterone dry powders. (a) Micronized progesterone, (b) Sample 2, (c) Sample 
14, (d) Sample 4, (e) Sample 11 and (f) Sample 12. Samples 2 and 14 were prepared 
using combined cooling and antisolvent crystallization, while samples 4, 11 and 12 
were prepared using antisolvent method. 
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were analyzed statistically using Design Expert 7.0 software without carrying out any 
transformation of the data. The input factors having a significant effect were coded 
alphabetically (A = addition rate of antisolvent, B = crystallization method whether antisolvent 
or combined cooling and antisolvent, C = drug concentration in g/L and D = mass percentage 
of antisolvent).  The two factor interaction terms were represented by combination of the main 
factors, e.g. AC = addition rate and drug concentration interaction. The model was constructed 
by step-wise backward elimination of statistically insignificant factorial terms and non-
hierarchical terms. The final model is presented in Tables 3-4 and 3-5 along with the regression 
coefficients which are a measure of the magnitude of the effect of a factor on the median 
diameter of progesterone microparticles. A statistical analysis of variance of the model is 
presented in Table 3-4. Briefly, although the model was significant (p < 0.0001) as indicated by 
its ability to account for 88% of the variance in the D(v,0.5) (adjusted R-squared = 0.88), there 
was a significant lack of fit to the data (p < 0.0001). Similar analysis conducted for other 
responses and the corresponding models developed in each case are presented in Table 3-6. 
Table 3-4 Results for analysis of variance (ANOVA) of model equations.  
Source 
Sum of  
squares 
Degree 
of  
freedom 
Mean  
square 
F value 
P value 
probability 
> F value 
Model 5.27 5 1.05 22.59 < 0.0001 
A: Addition rate 2.11 1 2.11 45.29 < 0.0001 
B: Crystallization  
method  
1.38 1 1.38 29.63 0.0003 
C: Drug  
concentration 
0.79 1 0.79 17.01 0.0021 
D: Mass percentage  
of antisolvent 
0.33 1 0.33 7.00 0.0245 
B/C: Crystallization 
method /   
drug concentration 
interaction 
0.65 1 0.65 14.03 0.0038 
R-squared 0.92 Adeq. percision 15.47 
Adj R-squared 0.88 Std. deviation 0.22 
Pred R-squared 0.79 Mean 1.86 
Table 3-5 Summary of effect lists and percentages contributions of crystallization 
variables on the median diameter of progesterone microcrystals. 
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Table 3-6 Final model equations in case of antisolvent and combined cooling and 
antisolvent crystallization. A: addition rate of antisolvent; C: drug concentration; D: 
mass percent of antisolvent; D0.5: Median geometric diameter; Da: Aerodynamic 
diameter; Y: percent theoretical yield; FPF: Percent fine particle fraction; MMAD: Mass 
median aerodynamic diameter; AI: Aggregation index. 
 
Antisolvent crystallization 
Combined cooling / antisolvent  
crystallization 
D0.5 = 15.19 - 0.03 A - 0.71 C - 0.05 D D0.5 = 7.53 - 0.03 A - 0.71 C - 0.05 D 
Da = 20.45 - 0.05 A -1.2 C Da = 9.03 -0.05 A -1.2 C 
Y = 40.78 + 0.11 A Y = 64.6 + 0.11 A 
FPF = 14.05 + 0.11 A + 1.4 C FPF = 23.88 + 0.11 A + 1.4 C 
MMAD = 7.19 - 0.01 A MMAD = 6.04 - 0.01 A 
AI = 2.79 - 5.92 A -0.16 C AI = 1.4 - 5.92 A - 0.16 C 
3.3.7  Response surface construction to optimize crystallization 
parameters 
From the particle sizing data presented in Table 3-2, it is clear that the four operating 
conditions of crystallization affect the PSD of the microcrystals. It was necessary to include 
Term 
Effect Sum of squares % Contribution 
A: Addition rate -0.727088 2.11463 36.8391 
B: Crystallization  
method  
-0.588063 1.38327 24.0981 
C: Drug  
concentration 
-0.445537 0.794013 13.8326 
D: Mass percentage  
of antisolvent 
-0.285733 0.326574 5.68928 
B/C: Crystallization 
method /   
drug concentration 
interaction 
0.04 0.65 11.41 
73 
 
 
 
three interaction terms (concentration of drug / addition rate, concentration of drug / mass 
percentage of antisolvent interaction and addition rate / mass percentage of antisolvent) to 
retain hierarchy of the response surface model for the median diameter and to improve the 
statistical fit. The response surfaces for the particle size distribution are presented in Figure 3-
6, while the analyses of variance and percentage contribution of each factor are presented in 
Tables 3-4 and 3-5.  
The median diameter was dependent on all terms included in the model response surface for 
the D(v,0.5) (p < 0.0001). Although the model for the percentage theoretical yield observed 
response surface described the data well (p < 0.05), a significant lack of fit existed (p < 0.05) as 
confirmed by the lower correlation coefficient (adjusted R-squared = 0.67). The suitability of 
IPA as a solvent for the antisolvent micronization of hydrophobic compounds was shown by 
the ability to produce particles with a median diameter in the low micron size range (Table 3-
2). The 2
4
 factorial design was effective for screening the experimental factor space to provide 
an indication of the major effects of the crystallization.  
In accordance with classical nucleation theory 
45
 when supersaturation increased (factors C, D 
and the two way interactions AC, AD and DC) the median particle diameter decreased. A 
higher supersaturation leads to a large number of smaller crystals when supersaturation is 
consumed by nucleation events rather than crystal growth. The decrease in median particle 
diameter as the addition rate of the antisolvent (water) increased indicated that the extent of 
nucleation was not only determined by the supersaturation, but also the rate and process of 
generation of supersaturation. Positive correlations between the median diameter and a number 
of factors were observed. These positive correlations (indicating an increased median diameter 
at the upper factor levels) arose from the slower rate of generation of supersaturation due to a 
slower descent down the solubility curve (interactions CD, AD and AC). 
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Figure 3-6 Response surface profile for the median geometric diameter of 
progesterone microcrystals.  
 In addition the resultant particle size was affected by the process of crystallization. The high 
D(v,0.9) values in the majority of cases indicated a significant proportion of the particles would 
be unsuitable for inhaled drug delivery. However, the potential of the antisolvent system for the 
controlled production of microparticles was shown by the relatively narrow PSD obtained 
(GSD values between 1.2 and 2).  
 Conclusions 3.4
In conclusion, it was clear that the four operating conditions of addition rate, crystallization 
method, drug concentration and mass percentage of the antisolvent affect the PSD of the 
microcrystals and hence, can improve pulmonary deposition. It was also possible to decrease 
the median diameter of the particles to a size suitable for inhalation drug delivery, and also to 
narrow the particle size distribution by decreasing the cumulative 90% undersize diameter. The 
optimum experimental conditions based on our current results was observed for batches 
number 2 and 14, in which we used combined cooling and antisolvent crystallization method at 
the highest antisolvent addition rate (100 mL /min) and 1 g/L drug concentration. High 
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respirable fraction values was obtained (50.00 and 49.22 % for runs 2 and 14, respectively) for 
both mass percentage of antisolvent (50 and 75%). IPA as a solvent for the antisolvent 
micronization of hydrophobic compounds showed the ability to produce particles with a 
median diameter in the low micron size range. Furthermore, the PSD was shown to depend on 
the hydrodynamic conditions prevailing in the crystallizer without the use of traditional 
crystallization inhibitors.  
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Chapter 4 
4 CONTROLLED RELEASE OF 5-FLUOROURACIL AND 
PROGESTERONE FROM MAGNETIC NANO-
AGGREGATES 
 
Abstract 
The potential use of magnetic nanoparticles in biomedical applications has witnessed an 
exponential growth in the last few years. In this study we use nano-aggregates of magnetic 
nanoparticles as carriers for controlled drug delivery. The nano-aggregates are formed due to 
the presence of the block co-polymer of polyethylene oxide-polypropylene oxide (pluronic F-
68) and beta cyclodextrin that surround the magnetic core of the nanoparticles. The 
administration of the drug carriers takes place by inhalation and the drug is delivered 
systemically by the pulmonary route. We test the delivery of 5-fluorouracil and progesterone, 
which are used as models of hydrophilic and hydrophobic drugs, respectively.  
The estimated nano-aggregates diameters are between 293 ± 14.65 nm and 90.2 ± 4.51 nm. In-
situ and post-synthesis techniques are two approaches for drug loading. The polymer 
composition of nano-aggregates and initial drug concentration showed a significant effect on 
the drug entrapment efficiency and release kinetics. Average drug entrapment efficiencies 
ranged between 16.11 and 83.25%. In-situ loaded samples showed significantly slower release 
rates. The drug release mechanism is investigated by mathematical curve fitting to different 
drug release kinetics models. In most cases, the Peppas model has shown good correlations 
(coefficients of correlation, R
2
, between 0.85 and 0.99) with the examined release profiles. The 
estimated release indices are less than 0.5; which indicates Fickian diffusion mechanism. For 
samples with an initial burst effect, modified the Peppas model can provide better 
understanding of the drug release mechanism for the samples loaded with progesterone or at 
high polymer concentrations.  
Our work prolonged the delivery of the drug (5-fluorouracil and progesterone) by diffusion 
from nano-aggregates with potential consequence to reduce dose related adverse effects.  
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 Introduction 4.1
Pulmonary drug delivery of therapeutic agents is currently an active field of research, 
especially after the approval of insulin dry powder inhaler. The pulmonary delivery of drugs 
has several advantages over the oral and injection delivery routes 
1-4
. The ability to circumvent 
the hepatic first-pass metabolism makes this route very promising for reducing the dose and 
side effects.  Additionally, the delivery of drugs through the pulmonary tract can be modulated 
to target the drug locally in the respiratory region; therefore it can be applied for the treatment 
of diseases such as asthma, chronic obstructive pulmonary diseases and cystic fibrosis 
1-3
. 
However, the pulmonary delivery has been recognized as an attractive route for systemic 
delivery due to the contribution of the large surface area (more than 100 m
2
) and thin 
epithelium layer (0.2 - 1 µm thickness) 
3
. Additionally, the pulmonary route has been 
associated with an improved bioavailability, which can be attributed to the relatively low 
enzymatic activity for this region 
4
.  
In pulmonary drug delivery, the inhaled particles are subjected to an alveolar phagocytosis 
clearance mechanism by the alveolar macrophage cells. Notably, the alveolar phagocytosis is a 
more effective mechanism for particles having a geometric diameter between 1 and 2 µm. 
Inhaled particles with geometric diameter smaller than 1 µm or larger than 2 µm are subject to 
reduced macrophage phagocytosis clearance 
5,6
. Therefore, nanoparticles offer many 
advantages to the systemic pulmonary drug delivery field. Hoet et al. 
7
 reported that the 
optimum particle size of inhalable particles should be less than 100 nm in order to maximize 
the alveolar deposition and minimize the phagocytic clearance mechanisms. In spite of the 
great advantages offered by nanoparticles in the field of drug delivery and development, their 
pulmonary application is not straightforward. Significant formulation challenges arise from 
their high Gibbs free energy as a result of their large surface area. Therefore, prevention of 
particle agglomeration creates a very challenging problem during manufacturing 
8
. In order to 
control this problem, two strategies have been proposed in the literature. The first approach is 
to manufacture large hollow carrier of agglomerated particle encapsulating the active 
therapeutic agent. This approach has been first introduced by Tsapis et al. 
9
 and was modified 
by Hadinoto et al. 
10
.   
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The second strategy to address the problem of nanoparticles high Gibbs free energy is through 
addition of surfactants. Surfactants can elevate the activation energy of inter-particulate 
agglomeration through the formation of electrostatic or steric barriers between the particles 
8, 11
.  
In the present study, we focus on the development of nano-carriers that can be magnetically 
targeted for the treatment of lung cancer and hormone replacement. Emphasis will be placed on 
polymers and surfactant self-assembly as an interesting approach for the synthesis of well-
defined nano-aggregates. Our approach follows directly from the second strategy. However, 
our method is different from other magnetic nano-carriers in the coating that surround the 
magnetic core 
12
. These nano-aggregates are formed spontaneously by self-assembly of block 
co-polymer and beta cyclodextrin without the application of cross linker. They have the 
advantages of facile preparation without the use of any organic solvents and of lack of toxic 
polymer degradation products. These nano-carriers have the capability to encapsulate both 
hydrophilic and hydrophobic drugs. Controlled drug delivery can be achieved by variation in 
the concentration of polymers and / or surfactant. To our knowledge, we are the first group to 
propose pluronic F-68 and beta cyclodextrin for preparation of diffusion controlled super-
paramagnetic nano-aggregates for both hormonal and anticancer drug delivery. The 
magnetization features (coercivity and retentivity) of our prepared nano-aggregates can also be 
modulated by varying the surfactant / polymer relative concentrations 
13
. 
Drug release by diffusion of biologically active molecules from nano-carriers is an important 
and commonly used approach to achieving controlled release. The release from porous systems 
has been previously reported in several publications 
14
. Depending on the composition of the 
porous system (type of the polymer and type of drug), topology of the nano-carrier (size and 
shape) and drug loading technique, one or more of the following physical phenomena affect the 
drug release kinetics: (1) Wetting of the nano-carrier drug delivery system with release 
medium, (2) penetration of the release medium into the porous structure nanoparticles, (3) 
creation of pores filled with water within the nanoparticles structure, (4) drug diffusion through 
the pores, and (5) drug diffusion to the release medium. 
 For mathematical modeling of drug release kinetics through a porous system, it is crucial to 
take into account only the dominant process for drug transport. From the transport processes 
point of view, the mechanism of drug release for porous systems consists mainly of exterior 
and interior diffusion phenomena 
15, 16
. 
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Additionally, the structure hollowness of nano-particulate carriers is specifically designed to 
enhance both the aerosolization efficiency and the therapeutic efficacy 
17
. Despite the 
advantages of introducing structural hollowness in nanoparticles, many challenges related to 
the drug release profile and drug release kinetics have to be addressed. Dailey et al. 
18
 have 
introduced the possibility of developing surfactant free nano-particulate carriers with variable 
physico-chemical properties for the pulmonary application via nebulization. Slow drug release 
rate has been observed for their nano-agglomerates, especially for hydrophobic drugs. They 
attributed their results to the large geometric diameter of agglomerated nanoparticles 
18
.  
The synergistic effect of combining the structure hollowness and magnetic properties appears 
to be promising for controlled and targeted drug delivery technology 
19
. For instance, magnetic 
liposomes and hollow capsules entrapped with magnetic nanoparticles have shown great 
potential for drug loading and encapsulation efficiency 
19-21
. In order to produce magnetic 
nano-aggregates with controlled drug release kinetics and magnetic retention, it is necessary to 
control the collective properties of magnetic nano-aggregates 
22
. In our study, the magnetic 
properties of nano-aggregates are dependent on the inter-particulate interactions between the 
block copolymer and beta cyclodextrin; these interactions also have a significant effect on the 
nanoparticles aggregation 
23
.  
Drugs can be loaded into the porous structures by two techniques: (1) Post-synthesis and (2) In-
situ loading 
15
. In the post-synthesis method, the nano-aggregates are synthesized and then the 
drug is absorbed to the porous structures. In this case, drug diffusion is the major mechanism 
for drug uptake. In the in-situ loading, the drug is mixed with nano-aggregates polymer 
precursors. The drug release will be determined by diffusion or degradation of labile covalent 
bonds. In this chapter, both drug loading methods will be analyzed based on different 
percentages of drug loadings and different formulation parameters. The drug release kinetics is 
also analyzed in terms of experiments and modeling in order to understand how the release is 
sustained. 
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 Materials and methods 4.2
4.2.1 Materials 
FeSO4.7H2O [VWR, Mississauga, ON, Canada], polyethylene oxide - polypropylene oxide 
block copolymer [pluronic F-68, Molecular weight 8400, Sigma-Aldrich Ltd, Oakville, ON, 
Canada], beta cyclodextrin [Molecular weight 1135, Sigma-Aldrich Ltd, Oakville, ON, Canada 
Canada]. The two modeled drugs; progesterone and 5-Fluorouracil were purchased from 
Sigma-Aldrich [Sigma-Aldrich Ltd, Oakville, ON, Canada]. Ammonium hydroxide, methylene 
chloride, acetonitrile and phosphate buffer saline tablets are products of VWR [VWR, 
Mississauga, ON, Canada].  
4.2.2  Preparation of magnetic nano-aggregates 
The magnetic nano-aggregates were synthesized according to a modified method reported by 
Xia et al. 
24
. The reaction involved two iron precursors (ferrous and ferric chloride salts) under 
nitrogen gas with vigorous stirring. In our method, we used a simple and easy synthetic 
method. Our experiments were all conducted under an aerobic environment and by the 
utilization of just one iron precursor (ferrous sulphate).  
Block copolymer polyethylene oxide- poly propylene oxide (pluronic F-68, molecular weight 
8400, 2.5 mmol, 21 g) was dissolved in 50 ml of distilled water with vigorous magnetic stirring 
(VWR 230 magnetic stirrer / hot plate, VWR, Mississauga, ON, Canada ) for 30 min. The iron 
precursor (ferrous sulphate hepta-hydrate FeSO4.7H2O, molecular weight 278.01, 5.895 mmol, 
and 1.396 g) was then added to the reaction mixture. The reaction was continued for 30 min of 
mixing under an aerobic environment. Then beta cyclodextrin (molecular weight 1135, 5 
mmol, and 5.675g) was dissolved in ammonium hydroxide and drop-wise added to the reaction 
mixture. The reaction was then continued for more than 90 min till homogeneous stable 
aqueous suspension appeared. The experiment was conducted without the need of purging 
nitrogen gas. The concentration of pluronic F-68 was varied between 0.5 and 3 mmol under 
fixed experimental conditions. To investigate the magnetic properties and drug release kinetics 
of the prepared nano-aggregates, the amount of beta cyclodextrin was varied from 0% to 25% 
as a fraction of total solids in the formulations. The prepared magnetic nano-aggregates were 
then thoroughly washed with ethanol and freeze-dried (Freeze Zone plus Freeze dryer, 
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Labconco Corporation, Kansas city, MO, USA). The chemical structure of the used drugs and 
polymers is presented in Scheme 4-1. 
 
Scheme  4-1 Chemical structures of beta cyclodextrin, polypropylene oxide / 
polypropylene oxide block copolymer (pluronic F-68, HO 
(C2H4O)n(C3H6O)m(C2H4O)n OH,  m = 80 and n = 27) and the two encapsulated 
drugs; progesterone and 5-fluorouracil. 
  
 Drug loading  4.3
4.3.1 In-situ drug loading of 5-Fluorouracil 
5-Fluorouracil (50 mg) and a predetermined amount of beta cyclodextrin were dissolved in 
28% ammonium hydroxide solution. In addition, the block copolymer and the iron precursor 
(FeSO4.7H2O) were dissolved in 50 ml of distilled water. The two mixtures were mixed 
together for at least 90 min at room temperature. The resulting 5-fluorouracil loaded aggregates 
were washed and then oven dried for further characterization.  
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4.3.2  Drug loading by freeze-drying of 5-Fluorouracil 
Freeze-drying technique for drug loading can be considered as a post-synthetic step. In this 
method, 10 mg of 5-fluorouracil was mixed with 20 mg of magnetic nano-aggregates in 
distilled water. The mixture was then stirred mechanically overnight at room temperature. The 
obtained mixture was freeze dried for twenty four hours.  
4.3.3  Progesterone loading through inclusion complex 
formation with beta cyclodextrin 
The progesterone loaded magnetic nano-aggregates were prepared according to the method 
reported by Lemos-Senna et al. 
25
. Briefly, progesterone (5mg) and beta cyclodextrin (25 mg) 
were dissolved in methylene chloride (3 ml). The mixture was then added to 28% ammonium 
hydroxide aqueous solution (50 ml). In a separate beaker, pluronic F-68 was mixed with an 
aqueous solution of the iron precursor (1.396 g of FeSO4.7H2O in 50 ml distilled water). The 
ammonium hydroxide solution containing progesterone and beta cyclodextrin was added to the 
iron/block copolymer solution and vigorously mixed for 90 minutes at room temperature. The 
precipitated magnetic nano-structures were washed and then oven dried.  
4.3.4  Characterization of 5-fluorouracil and progesterone 
loaded   magnetic nano-aggregates 
4.3.4.1 Particle size measurement 
The mean diameter of nano-aggregates and the polydispersity index were determined using 
dynamic light scattering technique (Zetasizer 300 HSA, Malvern Instruments Ltd, 
Worcestershire, UK). The size analysis was performed at a scattering angle of 90 º and at a 
temperature of 20 °C.  
4.3.4.2 Particle morphology  
The morphology of magnetic nano-aggregates was examined using scanning electron 
microscopy (SEM, JSM 600F model, Joel, Tokyo, Japan). The samples were prepared on 
aluminum stabs and coated with gold prior to the examination. 
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4.3.4.3 X-ray diffraction 
X-ray diffractometer (Rigaku-Miniflex, The Woodlands, Texas, USA) was utilized for 
examination of the crystal profile of loaded and unloaded samples. The samples were exposed 
to X-ray radiation (CuKα, 40 KV, 20 mA) at a wavelength of 1.54 Å. The samples were 
scanned over a 2-theta range between 15° to 70° and at a step size of 0.02 °.  
4.3.4.4 Fourier transform infra-red spectroscopy (FTIR) 
FTIR spectra were in the solid state by Bruker-Vector 22 FTIR spectrophotometer (Bruker-
Vector, Milton, ON, Canada).  
4.3.4.5 Powder magnetization 
 The magnetic properties were measured using vibrating sample magnetometer (VSM, Model 
74035, Lake Shore Cryotronics Inc., Westerville, OH, USA) at 300 K. The magnetic properties 
of nano-aggregates samples were studied at field range of ± 10,000 gauss. 
4.3.5  Investigation of drug release profile and kinetics of 5-
fluorouracil loaded magnetic nano-aggregates  
4.3.5.1 Drug loading and entrapment efficiency 
The drug loading can be defined as the amount of drug encapsulated per unit mass of 
nanoparticles. 5-Flurouracil and progesterone concentrations were determined for all 
formulations after dissolving a known amount of nano-aggregates sample in acetonitrile. The 
amount of the supernatants obtained after centrifugation at 15000 rpm was determined 
quantitatively for the amount of drug loaded. The ratio of the mass of drug recovered in the 
nanoparticles to the mass of drug initially loaded can be defined as the drug entrapment 
efficiency. Summary of experimental data and their effect on drug encapsulation is listed in 
Table 4-1.  
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Table 4-1 Entrapment efficiencies of 5-fluorouracil as a function of different initial drug 
concentrations and nano- aggregates average diameters. 
 
4.3.5.2 In-vitro release test 
A dialysis bag (cellulose membrane, MW cut-off 12400, Sigma-Aldrich Ltd., Oakville, ON, 
Canada) was utilized for conducting the in-vitro release experiments. The dialysis in-vitro 
experiments confirmed that only the free drug molecules diffuse into the release medium 
without the passage of nanoparticles carriers. The release study was conducted in phosphate 
buffer saline (pH 7.4) and the samples were withdrawn at predetermined time intervals for 14 
days.  
4.3.5.3 Analysis of 5-fluorouracil and progesterone release kinetics 
The drug release profile and kinetics can be controlled through modulation of the drug delivery 
architecture 
26,27
. 5-Fluorouracil and progesterone release data as a function of different 
formulation parameters were examined for fitting to the following release kinetics models; zero 
order, first order, Hixson-Crowell, Higuchi, Peppas, Weibull and Lonsdale models. Table 4A-1 
 
Concentration 
of pluronic F-68 
(mmol) 
 
Particle 
average 
diameter 
(nm ± RSD) 
 
Initial drug 
concentration 
(mg drug / mg 
nanoparticles) 
 
Drug 
loading 
(%) 
 
Drug entrapment efficiency 
(%) 
In-situ 
loading 
Freeze-drying 
loading 
0.5 293 ± 14.65 30 10 82.65 83.25 
1.0 207 ± 10.35 25 9.5 50.66 63.14 
1.5 146 ± 7.30 20 9 48.25 56.90 
2 124 ± 6.20 10 5 23.69 31.56 
2.5 98.70 ± 4.93 20 3 16.11 19.12 
3.0 90.20 ± 4.51 20 2 32.01 46.22 
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summarizes the previously mentioned functions together with the corresponding equations 
14-16
. 
The data were fit using SigmaPlot software (Systat Software Inc., San Jose, CA, USA) and 
regression analysis was utilized for computation of the coefficients of correlation and release 
parameters for each function. The student t-test was then applied to calculate the best fit 
mathematical parameters for each kinetic model. The results were found significantly different 
based on 95% probability values.  
4.3.6  In-vitro cytotoxicity study 
In-vitro cytotoxicity study was performed for the purpose of investigating the effect of 5-
fluorouracil loaded magnetic nano-aggregates on lung adenocarcinoma. The human 
tumorigenic lung epithelial cell line A549 was obtained from the American Type Culture 
Collection (CCL-185). For these experiments, lung cancer cells were plated in 100 µL of tissue 
culture medium at a density of 2.5x10
4
 cells. Examining the effect of nano-aggregates 
formulations on the growth of A549 cell line were carried out by adding serial dilutions of 5-
fluouracil loaded magnetic nano-aggregates to each well containing cells grown for one day. 
The studied concentrations of 5-fluouracil were 10
-4
, 10
-3
, 10
-2
, 0.1, 1, 10, 100 and 1000 µL of 
anticancer drug. The cells were incubated for four days at 37 C under 5 % CO2 atmosphere and 
then the cell viability was determined using Alamar Blue assay
28
. The cytotoxicity data were 
expressed as percentages of the residual viability using the plates cultured in absence of 5-
fluouracil as 100% viability samples. 
4.3.7  Test of statistical significance 
The correlations between our experimental data and the release kinetics models were computed 
using SigmaPlot software. The statistical significance of results was evaluated using a student 
t-test. The aim of the statistical study was to examine the dependence of the drug release 
profiles on the studied parameters, i.e., particle size, drug loading and the drug loading 
technique.  
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 Results and Discussion 4.4
4.4.1 Particle size and morphology  
SEM images of magnetic nano-aggregates with loaded drugs are presented in Figure 4-1. The 
presented images revealed that the powders consist of uniform almost spherical primary 
particles which are arranged in aggregated nano-structures. In the present work, magnetic 
nano-structures produced by the combination of polyethylene oxide - polypropylene oxide 
block copolymer and beta cyclodextrin having a wide range of primary particle diameters 
(Figure 4-2). These primary nanoparticles are further aggregated to give well organized nano-
structures with an aggregate diameter ranging from 90.20 ± 4.51 nm to a maximum of 293 ± 
14.65 nm. As shown in Figure 4-1, increasing the concentration of block copolymer does not 
have significant effect on the morphology of nano-aggregates. On the contrary, beta 
cyclodextrin does not show significant effect on the particle diameters; however it has more 
influence on the spherical organization of nano-aggregates. An increase in the concentration of 
beta cyclodextrin was associated with an increase in the degree of hollowness of nano-
aggregates. 
Figure 4-1 Scanning electron micrograph (SEM) images for different magnetic nano-
aggregates formulations. Effect of polymeric composition on morphology of nano-
aggregates: (a) 0.5 mmol block copolymer and 0 wt% beta cyclodextrin, (b) 3 mmol block 
copolymer and 0 wt% beta cyclodextrin, (c) 3 mmol block copolymer and 5 wt% beta 
cyclodextrin and (d) 3 mmol block copolymer and 25 wt% beta cyclodextrin. 
200 nm  
200 nm  
200 nm  
200 nm  
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The X-ray diffraction patterns of magnetic nano-aggregates prepared with 0.5 and 3 mmol of 
pluronic F-68 is presented in Figure 4-3. Addition of pluronic F-68 is usually associated with 
particle size reduction, which is indicated by the peak broadening. The five characteristic peaks 
for iron oxide magnetic nanoparticles were at 2-theta angles of 30.95, 35.89, 44.34, 55.06 and 
64.51. These five peaks correspond to the diffraction from the 111, 200, 211, 221, 310, 222 
planes of face centered cubic iron oxide crystals. 
 
 
 
 
Figure 4-2 Effect of block copolymer concentrations on the average primary and 
aggregated particle diameters. 
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Figure 4-3 X-ray diffraction profiles of magnetic nano-aggregates as a function of block 
copolymer concentration. (a) 0.5 mmol and (b) 3 mmol of block copolymer (pluronic F-
68). 
FTIR analysis was performed to confirm the presence of beta cyclodextrin and pluronic F-68 
on magnetic nano-aggregates. In the case of uncoated magnetic nano-aggregates, the presence 
of strong peaks in the region between 600 and 660 cm
-1
 was attributed to Fe-O bond of the iron 
oxide skeleton (Figure 4-4). Magnetic nano-aggregates coated with beta cyclodextrin and 
exhibited an intense band at 1010 cm
-1
 due to the glycoside vibrations (C-O-C). The same peak 
was observed for nano-aggregates samples coated with pluronic F-68; this belongs to the C-O-
C stretch vibrations of pluronic F-68. The broad peak in the region between 3000 and 3500 cm
-
1
 corresponded to the multiple hydroxyl groups of both beta cyclodextrin and pluronic F-68. A 
characteristic C-O stretch vibration band was clearly observed at 1750 cm
-1 
in pluronic F-68 
coated magnetic nano-aggregates; which indicate the presence of the polymer. The magnetic 
samples coated with both polymers didn’t show any C-O stretch vibration band at 1750 cm-1 
due to the formation of hydrogen bond between beta cyclodextrin and the ether oxygen of 
pluronic F-68 polymeric chain (Figure 4-5)  
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Figure 4-4 FTIR spectrum of uncoated magnetic nano-aggregates. 
 
Figure 4-5 FTIR spectra of different polymer coated magnetic nano-aggregates. 
Figure 4-6 represents the magnetization data for the 293 ± 20.51 nm and the primary magnetic 
core (15 ± 0.56 nm), prepared by conventional thermal decomposition method of iron 
precursor. The magnetic properties of all samples were studied at field range of ± 10,000 gauss. 
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Figure 4-6 Room temperature (300 K) magnetization curves of magnetic nano=aggregates 
prepared with 3 mmol of block copolymer and 5 wt% beta cyclodextrin compared to 
magnetic nanoparticles prepared with conventional method. 
The data obtained indicated the super-paramagnetic characteristics for both samples. The mass 
saturation magnetization values were 26.5 emu/g for the nano-aggregates prepared with 0.5 
mmol of pluronic F-68 compared to 16 emu/g for the as-prepared magnetic core. The observed 
significant reduction in the coercivity of the nano-aggregate (1.65 gauss for nano-aggregates 
compared to 168.19 gauss for the as-prepared magnetic core) together with the absence of 
hysteresis indicates the super-paramagnetic nature of the samples. Additionally, the retentivity 
data obtained for the primary magnetic nanoparticles prepared by the conventional thermal 
deposition method was significantly higher than their corresponding nano-aggregated samples 
(0.59 emu versus 0.0016 emu). This finding also confirmed the super-paramagnetic nature of 
our nano-aggregated structures. Similar super-paramagnetic behavior was observed for the 
samples prepared at different concentrations of beta cyclodextrin. 
Interestingly, increasing the concentration of beta cyclodextrin from 5 wt% to 25 wt% showed 
significant improvement in the mass saturation magnetization values of nano-aggregates. The 
saturation magnetization values for the 5 and 25wt% beta cyclodextrin were 38.71 and 81.22 
emu/g. This value is comparable to the published saturation magnetization value reported by 
Xia et al. 
25
 and also comparable to the commercially available magnetite nanoparticles 
supplied from Sigma-Aldrich. The increased magnetization observed upon increasing the 
96 
 
 
 
concentration of polymer can be explained by the reduction in the shell thickness. This will 
consequently lead to an increase in the size of the magnetic core. In other words, the decreased 
fraction of block co-polymer (pluronic F-68) is associated with an enhancement in the 
saturation magnetization. The presence of pluronic F-68 on the surface of magnetic 
nanoparticles can be considered as a magnetic dead layer; thus affecting the saturation 
magnetization as a result of quenching of the surface moment 
29
.  
4.4.2  Drug release profile through polymeric nano-aggregates 
as a function of different formulation parameters 
The release profiles of 5-fluorouracil and progesterone loaded nano-aggregates were 
investigated. The amount of drug loaded, loading technique and nano-aggregates morphology 
showed significant effect on the release patterns.  The drug encapsulation efficiency showed 
significant dependence on the loading technique for all samples smaller than 293 ± 14.65 nm. 
For the samples prepared with 3.0 mmol of block copolymer (nano-aggregate particle size = 
90.2 ± 4.51 nm), significant reduction in the drug entrapment efficiency was observed upon 
switching of the drug loading technique from freeze-drying to in-situ drug loading method 
(Table 4-1).  
4.4.2.1 Influence of drug loading and nano-aggregates size on 5-
fluorouracil release  
The results of 5-fluorouracil loaded magnetic nano-aggregates release profile as a function of 
the drug loading and particle diameter are presented in Figure 4-7. The samples examined in 
this figure were prepared at high 5-fluorouracil loading percentages (9, 9.5 and 10%). 
Increasing the particle diameter from 146 ± 3.0 to 293 ± 14.65 nm resulted in significant 
reduction in the drug release rate (Table 4A-2). In addition, samples prepared at lower 
percentages of drug loading (2, 3 and 5%) showed more dependence on the drug loading 
technique. A comparison between the calculated release rates as a function of the drug loading 
technique is presented in Table 4-2. The release rate is significantly higher for all samples 
loaded with freeze drying, especially for the sample loaded with 5% 5-fluorouracil. This high 
release rate could be attributed to the additional drug lost during the decomposition reaction of 
iron precursor for the in-situ loaded samples. Upon analysis of the release kinetics of these 
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three samples, the three release profiles showed perfect correlations to Peppas model of release 
kinetics. The release calculated indices in all cases are less than 0.5; which indicates the 
Fickian diffusion mechanism. It should be noted that, increasing the drug loading from 2 to 5% 
was associated with significant enhancement in the drug release rate. Further increase in the 
drug loading (from 5% to 9%) results in a drop in the release rate and consequently in the 
release index. For example, the calculated release rate based on Peppas model is 40.43 day 
-1
 
for the sample loaded with 9% 5-fluorouracil compared to 64.08 day 
-1
  at 5% drug loading. 
Interestingly, the sample loaded with 2% of 5-fluorouracil showed good correlations with both 
Peppas and first order release models for the two drug loading techniques. The drug release 
rate for the samples loaded by freeze drying is significantly higher than the corresponding 
samples loaded by in-situ technique.  
Table 4-2 Estimated Peppas parameters as a function of drug loading percentages and 
loading techniques. 
 
 
98 
 
 
 
 
Figure 4-7 Drug release profiles of 5-fluorouracil nano-aggregates prepared by in-situ 
loading method. 
The influence of drug loading on progesterone release was also investigated. Figure 4A-1 
shows the release patterns of different progesterone loaded nano-aggregates produced with 
freeze drying technique. Because of the limited aqueous solubility of progesterone, the drug 
loading and entrapment efficiency were low for the samples with an average diameter less than 
293 ± 14.65 nm. The release profile of samples prepared with 2 to 10% progesterone is 
demonstrated in Figure 4A-1. The variation in the drug release rate can be attributed to the 
differences in the average particle diameter, particle morphology as well as the physico-
chemical properties of the drugs. For example, the nano-aggregates loaded with 5% of 
progesterone demonstrated an average particle diameter of 124 ± 6.2 nm compared to 89.5 ± 
4.95 nm for the corresponding sample loaded with 5-fluorouracil.  
The dependence of the drug release kinetics on the particle diameter can be directly correlated 
to the variation on the drug loading. Figure 4A-2 focuses on the effect of the particle average 
diameter on 5-fluorouracil release rate through nano-aggregates with approximately equal drug 
loading. The selected drug loading in all samples was adjusted to be 10%. It should be noted 
that there is little effect of the particle size on the drug release rate for the samples loaded by 
in-situ method. A comparison between the release profiles of the in-situ loaded and freeze dried 
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samples prepared at 10% drug loading is shown in Figure 4A-2. Based on our previously 
discussed data, the drug loading, particle size and loading techniques all contribute to the 
release profile of examined samples. The drug loading technique exhibited more significant 
role in controlling the release rate.  
4.4.2.2  Influence of beta cyclodextrin mass fraction on the drug 
release rate and profile 
The incorporation of beta cyclodextrin in the nano-aggregates formulation was found to 
significantly influence the produced nano-aggregates size and morphology. Most crucially, 
variations in the beta cyclodextrin concentration added to the nano-aggregates formulation 
affected the particle aggregation index and the degree of nano-aggregates hollowness. 
However, the incorporation of beta cyclodextrin in the nano-aggregates formulation had no 
significant effect on the primary particle size distribution. The experiments were conducted for 
both drugs (progesterone and 5-fluorouracil). The samples with an average diameter of 146 ± 
7.3 nm and 293 ± 14.65 nm were loaded with progesterone (the drug loading was 9 and 10%, 
respectively). 5- Fluorouracil was loaded to the samples with an average diameter of 207 ± 
10.35 nm. Beta cyclodextrin was dissolved in 5 -10 ml of 28% ammonium hydroxide solution 
and added to 50 ml of iron precursor - block copolymer solution. The addition of beta 
cyclodextrin had significant effect on the initial percentage progesterone release for the sample 
prepared with an average diameter of 293 ± 14.65 nm (the initial percentage release increased 
to 50% within the first hour). Furthermore, the cumulative amount of progesterone released 
remained constant for all the samples examined at variable concentration of beta cyclodextrin 
added (ranging from 5% to 25% of the total solid added). After 72 hours release experiments, 
the change in the release profile for these nano-aggregate samples as a function of increasing 
beta cyclodextrin concentration became more significant. The cumulative percentage of drug 
released after 7 days decreased from 83.35% for the nano-aggregate samples prepared in the 
absence of beta cyclodextrin to about 72.36% for the samples prepared at 15% beta 
cyclodextrin concentration. Increasing the concentration of beta cyclodextrin up to 25% was 
associated with the reduction in the cumulative drug release of progesterone to 65.95% after 7 
days (Figure 4-8). 
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Additionally, 5-fluorouracil release profile was also investigated as a function of beta 
cyclodextrin concentration. The 124 ± 6.2 nm nano-aggregates formulation loaded with 2% of 
the anticancer drug were examined for the release rate and profile as a function of increasing 
the concentration of beta cyclodextrin. The effect of beta cyclodextrin concentration on the 
initial burst was more significant in case of 5-fluorouracil (Table 4A-3).   
 
Figure 4-8 Effect of beta cyclodextrin mass fraction on the release of progesterone 
samples loaded by freeze drying. 
4.4.2.3  Analysis of release mechanism and mathematical model 
fitting 
Successful curve fittings were obtained when the Peppas model equation was fit to the entire 
release curves. A typical example of curve fitting is exemplarily shown in Figure 4-9. An 
overview of the derived estimates for the release index (n) is listed in Table 2. The calculated 
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values of the standard error and the correlation coefficients of the non-linear regression 
analysis are indicative of the good fitting of the Peppas model equation to the experimental 
data (Table 4A-4). For all examined samples, the estimates for the release index (n) is less than 
0.5; which indicates pure diffusion controlled release from a sphere 
30
.  
Interestingly, good coefficients of correlation were obtained when the Weibull empirical 
equation was fitted to the release curves for the samples loaded with 5-fluorouracil. The 
computed parameter, b, for Weibull curve fitting was 0.74 for the in-situ sample loaded with 
9% 5-fluorouracil; which is consistent with the parameter values for Fickian diffusion reported 
by Costa et al. 
30
 (Figure 4-9). The mathematical and physical relevance between the Peppas 
and Weibull models have been previously reported 
30
. Therefore, Weibull function can be 
considered as an additional confirmation for the drug release mechanism.  
 
Figure 4-9 Mathematical modeling of 5-fluorouracil release from 146 nm magnetic nano-
aggregates. 
The drug loading technique appears to affect both the release rate and the drug release 
mechanisms. Peppas model fitting to the release data of 5-fluorouracil nano-aggregates loaded 
by freeze drying showed a significant reduction in the coefficient of correlations for the 293 nm 
and 146 nm samples. However, good coefficients of correlation were obtained with the Weibull 
function. The estimates for the b values were 1.12 and 1.14 (close to 1) which is compatible 
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with the first-order release. In this case, the concentration gradient in the release medium was 
believed to control the release rate. A typical example of Weibull curve fitting is shown in 
Figure 4-10. Moreover, the dissimilarity in the fitting parameters between 5-fluorouracil and 
progesterone could be attributed to the difference in their aqueous solubility. In addition, the 
differences in the estimates of release index (n) were more significant with increasing the mass 
fraction of beta cyclodextrin. The Peppas model equation failed to fit the release data for 
progesterone loaded samples prepared with 15 and 25% mass fraction of beta cyclodextrin. The 
calculated coefficients of correlations were 0.78 and 0.70, respectively. The correlations for 
Weibull model equation showed perfect fitting for these samples. The estimates for the b 
parameter are 0.09 and 0.1 for samples prepared with 15 and 25% beta cyclodextrin, 
respectively. The predicted mechanism in this case is diffusion through highly disordered 
spaces.  
 
Figure 4-10 Mathematical modeling of 5-fluorouracil release from 293 nm magnetic 
nano-aggregates. 
In addition, an increase in the initial burst effect for progesterone loaded nano-aggregates 
prepared with high percentage of beta cyclodextrin could be attributed to the enhancement of 
the drug aqueous solubility. Therefore, a modified form of Peppas model equation was 
developed to accommodate the initial burst effect. Figures 4A-3 and 4A-4 are typical examples 
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for curve fitting of our experimental release data to the modified Peppas model. A 
mathematical presentation for the modified Peppas function is presented in Equation 4-1: 
𝑄 = 𝑎 𝑡𝑛 + 𝑏  
 
Equation 4-1 
where, Q is the amount of drug released at time t, a is a constant incorporating structural and 
geometrical characteristics of the drug dosage form, n is the release exponent and b is a 
parameter which is indicative of the initial burst effect. In the absence of initial burst effect, b 
value would be zero and only the term, at 
n
, is used. Table 4-3 summarizes the results for the 
curve fitting parameters for progesterone loaded nano-aggregates prepared at two different 
concentrations of beta cyclodextrin; 5 and 25%. The samples prepared with 25% beta 
cyclodextrin showed a higher coefficient of correlation to the modified Peppas model. The 
estimated initial burst parameter is higher for the 25% beta cyclodextrin sample. This could be 
attributed to the relatively small fraction of hydrophobic drug that enters the cyclodextrin 
cavity. At high concentration of beta cyclodextrin, it is highly probable that a larger fraction of 
progesterone interacts with the long aliphatic chain of the polymer. This is consistent with the 
results obtained by Memisoglu et al. 
31
. In addition, the presence of block co-polymer as 
solubilizer influences the rapid initial release of progesterone.  
Table 4-3 Release parameters for mathematical modeling of progesterone loaded 
magnetic nano-aggregates. 
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In the present work, we analyzed the effect of different formulation parameters on the viability 
of A549 lung cancerous cells. First, we examined the effect of different percentages of 5-
fluouracil loading on the living cells. Thereafter, the effect of different drug loading techniques 
was also investigated.  
4.4.3 In-vitro cytotoxicity study 
4.4.3.1 Effect of drug loading percentages on the viability of lung 
cancer cells 
Nano-aggregates loaded with different percentages of 5-fluouracil were found to exert a 
cytotoxic effect on the A 549 cancerous cell line in a dose dependent manner (Figure 4-11). 
The samples exhibited different sensitivity based on their loading percentages. The higher 
percentage of cytotoxicity was observed for the sample loaded with 5% 5-fluouracil. Increasing 
the percentage drug loaded up to 10% did not result in enhanced cytotoxicity. The lowest 
inactivation rate of the cells was observed for the samples loaded with 10% 5-fluorouracil; 
which could be attributed to the decreased release rate of drug.  
4.4.3.2 Effect of drug loading technique on viability of lung cancer 
cells 
 The effect of drug loading technique on the viability of A 549 cells was demonstrated in 
Figure 4-12. Lung cancer cells were treated with magnetic nano-aggregates formulations 
loaded by in-situ and freeze drying techniques. Similarly, all samples induced cytotoxicity in a 
dose dependent manner. The higher cells inactivation rate was recorded for the samples loaded 
by freeze drying technique. In addition, the effect of freeze dried samples seemed to be 
extremely strong; the residual cells viability was found to be 6.25% at 100 nM drug 
concentration.  
105 
 
 
 
 Conclusions 4.5
Magnetic nano-aggregates based on block copolymer and beta cyclodextrin can be described as 
a good candidate for controlled drug delivery of both hydrophilic and hydrophobic drugs. The 
drug loading and encapsulation efficiency can be modulated by controlling different 
formulation parameters. Significant enhancement in drug encapsulation was observed for the 
post-synthesis drug loaded samples. However, by using in-situ loading method at 0.5% of 
pluronic F-68, it was possible to obtain nano-aggregates with high amount of drug (up to 10% 
drug loading). Additionally, the drug release mechanism was investigated by mathematical 
 
Figure 4-11 Effect of drug loading percentages on the viability of cancer cells. 
 
Figure 4-12 Effect of drug loading technique on viability of lung cancer cells. 
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curve fitting to different drug release kinetics models. In most cases Peppas model showed 
good correlations with the examined release profiles with estimated release indices less than 
0.5. In case of drugs with limited aqueous solubility or at high polymer concentrations, Peppas 
model failed to fit the entire release curve. Therefore, estimation of the Weibull parameters can 
provide an insight into the drug release mechanism. 
Our designed polymeric magnetic nano-aggregates were verified to be more efficient for 
encapsulation of both hydrophilic and hydrophobic drugs relative to poly (alkylcyanoacrylates) 
which are the most investigated polymers in the development of 5-fluorouracil magnetic nano-
carriers. The nano-aggregates that we proposed are advantageous by their facile and organic 
solvent free method of preparation and lack of toxic degradation products which comes from 
polymeric degradation. In addition, these nano-aggregates exhibited super-paramagnetic 
properties at approximately body temperature. In terms of the development of drug carrier 
system, the post-synthesis drug loading of both progesterone and 5-fluorouracil showed better 
drug loading results than in-situ loading method. Our nano-aggregates were easily loaded with 
progesterone and 5-fluorouracil. Both the polymer composition and the initial drug 
concentration were found to play the most effective role in drug loading and release kinetics. 
The drug release mechanism was found to be controlled by diffusion. The release profile was 
sustained for 14 days with considerable release of both drugs within the first few hours. The 
kinetics of drug release (release rate and indices) was mainly controlled by the type of drug 
incorporation and the amount of drug loaded. Modified Peppas model with an initial burst 
effect can provide better understanding of the drug release mechanism for the samples loaded 
with progesterone or at high polymer concentrations. The burst effect could be advantageous 
for drugs that show considerable lag time between the dose administration and therapeutic 
effect. In addition, we studied the cytotoxic effect of 5-fluouracil loaded magnetic nano-
aggregates on the viability of A549 lung cancer cells. The cell viability was determined in 
relation to different percentages of drug loadings. Both in-situ loaded and freeze dried 
magnetic nano-aggregates inhibited the proliferation of lung cancer cells. The cytotoxic effect 
was significantly affected by different polymer concentrations in a dose dependent manner. 
These results highlight the biological applicability of our synthesized magnetic nano-
aggregates as carriers for anticancer drugs. Further examination for the pulmonary deposition 
of our proposed nano-aggregates is being investigating. 
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Appendix 4A 
 
4A.1 Methodology of quantitative drug measurement 
 
4A.1.1 HPLC assay of 5-fluorouracil 
5-Fluorouracil was quantified by high performance liquid chromatography (HPLC). A Varian 
HPLC system (Varian ProStar 230, USA) with RP C-18 column (250 mm x 4.6 mm, particle 
size 5µm) and variable wavelength UV / Vis detector was used.  A mixture of methanol and 
sodium acetate buffer (pH = 4.0) was used as a mobile phase. The eluent was detected by UV 
detector at 260 nm.  
 
4A.1.2 UV spectrophotometric assay of progesterone 
Quantitative determination of progesterone was performed using UV spectrophotomeric 
method at wavelength 254 nm (Cary UV / Visible spectrophotometer, USA).  
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Figure 4A-1 Drug release profiles of 5-fluorouracil nano-aggregates prepared by 
in-situ loading method (a). The corresponding calculated release rate, regression 
coefficient and release index (b). 
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Figure 4A-2 Effect of particle size and loading procedures on the release profile of 5-
fluorouracil loaded nano-aggregates at constant percentage of drug loading (a). The 
corresponding calculated release rate, regression coefficient and release index (b). 
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Figure 4A-3 Modified Peppas model equation for prediction of initial burst effect of 
progesterone loaded nano-aggregates prepared at 0% Beta cyclodextrin. 
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Figure 4A-4 Modified Peppas model equation for prediction of initial burst effect of 
progesterone loaded nano-aggregates sample prepared at 0% (a) and 25% (b) Beta 
cyclodextrin. 
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Table 4A-1 Mathematical models describing release rate of 5-fluorouracil and 
progesterone from the hollow nano-aggregates. 
Model Equation 
Zero order  
First order 
 
Hixson-Crowell 
 
Higuchi  
Peppas  
Modified Peppas  
Weibull  
Lonsdale and Baker  
 
 
 
where C is the concentration of drug released, 𝐶  is the initial concentration of drug, K 
is the release rate constant in units of concentration / time, Q is the amount of drug 
released in time t, Q0 is the initial amount of drug loaded into the nano-aggregates and 
the release index is symbolized as n.  
Table 4A-2 Effect of drug loading on the estimated release rates and release indices 
according to Peppas model equation. 
 
Drug loading 
Release rate constant 
(K, day
-1
) 
Regression coefficient 
(R
2
) 
Release index 
(n) 
9% 5-fluorourcil 40.43 ± 0.47 0.97 0.075 ± 0.005 
9.5 % 5-fluorourcil 35.29 ± 0.39 0.92 0.069 ± 0.002 
10%  5-fluorourcil 32.76 ± 0.32 0.98 0.071 ± 0.004 
The samples are all loaded by in-situ method. 
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Table 4A-3 Effect of beta cyclodextrin mass fraction on the release parameters of 
progesterone and 5-fluorouracil freeze dried loaded samples. 
 
Drug loading 
Release rate constant 
(K, day
-1
) 
Regression coefficient 
(R
2
) 
Release index 
(n) 
Progesterone, 0% Beta 
cyclodextrin 
64.08 ± 0.14 0.92 0.14 ± 0.01 
Progesterone, 5 % Beta 
cyclodextrin 
67.67 ± 1.72 0.83 0.07 ± 0.01 
Progesterone, 15%  Beta 
cyclodextrin 
65.94 ± 0.05 0.78 0.05 ± 0.01 
Progesterone, 25% Beta 
cyclodextrin 
61.76 ± 1.42 0.70 0.03 ± 0.01 
5-Fluorouracil, 0% Beta 
cyclodextrin 
66.22 ± 2.94 0.91 0.18 ± 0.02 
5-Fluorouracil,  5 % Beta 
cyclodextrin 
44.29 ± 1.81 0.93 0.19 ± 0.02 
5-Fluorouracil, 15%  Beta 
cyclodextrin 
39.13 ± 1.34 0.95 0.21 ± 0.01 
5-Fluorouracil, 25% Beta 
cyclodextrin 
33.13 ± 1.18 0.94 0.17 ± 0.02 
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Table 4A-4 Results for the curve fitting parameters of different model functions for 5-
fluorouracil release profiles. 
 
 
Model function 
 
% 5-FU 
loading 
Release rate 
constant 
(K, day
-1
) 
 
Regression 
coefficient 
(R
2
) 
Release index 
(n) 
Probability 
(P) 
Lonsdale 
model 
9% 5-FU 0.01 ± 0.002 0.01 -- 0.003 
Peppas model 9% 5-FU 40.43 ± 0.47 0.97 0.075 ± 0.005 < 0.001 
Hixson model 9% 5-FU 0.02 ± 0.004 0.03 -- < 0.001 
Higuchi model 9% 5-FU 16.82 ± 1.71 0.01 -- < 0.001 
First order 
model 
 
9% 5-FU 0.08 ± 0.02 0.02 -- < 0.001 
Lonsdale 
model 
9.5% 5-FU 
0.004 ± 
0.0001 
0.79 -- < 0.001 
Peppas model 9.5% 5-FU 35.29 ± 0.39 0.92 0.069 ± 0.002 < 0.001 
Hixson model 9.5% 5-FU 0.02 ± 0.003 0.03 -- < 0.001 
Higuchi model 9.5% 5-FU 14.67 ± 1.42 0.09 -- < 0.001 
First order 
model 
 
9.5% 5-FU 0.06 ± 0.01 0.02 -- < 0.001 
Lonsdale 
model 
10% 5-FU 0.04 ± 0.01 0.01 -- 0.004 
Peppas model 10% 5-FU 32.76 ± 0.32 0.98 0.071 ± 0.004 < 0.001 
Hixson model 10% 5-FU 0.02 ± 0.002 0.03 -- < 0.001 
Higuchi model 10% 5-FU 13.48 ± 1.41 0.01 -- < 0.001 
First order 
model 
 
10% 5-FU 0.06 ± 0.01 0.02 -- < 0.001 
 
5-FU: 5-Fluorouracil 
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CHAPTER 5 
5 CUBIC MAGNETICALLY GUIDED NANO-AGGREGATES 
FOR INHALABLE DRUG DELIVERY: IN-VITRO MAGNETIC 
AEROSOL DEPOSITION STUDY 
Abstract 
The present work describes the in-vitro aerosol deposition and enhanced deaggregation 
behavior of superparamagnetic iron oxide nano-aggregates (SPIONs). SPIONs were surface 
coated with amine functionalized polyrotaxane and were proposed as a carrier for inhalation 
dry powders. Polyrotaxane is primarily composed of beta cyclodextrin rings which are 
spontaneously threaded on the block copolymer, poly (propylene glycol) bis (2-
aminopropylether). Variable concentrations of surface coating polymers showed controlled 
manipulation of the crystal size and morphology. Magnetic nano-aggregates fabricated with 
low concentration of polyrotaxane showed cubic crystal morphology. However, these nano-
aggregates exhibited rhombic dodecahedron crystal structure upon increasing the coating 
polymer concentration. In comparison to the spherical uncoated magnetic nanoparticles, cubic 
phase magnetic nano-aggregates demonstrated an enhanced in-vitro aerosol deposition using 
magnetic field alignment. This enhancement can be accomplished at low inhalation flow rates 
(15 and 30 L/min). However, transformation to the cubic crystal structure was observed to be 
associated with a reduction in the powder geometric standard deviation (GSD). Using a 
mathematical modeling approach, we noted significant enhancement in the deaggregation 
behavior of inhalation dry powders; that can be achieved with small amounts of magnetic 
nano-aggregates.  Aggregates of cubic nanoparticles showed promise for targeted pulmonary 
deposition of anticancer drugs.   
Keywords: Magnetic next generation impinge; Magnetic nano-aggregates; In-vitro aerosol 
deposition; Saturation magnetization; Polyrotaxane. 
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 Introduction 5.1
Polymeric nanoparticles have been successfully applied for pulmonary delivery of both 
local and systemic drugs 
1
. The respiratory route is particularly advantageous due to the large 
alveolar surface area, the low thickness of the epithelial barrier as well as the extensive 
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vascular properties 
2
. With the recent development of nanotechnology, aerosols composed of 
magnetic nanoparticles showed several attractive properties for application in respiratory drug 
delivery 
3,4
. Magnetic nanoparticles have been applied in waste water treatment 
5
. Presently, 
magnetic nanoparticles have gained increasing attention in biomedical applications such as 
magnetic resonance imaging (MRI) 
5,6,7
, virus detection 
8,9
, magnetic cell separation
10
, gene 
therapy 
11
, targeting chemotherapy  
12
 and pulmonary drug delivery  
3,6
.  
A major challenge in pulmonary drug delivery is the low efficiency of the inhalation system. 
Optimum particle size is very important for deep lung delivery 
13
.  Therefore, large doses of 
drugs need to be administered to achieve the effective drug concentration at the specific site of 
action. Current efforts are focused on developing magnetic nanoparticles that can be directed to 
a specific location of the pulmonary tract. These nanoparticles are responsive to an external 
thermal stimulus, i.e. the heating effect associated by alternating an external magnetic field 
14
. 
Given the limited knowledge of selective cancer biomarkers, specific cell targeting can be 
managed through conjugation of magnetic nanoparticles with a specific ligand 
4,
 
15,
 
16
.  
Magnetic nanoparticles need to be stable in water at neutral pH (7.4) and normal saline 
condition (150 mmol) for biological, medical diagnostic and therapeutic applications. Thus, the 
surface of magnetic iron oxide cores needs to be modified to prevent the formation of large 
aggregates and provide functional groups (amine or carboxylic groups) for bio-conjugation to 
anticancer drugs and / or targeted ligands. Various surface coatings have been reported 
previously, such as liposomes 
17,18
, polyethylene glycol (PEG) 
19
 and other polymers 
20
. In the 
case of the surface coating with another material, this technique leads to the formation of 
“hybrid nanostructure” 21. 
Magnetic nanoparticles coated with polyethylene glycols (PEGs) and beta cyclodextrin have 
been reported to improve the drug loading and release kinetics of hydrophobic drugs 
22
, 
increase the specific cancer targeting, and enhance permeability and retention effects 
23-24
.  
Harada and coworkers have reported the complex formation between polypropylene glycol and 
beta cyclodextrin 
25
. The proposed structure for these complexes is that the beta cyclodextrin 
rings are spontaneously threaded onto polypropylene glycol chains in either a head-to-head or 
tail-to-tail arrangements without any covalent bonding between the two polymers (beta 
cyclodextrin and polypropylene glycol). In the current study, we proposed a modified method 
for the synthesis of amine functionalized polyrotaxane through the formation of beta 
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cyclodextrin/ poly (propylene glycol) bis (2-aminopropylether) inclusion complex. Introducing 
an amino- functional group into the structure of polyrotaxane leads to the formation of highly 
functional and biocompatible hybrid nanostructures. These magnetic nanostructures possess an 
enhanced localization of anticancer loaded nanoparticles into the lung cancer cells. Therefore, 
they are promising materials for use in the treatment of lung cancer 
26
.   
The present study deals with amine functionalized polyrotaxane / iron oxide hybrid aggregates 
for pulmonary drug delivery. These hybrid nanostructures composed of magnetic iron oxide 
cores and polyrotaxane (PR) shells (Fe3O4 aggregates / PR). Magnetic nanoparticles coated 
with polyethylene block copolymers possess the ability to circulate for longer time in the blood 
stream by avoiding the uptake by the reticulo-endothelial system (RES) 
27, 28
. The influence of 
the magnetic field on the systemic absorption and clearance of magnetic nanoparticles was 
previously reported 
29,30
. The magnetic field application resulted in considerable enrichment of 
therapeutic agent in the lungs, and a depletion in the liver of the magnetic carrier compared to a 
reference without a magnetic field 
29
. 
However, the application of an external magnetic field did not change the accumulation of 
magnetic nanoparticles in the lung following their intravenous injection. Therefore, pulmonary 
delivery of magnetic nanoparticles showed promise for an enhanced therapeutic effectiveness 
30
.  
In the current research we investigated the in-vitro aerosol deposition of magnetic aggregates 
loaded for the potential aerosol delivery of anticancer drugs. The aerosol deposition was 
assessed with the application of an external magnetic field. The influence of variable 
concentration of poly (propylene glycol) bis (2-aminopropylether), PPG-NH2, showed 
significant effect on the particle shape. In addition, we investigated the aerosolization behavior 
of magnetic aggregates exposed to an external magnetic field with field strength of 1 Tesla. 
This study was conducted using a modified next generation magnetic setup. To the best of our 
knowledge, there is no previous study dealing with the utilization of magnetic next generation 
impinger (mNGI) in measurement of the aerodynamic diameter. However, a previous study 
conducted on the in-vitro deposition of magnetic particles in a simulated lung model 
31
. 
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 Materials and methods 5.2
5.2.1 Materials 
The following materials were used: FeSO4.7H2O [VWR, Mississauga, ON, Canada], poly 
(propylene glycol) bis (2-aminopropylether) [average molecular weight, Mn, 230,  Sigma-
Aldrich Ltd, Oakville, ON, Canada] beta cyclodextrin [molecular weight 1135 Da, Sigma-
Aldrich Ltd, Oakville, ON, Canada], tetra hydrofuran [Sigma-Aldrich Ltd, Oakville, ON, 
Canada], ethanol and ammonium hydroxide [VWR, Mississauga, ON, Canada].  
5.2.2 Synthesis of magnetic nanoparticles 
5.2.2.1  Spherical magnetic nanoparticles (Fe3O4)  
Spherical magnetic nanoparticles were prepared by chemical precipitation of (ferrous sulfate 
hepta hydrate, FeSO4.7H2O) 
22,
 
32
. The prepared nanoparticles showed a relatively wider size 
distribution than the polymer coated formulae (polydispersity index = 0.39). Results for the 
polydispersity indices are presented in Table 5-1.  
Table 5-1 Influence of PPG-NH2, Poly (propylene glycol) bis (2-aminopropylether), 
concentration on the estimated TEM and XRD particles’ diameters, and on the MMAD 
(measured by the magnetic next generation impinger). 
 
PPG-NH2 
concentration  
(mg/100 mg 
nanoparticles) 
TEM Particle 
diameter 
(nm ± RSD) 
Polydispersity 
 index 
XRD particle 
diameter 
(nm) 
Nano-
aggregates 
MMAD at 60 
L/min 
(µm ± GSD ) 
0 92.54 ± 10.11 0.39 106.48 3.52 ± 1.80 
50 75.50 ± 7.55 0.29 63.74 3.37 ± 1.48 
100 60.60 ±  7.58 0.12 55.66 2.97 ± 1.41 
150 53.30 ±  7.19 0.24 52.25 2.44 ± 1.53 
200 26.50  ± 3.71 0.19 26.28 2.06 ± 1.32 
250 18.70  ± 2.06 0.14 23.90 1.89 ± 1.25 
300 17.79  ± 2.31 0.08 17.99 1.79 ± 1.20 
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5.2.2.2  PPG-NH2 coated magnetic nanoparticles 
PPG-NH2 surface modified magnetic nanoparticles were prepared by mixing a predetermined 
amount of iron precursor with the amine functionalized poly (propylene glycol) block 
copolymer (PPG-NH2).  
5.2.2.3  Synthesis of amine functionalized polyrotaxane 
The synthesis of polyrotaxane inclusion complex was previously reported by Harada et al. 
25
. 
The modification we introduced to the synthesis was the inclusion of amine functionalized poly 
(propylene glycol) block copolymer into the cavity of beta cyclodextrin. The detailed synthetic 
method and the molar ratios of both polymers are provided in Appendix A. The chemical 
structure of the prepared inclusion complex is presented in Scheme 5-1.  
 
Scheme  5-1 Chemical structure polyrotaxane inclusion complex showing two beta 
cyclodextrin molecules threaded onto Poly (propylene glycol) bis (2-aminopropylether). 
 
5.2.2.4  Polyrotaxane coated magnetic nanoparticles  
In these samples, the amounts of amine functionalized polyrotaxane were varied from 50 to 
300 mg / 100 mg of nanoparticles. Increasing the inclusion complex concentration resulted in 
morphological transformation of magnetic nanoparticles from cubic to rhombic dodecahedron 
crystals.  
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5.2.3 Characterization of magnetic aggregates 
5.2.3.1  Particle size and morphology 
Magnetic nanoparticles size and morphology were evaluated using Transmission Electron 
Microscope (TEM) (Hitachi High-Technologies GmbH, Krefeld, Germany). The morphology 
of particles was also examined using scanning electron microscopy, with a scanning electron 
600F model microscope (Jeol Ltd, Tokyo, Japan). The samples were prepared on aluminum 
stabs and coated with gold prior to the examination. 
5.2.3.2 X-ray diffraction 
X-ray diffractometer (Rigaku-Miniflex, The Woodlands, Texas, USA) was utilized for 
examination of the crystal profile of loaded and unloaded samples. The samples were exposed 
to X-ray radiation (Cu K α, 40 KV, 20 mA) at a wavelength of 1.54 Å. The samples were 
scanned over a 2-theta range between 15° to 70° and at a step size of 0.02°.  
5.2.3.3 Fourier transforms infrared spectroscopy (FTIR) 
FTIR spectra were in the solid state by Bruker-Vector 22 FTIR spectrophotometer (Bruker-
Vector, Milton, ON, Canada).  
5.2.3.4 Thermo-gravimetric analysis (TGA)   
Magnetic aggregates samples were examined using TGA-SDTA 851 instrument (Mettler 
Toledo, Mississauga, Canada). Samples (10 mg) were heated from 25 ºC to 600 ºC at a rate of 
20 ºC/min under continuous purge of nitrogen gas.  
5.2.3.5 Dynamic light scattering (DLS)  
Malvern DLS (Malvern Instruments Ltd., Worcestershire, United Kingdom) was utilized to 
examine the size of synthesized polymer-coated magnetic aggregates.  The polydispersity 
index as well as the mean volume diameter was examined. The obtained data represents the 
volume median diameters of nanoparticles (VMD). The corresponding aerodynamic diameter 
was theoretically calculated as follows:         
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𝐷𝑎 =   
𝜌
𝜌1
 𝑉𝑀𝐷 
 
Equation 5-1 
where ρ is the powder density and ρ1 = 1 g / cm
3
 
33
. The powder density was measured using a 
TAP-2S tap density tester (Logan Instruments CORP, Somerset, NJ, USA).  
5.2.4 In-vitro magnetic aerosol deposition  
 The purpose of these experiments was to investigate the in-vitro aerosol deposition of 
magnetic nanoparticles using a magnetic next generation impinger setup (mNGI) (Scheme 5-
2). The construction of the mNGI was modified based on the design outlined for the next 
generation impinger in previous publications 
34,35
. For each magnetic aggregates sample, the 
flow rate throughout the mNGI was varied between 15 and 100 L/min by the utilization of a 
calibrated flow meter (TSI 3063, TSI instruments Ltd., Buckinghamshire, UK). The magnetic 
field values were measured as a function of the calculated upper cut-off diameter on each stage 
of mNGI and at variable flow rates. The cut-off diameters for the mNGI at different inhalation 
flow rates are listed in Table 5A-1. The magnetic dry powders are delivered through a 
Handihaler
®
 (Boehringer Ingelheim Inc., Ridgefield, CT, USA).  
A preliminary experiment was conducted on a standard lactose sample (MMAD = 5 µm, GSD 
= 1.82) in order to evaluate the cut-off diameters for NGI and mNGI. The data examined for 
both impingers indicate similarity in MMAD and GSD for both impingers; which suggests that 
the modifications made to the NGI have not significantly affected its particle sizing 
capabilities. All modifications done to the NGI is the application of an external magnetic field; 
which has no effect on the function of the collection cups. The cumulative mass of particles 
deposited on each stage of mNGI was calculated and plotted as percentage of the total mass of 
powder exiting the inhaler device. The mass median aerodynamic diameter (MMAD) and the 
geometric standard deviation (GSD) were calculated for each sample based on the previously 
reported expressions 
33
.  
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5.2.5 Magnetic field and powder magnetization 
 The magnetic field at each stage of mNGI  was measured by a Gaussmeter (5180 Gaussmeter, 
Pacific-Scientific-OECO, Milwauki, OR, USA) and the powder magnetization values were 
measured using vibrating sample magnetometer (VSM, Model 74035, Lake Shore Cryotronics 
Inc., Westerville, OH, USA) at 300 ºK. The magnetic properties of aggregates samples were 
studied at field range of ± 10,000 gauss. 
5.2.6  Mathematical modeling of powder dispersion behavior 
For further monitoring of the extent of powder dispersion upon exposure to an increasing 
airflow rate, a deaggregation index was introduced. The deaggregation index was calculated by 
dividing the theoretically calculated Da by the experimentally measured MMAD 
33
. The change 
in the calculated deaggregation index as a function of the airflow rate was monitored. This 
 
Scheme  5-2  Schematic diagram of magnetic next generation impinger setup. 
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experiment was continued till complete powder dispersion was achieved; which can be 
confirmed by a plateau in the de-aggregation index-airflow rate profiles. In order to compare 
the dispersion behavior of different magnetic samples, the calculated de-aggregation index-
airflow rate profiles were mathematically fitted to the following 3-parameters sigmoid 
relationship (Equation 5-2). 
𝐷𝑒𝑎𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑖𝑜𝑛 𝑖𝑛𝑑𝑒𝑥 =  
𝐷𝑎
𝑀𝑀𝐴𝐷
=  
𝑎
1 + 𝑒−
 𝑥− 𝑥0 
𝑏  
 
 
Equation 5-2 
                                                                                                                                                                              
where, parameter (a) is the maximum de-aggregation index that can be achieved upon 
increasing the airflow rate to 100 L/min and  (x0) is the minimum airflow rate required to 
produce a de-aggregation index value equals to 0.5. The rate of dispersion process is presented 
by parameter (b), which is the difference between the two airflow rates required to achieve a 
de-aggregation index values equals to 0.75 and 0.25 
36
. In other words, the curve fitting 
parameters (a) and (b) represent the extent and rate of dispersion process, respectively.  
 Results 5.3
5.3.1  Characterization of aggregates 
5.3.1.1 TGA, DTGA and FTIR 
In this paper, we examined the effect of using PPG-NH2 or polyrotaxane on the morphological 
and crystal structure of magnetic nanoparticles. Recently, we reported the capability of these 
magnetic aggregates to encapsulate anticancer therapeutic agent (5-fluorouracil) 
22
. In the 
current study, magnetic aggregates were examined for their regional aerosol deposition using a 
magnetic next generation impinger (mNGI) setup.  
Primarily, we investigated the ability of PPG-NH2 and polyrotaxane to encapsulate Fe3O4 
magnetic nanoparticles. The FTIR (Figure 5-1) and TGA (Figure 5-2) profiles indicated the 
surface adsorption of PPG-NH2 and polyrotaxane on magnetic iron oxide nanoparticles. The 
first stage of weight loss occurred in the temperature range between 125 ºC and 225 ºC; which 
is attributed to the loss of water molecules. Significant weight loss was observed for the 
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polymer coated samples at a temperature above 225 ºC. Thermal decomposition happened 
gradually with a maximum temperature (Tmax) value of 245 ºC, and this could be referred to the 
decomposition of beta cyclodextrin residues. The observed temperature range for 
decomposition of polyrotaxanes is 225 º - 310 ºC; which is consistent with the reported values 
37
.  
The FTIR data verified the ability of both polymers to encapsulate magnetic nanoparticles at 
the examined concentrations (Figure 5-1). Surface modified polyrotaxane coated magnetic 
aggregates revealed a broad band in the range between 1000 and 1300 cm
-1
; this could be due 
to the stretching of the ether bond of beta cyclodextrin. In addition, some of these bands 
correspond to the vibrations of polypropylene oxide chains of PPG-NH2. The FTIR data of 
magnetic aggregates coated with amine functionalized polyrotaxane confirmed that magnetic 
nanoparticles were surrounded with PPG-NH2 and beta cyclodextrin polymers.  
 
Figure 5-1 FTIR spectra of uncoated magnetic core, beta cyclodextrin, Poly (propylene 
glycol) bis (2-aminopropylether) “PPG-NH2”, polyrotaxane inclusion complex and 
polyrotaxane coated magnetic aggregates. 
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Figure 5-2 TGA profile of polyrotaxane-coated magnetic aggregates and its first 
derivative plot. 
5.3.1.2  Particle size and morphology 
Addition of PPG-NH2 or polyrotaxane seemed to significantly affect the particle size and 
morphology. Increasing the concentration of both polymers resulted in a reduction in the 
particles’ geometric diameters (Table 5-1); which could be related to the content of Fe3O4 in 
the obtained aggregates. Upon screening the particle size, it was observed that all magnetic 
samples revealed a mono-disperse size distribution (Figure 5-3). The polydispersity index for 
PPG-NH2 coated magnetic aggregates ranged from 0.08 to 0.29. An exemplarily TEM image 
for spherical magnetic PPG-NH2 aggregates is presented in Figure 5A-1. In addition, magnetic 
aggregates coated with polyrotaxane presented a morphological transformation from spherical 
to cubic shape (Figure 5-4). The change in morphology could be referred to the rapid 
consumption of Fe3O4/polyrotaxane nuclei, due to the increased rate of crystal growth 
38,39
. 
Figure 5-5 demonstrates a comparative SEM image for the aggregates of spherical magnetic 
nanoparticles and those of cubic magnetic nanoparticles. As seen in the images, no significant 
difference is observed between both cases. XRD and estimation of {200}/{110} crystal plane 
ratio Comparing the XRD patterns of synthesized magnetic nanoparticles with the standard 
diffraction spectrum (Aldrich catalogue: 31,006-9), revealed that the synthesized products 
showed a crystalline Fe3O4. The five characteristic peaks for Fe3O4 were found at 2-theta 
angles of 30.95º, 35.89º, 44.34º, 55.06º and 64.51º. These five peaks correspond to the 
131 
 
 
 
diffraction from the 110, 200, 211, 220, 310, 311 planes of face centered cubic iron oxide 
crystals. Results for the nanoparticles size data computed by Scherrer’s equation 40 are 
summarized in Table 5-1. Addition of PPG-NH2 or polyrotaxane was usually associated by 
more organized nanostructures.   
 
Figure 5-3 Raw data for particle size measurements. 
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The XRD patterns of magnetic aggregates with different crystal morphologies are shown in 
Figure 5-6.  
 
 
Figure 5-4 FESEM images showing the difference in particles’ morphology. (a) PPG-
NH2-coated spherical, (b) cubic and (c) rhombic dodecahedron-polyrotaxane-coated 
magnetic aggregates of nanoparticles. 
 
 
Figure 5-5 SEM images of aggregates of spherical magnetic nanoparticles (A) and aggregates of cubic 
magnetic nanoparticles (B). 
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Figure 5-6 XRD patterns of magnetic nano-aggregates coated with different surface 
coatings (A) and the predicted crystal morphologies for different magnetic aggregates 
(B). 
The calculated {200}/{110} diffraction planes ratio helped in estimation of the magnetic 
crystal structure. For PPG-NH2 coated-magnetic aggregates, the diffraction planes ratios are 
generally less than 0.5; which confirms the observed spherical morphology. However, 
polyrotaxane-coated aggregates demonstrated higher crystal plane ratios; which indicates 
transformation in the crystal morphology from cubic to dodecahedron.  
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5.3.2 Saturation magnetization of aggregates as measured with 
vibrating sample magnetometer (VSM) 
The relation between the induced moment of magnetic samples and the applied magnetic field 
is presented in Figure 5-7. The measured saturation magnetization value was 0.32emu/g. This 
saturation magnetization value was much smaller than the literature value for magnetite 
4,20
; 
which could be attributed to the smaller size of magnetic nanoparticles or the surface oxidation 
of magnetite at the surface of nanoparticles. Polyrotaxane-coated samples showed a saturation 
magnetization value 3.56 emu/g; which could be referred to the surface coverage of aggregates 
with polyrotaxane inclusion complex.   
 
Figure 5-7 Hysteresis loop for uncoated spherical magnetic nanoparticles of magnetite 
(Fe3O4). 
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5.3.3  Selection of a dry powder inhaler device for magnetic 
aerosol delivery 
The selection of an inhaler device for delivery of magnetic aggregates was based on 
preliminary experiments conducted using two proposed inhaler devices; the Handihaler
®
 and 
Aerolizer
®
. The internal geometries for both devices are demonstrated in Figure 5-8. Based on 
our observations, the Handihaler
®
 demonstrated better dispersion and less capsule and device 
retention. This could be attributed to the different mechanisms of operation of both inhaler 
devices 
41
. The Handihaler
®
 exihibits different mechanism of operation; which showed impact 
on the FPF (fine particle fraction) and ED (emitted dose).  
In case of the Aerolizer
®
, the airflow enters the inhaler device through the two opposite 
tangential inlets of the capsule chamber. The turbulent airflow is the only major factor that 
assists in capsule ejection. However in the case of the Handihaler
®
, the air stream passes 
through a single inlet in the inhaler device and then the inhalation flow stream is suddenly 
expanded as it passes through the capsule chamber. The sudden opening during the air passage 
from the inlet to capsule chamber resulted in a pressure loss in this region associated with an 
annular circulation of air. The incoming flow of air pushes the capsule towards the grid 
simultaneously with the low-pressure regions that are continuously attracting the capsule 
towards the grid. The alternating attraction and pushing causes the capsule to spin and vibrate 
in the chamber. For this reason, better capsule evacuation is obtained in case of the 
Handihaler
®
.   
5.3.4  Application of magnetic next generation impinger for 
estimation of aerosol deposition characteristics 
The deposition of coated magnetic aerosol particles in an in-vitro lung model has been reported 
by Xie et al. 
31
. In the current study, the aerosolization performance of magnetic aggregates 
was examined using a magnetic next generation setup (Scheme 5-1).  
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Figure 5-8 Images and schematic views of the two examined dry powder 
inhalation devices; Handihaler
®
 (A) and Aerolizer
®
 (B).  
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A preliminary experiment on a standard sample (MMAD = 5 µm, GSD = 1.83) was conducted 
in both NGI 
42
 and mNGI in order to validate the cut-off diameters for each stage of magnetic 
setup. The results obtained indicate similarity in MMAD and GSD values measured in both 
devices; which suggests that the modifications made to NGI have not significantly affected its 
particle sizing capabilities.  
Different samples were examined for their magnetic aerosol deposition at variable flow rates. 
The dependence of magnetic field on the position of the permanent magnet (1 Tesla) is 
presented in Figure 5-9. Generally, the magnetic field showed a two fold increase on increasing 
the inhalation flow rate from 15 to 100 L/min. At 60 L/min, the average magnetic field at 
mNGI stages 1 (cut-off diameter higher than 4.46 µm) was 0.088 Tesla. In comparison, at cut-
off diameter less than 4.46 µm, the average magnetic field approximately increased from 0.22 
to 0.731 Tesla upon moving from stage 2 to stage 7.    
The aerosol deposition performance of polymer-coated magnetic aggregates was presented in 
Figures 5-10, 5-11 and 5-12. In these figures, the fractional mass deposition of nanoparticles 
was plotted versus the upper cut-off diameter of each impinger stage. The aerosol deposition 
performance for each sample was qualified based on calculation of two parameters; the fine 
particle dose (FPD) and the fine particle fraction (FPF). 
5.3.5 Effect of flow rate on magnetic aerosol deposition 
Generally, the samples coated with PPG-NH2 showed a unimodal particle size distribution 
(Figures 5-10 and 5-11). However, polyrotaxane-coated samples induced bimodality in the size 
distribution profile (Figure 5-12). The observed bimodality for the polyrotaxane coated 
samples (from 50 to 150 mg polyrotaxane /100 mg nanoparticles) reflects greater fraction of 
aggregates for these samples; which is diminished upon increasing the coating polymer 
concentration. 
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Figure 5-9 Effect of airflow rate on the measured magnetic field values on each stage of 
magnetic next generation impinger (mNGI). 
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Figure 5-10 Effect of Poly (propylene glycol) bis (2-aminopropylether), PPG-NH2, on the 
percentage aerosol deposition on mNGI. The mass deposition on each stage was measured 
at 15 L/min (A), 30 L/min (B) and 60 L/min (C). 
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Figure 5-11 Magnetic in-vitro aerosol deposition of magnetic aggregates coated with 
higher concentrations of Poly (propylene glycol) bis (2-aminopropylether) “PPG-NH2” 
and measured at 60 L/min. 
 
The inhalation flow rate seemed to have significant impact on magnetic aerosol deposition 
(Figure 5-11). This effect could be attributed to the improved dispersion behavior as a result of 
the increased turbulence and decreased capsule and device retention. PPG-NH2-coated samples 
showed major aerosol deposition between stage 1 and 4; which suggests poor dispersion 
behavior for the aggregates. The calculated MMAD values for PPG-NH2- and polyrotaxane-
coated magnetic nanoparticles are listed in Tables 5-1 and 5-2, respectively. These values 
indicate the dual dependence of magnetic aerosol deposition on the inhalation flow rate and 
crystal morphology.  
5.3.6  Effect of polymer concentration on the calculated FPF 
and ED 
The increase in the FPF was significant between 15 and 30 L/min for both spherical and cubic 
aggregates, where an increase in the FPF from 36.28% to 43.39% and from 54.57% to 67.10% 
was observed for the 50 mg and 150 mg PPG-NH2 coated samples, respectively (Table 5-3).  
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Figure 5-12 Bimodal (A) and unimodal (B) in-vitro aerosol deposition of polyrotaxane-
coated magnetic aggregates measured at 60 L/min. 
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Table 5-3 Percentages fine particle fraction and emitted dose of different PPG-NH2, Poly 
(propylene glycol) bis (2-aminopropylether), coated magnetic aggregates measured in 
magnetic next generation impinger. 
 
PPG-NH2 concentration 
(mg) 
Percentage 
fine particle fraction 
(FPF, %) 
60 L/min 
Percentage 
emitted dose 
(ED, %) 
60 L/min 
0 35.88 40.32 
50 49.98 51.99 
100 59.4 60.35 
150 69.67 70.78 
200 64.97 65.95 
250 52.98 53.21 
300 44.99 45.56 
 
To the author’s knowledge, no comparative data exists for magnetic aggregates. The same 
observation obtained upon increasing the flow rate from 30 to 60 L/min (Table 5A-2). A 
further increase in inhalation flow rate from 60 to 100 L/min shows no significant effect on the 
FPF of magnetic samples. Nevertheless, a significant reduction in the percentage emitted dose 
Table 5-2  Effect of Polyrotaxane concentration and airflow rate on the calculated 
mass median aerodynamic diameter (MMAD) of magnetic aggregates. 
Polyrotaxane 
concentration  
(mg / 100 mg 
nanoparticles) 
Nano-
aggregates 
MMAD 
(µm ± GSD) 
15  
(L/min) 
Nano-
aggregates 
MMAD 
(µm ± GSD) 
30 
(L/min) 
Nano-
aggregates 
MMAD 
(µm ± GSD) 
60 
(L/min) 
Nano-
aggregates 
MMAD 
(µm ± GSD) 
100 
(L/min) 
    
0 1.79 ± 1.20 1.15 ± 1.24 0.78 ± 1.26 0.59 ± 1.29 
50 1.51 ± 1.31 0.94 ± 1.37 0.63 ± 1.41 0.46 ± 1.45 
100 1.35 ± 1.11 0.82 ± 1.14 0.55 ± 1.16 0.40 ± 1.17 
150 1.27 ± 1.15 0.76 ± 1.20 0.50 ± 1.23 0.36 ± 1.25 
200 1.21 ±1.13 0.71 ± 1.17 0.46 ± 1.19 0.33 ± 1.21 
250 1.16 ± 1.10 0.67 ± 1.14 0.44 ±1.15 0.31 ± 1.16 
300 1.09 ± 1.14 0.62 ± 1.19 0.40 ± 1.21 0.28 ± 1.22 
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was observed for the sample coated with 300 mg of PPG-NH2 (Table 5-3). This could be 
attributed to the reduction in the Fe3O4 content as compared to the polymer; which resulted in 
less magnetic collection.  
The magnetic formulation coated with 100 mg PPG-NH2/ 100 mg nanoparticles showed a 
polydispersity index of 0.12 (Table 5-1); which is reflected on the FPF (fine particle fraction) 
and ED (emitted dose). The calculated MMAD for this sample is 2.97 µm and the GSD is 1.41. 
The decreased value of the polydispersity index is only reflected on the GSD; which means 
lower deposition of particles in stage 1 and 2 of NGI. This can be reflected in lowering the 
mouth and throat deposition of inhaled powders following their in vivo administration. 
However, the sample coated with 250 mg of PPG-NH2 showed a comparable value of 
polydispersity index and a greater deep aerosol deposition (indicated by the lower value of 
MMAD). This is because the aerosol deposition is a complex function of the particle size and 
size distribution profile. 
5.3.7 Dependence of magnetic aerosol deposition on individual 
particle’s magnetization  
The individual particle’s magnetization was calculated based on the experimentally measured 
saturation magnetization data and the mass distribution profiles determined using mNGI 
(Figure 5-13). The dependence of particles’ saturation magnetization on their diameters was 
previously reported 
43,44
. The magnetic moment distribution per each particle was calculated 
and plotted versus the cut-off diameter of mNGI and presented in Figures (5-14, 5-15 and 5-
16). Our results are in agreement with the previously validated data 
44
. The magnetic moment 
followed an exponential distribution as a function of the upper cut-off diameters of mNGI (R
2
 
= 0.9974).  Increasing the saturation magnetization of magnetic aggregates samples from 0.32 
emu / g to 1.16 emu / g resulted in a shift in the saturation magnetization distribution, primarily 
towards the lower stages of impinger. This shift could be attributed in the increased retention 
by the magnetic field (1 Tesla) in the stages with cut-off diameters < 4.46 µm.  
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Figure 5-13 The influence of airflow rate on the distribution of saturation 
magnetization per each stage of mNGI for magnetic aggregates samples coated 
with variable amounts of PPG-NH2 / 100 mg nanoparticles. 
 
These results suggest better deposition in the lower stages of impinger upon increasing the 
magnetization of the prepared magnetic samples.   
Interestingly, a shift in the mass magnetization distribution profile towards the upper stages of 
mNGI was observed for the sample prepared with 1.51 µm MMAD and 1.21 GSD (measured 
at 15 L.min
-1
). This shift could be attributed to the higher particle magnetization which may 
lead to an increased particles’ aggregation. An increase in the inhalation flow rate from 15 
L.min
-1 
to 30 L.min
-1 
resulted in a change in the magnetization distribution profile showing an 
increased positive slope with the upper cut-off diameter of mNGI. Further increase in the 
inhalation flow rate from 30 L.min
-1 
to 60 L.min
-1
 resulted in a significant shift in the 
magnetization profile towards the upper stages of the impinger. This could be primarily 
attributed to the reduced exposure time to the magnetic field gradient, as the inhalation flow 
rate increased. The results illustrated above indicate the direct proportionality between the 
individual particle magnetization and the amount of magnetic field applied (position of 
nanoparticles on different stages of mNGI relative to the magnet), when the particles’ MMAD 
is smaller than 3.37 µm.  
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Figure 5-14 The influence of airflow rate on the magnetization per particle (emu/particle) 
measured in mNGI at 15 L/min (A), 30 L/min (B) and 60 L/min (C) for magnetic 
aggregates coated with variable amounts of PPG-NH2 / 100 mg nanoparticles. 
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Figure 5-15 Exponential increase in particle’s magnetization upon moving towards the 
mNGI stages with higher cut-off diameter. This exponential profile is valid only for 
samples with MMAD less than 3 microns. 
5.3.8  Mathematical modeling of the dispersion process  
A powder deaggregation index was proposed and calculated by dividing the geometric 
diameter of powder aggregates (measured by the dynamic light scattering technique) by the 
MMAD (estimated from the magnetic aerosol deposition data). Thereafter, a flow rate titration 
was performed for the calculated deaggregation index. The deaggregation index-flow rate 
curves showed a sigmoid profile; which can be perfectly fit to Equation 5-2.The calculated 
kinetics parameters for polyrotaxane coated samples are presented in Table 5-4. The efficiency 
of the dispersion process was expressed as parameter (a) in Equation 5-2. The calculated values 
for parameter (a) ranged between 0.13 and 0.32 for the samples coated with PPG-NH2 (in the 
concentration range from 50 to 150 mg / 100 mg nanoparticles); which indicates incomplete 
powder dispersion by the inhaler device. Significant increase in parameter (a) values was 
detected for the samples coated with high concentrations of PPG-NH2 (more than 150 mg / 100 
mg nanoparticles) and polyrotaxane (in the concentration range from 50 to 300 mg / 100 mg 
nanoparticles). The reduction in parameter (a) values indicates the ability of the inhaler device 
together with the applied magnetic field to approximately achieve complete powder dispersion 
of the aggregates into primary particles.  
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The rate and extent of the dispersion process was expressed by parameters (b) and (x0), 
respectively. The presence of coating polymer on the surface of magnetic nanoparticles affects 
the force required to break up the aggregates into primary particles; which consequently affects 
the rate of dispersion process. Polyrotaxane coated magnetic aggregates showed better 
dispersion behavior; which is indicated by the higher values of parameter (b). The highest 
dispersion was observed for the sample coated with 300 mg of polyrotaxane / 100 mg 
nanoparticles with a parameter (a) value of 0.98 and parameter b value of 27.59.  A reduced 
parameter (b) value indicates the possibility of powder dispersion at relatively lower airflow 
rates. TEM images showing the dispersion process as a function of airflow rate were presented 
in Figure 5A-2. 
Table 5-4 The estimated parameters for the mathematical curve fitting of deaggregation 
index-airflow rate profiles for polyrotaxane coated magnetic aggregates compared to the 
uncoated magnetic Fe3O4 nanoparticles. 
 
Polyrotaxane concentration 
mg / 100 mg nanoparticles 
a b x0 
0 0.14 33.44 34.31 
50 0.78 28.67 40.49 
100 0.77 27.59 42.15 
150 0.92 27.85 42.03 
200 0.92 27.14 42.45 
250 0.94 22.12 44.31 
300 0.98 18.68 45.07 
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Figure 5-16 The estimated particle’s magnetization for magnetic nano-aggregates prepared with variable 
amounts of polyrotaxane / 100 mg nanoparticles. The samples were examined using mNGI operated at 60 
L/min. 
 
 Discussion 5.4
The morphological change associated with the addition of polyrotaxane can be attributed to the 
increased rate of crystal growth. It is well known that, increasing the growth rate is always 
associated with a rapid consumption of small nuclei of Fe3O4 / PR. Therefore, the morphology 
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will be forced towards the cubic shape nanoparticles 
38,39
. Our results indicate a significant 
reduction in the particle size of cubic magnetic nanoparticles upon increasing the concentration 
of polyrotaxane (from 50 to 300 mg). This can be also confirmed by the peak broadening in the 
x-ray diffraction pattern (Figure 5-6). Results for the particle size distribution in mNGI 
suggests the dependence of in-vitro aerosol deposition on the applied inhalation flow rate; 
which is confirmed by previously reported studies 
45-46
. Therefore, we applied a flow rate 
titration for investigation of the kinetics of dispersion process. Measurement of the dispersion 
behavior of powders at a sequence of airflow rates was previously investigated 
36
. In the 
current study, we modified the method proposed in the literature 
36
 by estimating a novel 
deaggregation index based on the data obtained from the mNGI. Different samples can be 
compared based on the maximum extent of dispersion achieved at 100 L/min. Therefore, the 
estimated deaggregation indices can be seen as a valuable tool for the potential development of 
magnetic dry powders for inhalation.  
The change in the individual particle’s morphology is not reflected on the aggregates shape 
(Figure 5-5), it only affects the deaggregation behavior upon exposure to an airflow stream. 
Based to our knowledge, the shape of aggregates has an impact on their aerodynamic drag 
forces and considerably affects their entrainment in air stream. Previous mathematical studies 
were conducted to describe the effect of drag forces on the local aerosol deposition of 
nanoparticles 
31
. The transport and deposition equation of magnetic aerosols can be written: 
 
𝑑𝑣
𝑑𝑡
=  
𝑓
𝜏𝑝
  𝑢𝑖 −  𝑣𝑖   + 𝑔𝑖   1 −  𝛼 + 𝑓𝐵𝑟𝑜𝑤𝑛𝑖𝑎𝑛 ,𝑖 + 𝑓𝑀,𝑖  
 
Equation 5-3 
                                                                                                                                                                                
where, vi and ui are the components of the particle and local flow velocity, respectively. Ʈp is 
the characteristic time required for the particle to respond to changes in fluid motion. The local 
deposition of particles in a model respiratory tract is affected by gravitational forces (gi), 
Brownian motion (f Brownian) and drag factor (f). Based on the SEM imaging, we assumed that 
aggregates have similar shape. Nevertheless, evaluation of the aggregate geometries is needed 
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for the development of geometric shape factor that can be used in drag coefficient calculations; 
which is an interesting area of research for perspective studies.  
On the other hand, the variation in the dispersion process between cubic and spherical 
nanoparticles could be connected to the different fractal geometry of individual particles 
47
. 
The change in the geometric network structures results in variations in the work of adhesion 
between primary neighboring particles 
48
. Therefore, the airflow rate and magnetic field can 
influence the dispersion behavior of magnetic aggregates with different fractal geometries.  
 Conclusion 5.5
Variation of coating polymer concentrations can be regarded as a primary factor for controlling 
the particle size, shape and dispersion behavior of magnetic aggregates. The change in the 
particle size concurrently with the particle shape can suggest the moderate rate of thermal 
decomposition of iron precursor; thus giving sufficient time for the formation of aggregates. In 
the current study, we demonstrated the morphological transformation of polymeric coated 
magnetic aggregates from spherical to rhombic passing through the cubic crystal structure.  
In addition, we introduced a modified setup of the next generation impinger for investigating 
the in-vitro aerosol deposition of magnetic nanoparticles. The magnetic deposition of 
polymeric coated magnetic aggregates seemed to be complex and dependent on various 
interactive factors. Therefore, we investigated the dispersion profile of different aggregate 
samples and showed how it was affected by the magnetization value on each particle. 
Mathematical modeling of the in-vitro dispersion profile leads to better selection of the ideal 
formulation; which provides high deaggregation index at relatively low airflow rate.  
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Appendix 5A 
5A.1 Preparation of Spherical magnetic nanoparticles (uncoated magnetic 
core, Fe3O4)  
Spherical magnetic nanoparticles were prepared by chemical precipitation of (ferrous sulphate 
heptahydrate, FeSO4.7H2O). Magnetic nanoparticles were prepared with a single iron precursor 
in air atomsphere instead of two iron precursors (Fe
+2
 and Fe
+3
) with protective gas (nitrogen, 
N2, atomsphere). At a temperature of 90 ºC, magnetic nanoparticles black precipitate was 
obtained by slow addition of alkaline solution (NH4OH) with vigorous mixing in order to 
confirm uniform distribution of magnetite (Fe3O4).  
 
5A.2 Synthesis of PPG-NH2 coated magnetic nanoparticles 
PPG-NH2 surface modified magnetic nanoparticles were prepared by mixing the same amount 
of iron precursor (1.39 g of FeSO4.7H2O) and 50 mg of PPG-NH2. The mixture was 
magnetically stirred (400 r p m) for 30 min at 50 ºC. Ammonium hydroxide solution was then 
slowly added to the reaction mixture and the speed of mixing was increased to 1000 r p m. The 
reaction temperature was raised to 90 ºC with continuous mixing for 90 min. The obtained 
magnetic nanoparticles were washed several times with ethanol / water mixture and then dried 
under vacuum for overnight. Different samples of PPG-NH2 surface modified magnetic 
nanoparticles were prepared using different concentrations of PPG-NH2 (50 to 300 mg). 
 
5A.3 Synthesis of amine functionalized polyrotaxane [inclusion complex of 
amine functionalized block copolymer (PPG-NH2) and beta cyclodextrin 
(BCD)] 
A poly (propylene glycol) bi (2-aminopropylether) (PPG-NH2) was mixed with a saturated 
aqueous solution of BCD in the molar ratio of 1:8 (PPG-NH2: BCD). The mixture was 
sonicated for 10 min at room temperature and allowed to stand for 24 hours. The precipitated 
inclusion complex was then collected by centrifugation and freeze dried for overnight. 
Thereafter, washing of the dried product was performed with tetra hydro furan (THF) to give 
the PPG-NH2-BCD inclusion complex. 
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5A.4 Polyrotaxane coated magnetic nanoparticles (magnetic nanoparticles 
with variable morphological crystal structures) 
These formulations were prepared by mixing FeSO4.7H2O (1.39 g) and varying amounts of 
polyrotaxane inclusion complex (50 to 300 mg) in 50 ml distilled water. The concentrations of 
polyrotaxane were selected based on the morphological transformation of the obtained 
magnetic nano-aggregates.  
 
5A.5 Experimental set up for in-vitro aerosol deposition with permanent 
magnet 
The modification done to the mNGI was the attachment of a permanent magnet to the outside 
surface of the impinger (particularly to the stages corresponding to the lower respiratory tract). 
Control experiments were conducted in the same manner without the magnet. After assembling 
all stages of mNGI set up, the inhaler device was connected to the throat segment and being 
subjected to the predetermined flow rate for a time of 7 seconds. The percentage deposition on 
each stage of the impinger was computed as a function of the different coated nano-aggregates 
formulae. The USP throat piece and all stages of the impinger was rinsed with a known volume 
of solvent and assayed by UV spectrophotometry.  
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Figure 5A-1 TEM image of magnetic nano-aggregates coated with 300 mg 
of PPG-NH2 / 100 mg nanoparticles. 
 
  
 
Figure 5A -2 TEM image showing the effect of airflow rate on the deaggregation index of 
magnetic nano-aggregates coated with 300 mg polyrotaxane / 100 mg nanoparticles. 
These images are based on the samples collected from stage 3 in the magnetic next 
generation impinger operated at 15 L/min (A), 30 L/min (B), 60 L/min (C) and 100 L/min 
(D) 
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m NGI stage 
Cut-off diameter 
(µm, 15 L/min) 
Cut-off diameter 
(µm, 30 L/min) 
Cut-off diameter 
(µm, 60 L/min) 
Cut-off diameter 
(µm, 100 L/min) 
Stage 1  14.10  11.70 8.06  6.12  
Stage 2  8.61  6.40  4.46  3.42 
Stage 3  5.39  3.99  2.82  2.18 
Stage 4  3.30  2.30  1.66  1.31 
Stage 5  2.08  1.36  0.94  0.72 
Stage 6  1.36  0.83  0.55  0.40 
Stage 7  0.98  0.54  0.34  0.24 
Filter  N/A   N/A  N/A   N/A  
Table 5A -1 Cut-off diameters for the mNGI at different inhalation flow rates 
41
. 
Table 5A -2 Effect of PPG-NH2 concentration and airflow rate on the 
percentage fine particle fraction (FPF) of magnetic nano-aggregates. 
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CHAPTER 6 
6 CHITOSAN-IONIC LIQUID FUNCTIONALIZED MAGNETIC 
NANORODS FOR CONTROLLED DRUG DELIVERY OF 
PROGESTERONE 
 
Abstract 
The current work deals with the synthesis, characterization and controlled drug delivery 
application of novel chitosan (CS) - ionic liquid functionalized magnetic nanorods. CS - ionic 
liquid, methyl imidazolium acrylic acid (MIAA), composite was prepared and applied as a 
surface coating for magnetic nanorods through a simple one-step chemical co-precipitation 
method. CS-MIAA-nanorods not only exhibited excellent drug encapsulation efficiencies, but 
also showed a controlled initial burst release of the loaded drug. Progesterone was loaded into 
CS-MIAA-nanorods and demonstrated a percentage drug loading ranging from 30 ± 2.75 to 
37.5 ± 2.85. The release of progesterone followed the Fickian diffusion mechanism with a well 
fitted profile to the Korsmeyer-Peppas model. Increasing the concentration of ionic liquid 
(MIAA) in the composite resulted in a release profile fitted to the Peppas-Sahlin model, which 
indicated the non-Fickian diffusion mechanism. The produced nanorods showed high aspect 
ratio morphology with an average diameter ranging from 23.2 ± 1.98 to 32.4 ± 2.95 nm and an 
approximate length of 140 nm. The major advantage of this study is the elucidation of the 
underlying drug release mechanism based on the molecular structure of CS-MIAA. Increasing 
the ionic liquid concentration in the composite, significantly affected the physical properties of 
chitosan, such as viscosity and water uptake. The approach developed in this work can be 
potentially used to develop sustained release formulations of progesterone by controlling the 
chemical configuration of the composite.  
Keywords: Magnetic nanorods; Chitosan; Drug release kinetics; Ionic liquid; Progesterone. 
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 Introduction 6.1
Magnetic nanoparticles (MNPs) have gained great interest in biomedical applications. 
They were traditionally used as contrast agents in magnetic resonance imaging (MRI) and 
magnetic cell sorting 
1-3
. MNPs of iron oxide combine both the desirable features of organic 
and inorganic compounds 
4
; which facilitates their wide application in biomedical 
5-7
 and 
diagnostic fields 
8, 9
. Furthermore, the encapsulation of therapeutic agents within MNPs has 
been favored due to the biocompatibility of magnetic carriers and the ease of surface 
modification for targeting a specific cell type 
10
. 
Generally, MNPs could be utilized in various applications for controlled drug delivery; similar 
to the conventional non-magnetic nanoparticles. However, the magnetic properties have 
opened up a new application; which is localization of therapeutic molecules in the target site. 
The drug loaded MNPs can be attracted from blood circulation using an external magnetic 
field. Therefore, MNPs were suggested as potential carriers for anticancer agents due to the 
enhanced therapeutic potentials 
11
 and also the decreased accompanying non-specific toxicity. 
Biomedical applications of MNPs require water soluble nanoparticles with diameter smaller 
than 30 nm with a decreased polydispersity index. Due to the high magnetization observed for 
MNPs combined with their large surface energies, aggregation of nanoparticles is often severe. 
Therefore, surface coating polymers are used to stabilize the synthesis of MNPs 
12-14
. 
Versatile methods can be applied for the development and optimization of MNPs synthesis. 
Commonly, the high-temperature organic phase decomposition method has been applied for 
the synthesis of monodisperse iron oxide nanoparticles 
16-18
. Nevertheless, the nanoparticles 
produced by this method were only soluble in organic solvents; which limits their biomedical 
applications. For that reason, the major challenge in fabricating MNPs for biomedical 
applications was to maintain the required particle diameter and water soluble characteristics 
15
. 
One possibility for fabricating water soluble MNPs is the surface coating with a hydrophilic 
polymer, such as chitosan (CS) 
19. Chitosan, [poly β(1-4)-glucopyranosamine], is a hydrophilic 
polysaccharide. It is the second abundant natural polysaccharide, which possesses many 
attractive properties, such as nontoxicity, biodegradability, biocompatibility, bioactivity and 
anti-microbial properties 
20
,
21
. However, the major imperfections of CS, such as the poor 
solubility of chitosan at physiological pH and high swelling (water uptake) in aqueous medium 
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resulted in limited biomedical applications 
22,
 
23
.   Therefore, an effective method to overcome 
these drawbacks is to blend CS with another polymer to develop a composite 
20
.  
Ionic liquids are ionic salts, which exist in the liquid state at ambient temperature. They are 
composed of an organic cationic and an anionic compound, which can be either an organic or 
inorganic compound. Ionic liquids possess some unique properties such as high thermal 
stability and the ability to dissolve both organic and inorganic polymeric compounds. Because 
of their negligible vapor pressure (non-volatile), ionic liquids can be used as a green alternative 
for organic solvents 
24
. Ionic liquids have been reported to enhance the bioavailability and 
hence therapeutic efficacy of acetylsalicylic acid 
25
.  
Recently, an intense work has been conducted for investigating the pharmaceutical applications 
of ionic liquids such as enhancing the solubility of poorly soluble drugs 
26
, as a reservoir for 
controlled release formulations of active pharmaceutical ingredients (APIs) and as a stabilizer 
of micro-emulsions for transdermal delivery of acyclovir 
27
 . Furthermore, incorporation of 
ionic liquids into pharmaceutical formulations has been considered as a design strategy to 
overcome the potential problems associated with the solid state APIs, such as polymorphism, 
solubility and bioavailability 
28
. The physical and chemical properties of ionic liquids can be 
tuned by changing the cationic-anionic combinations 
29
.   
The most investigated ionic liquids are those incorporating imidazolium compounds 
29, 30
. In 
the present study, the effect of ionic liquid, methyl imidazolium acrylic acid (MIAA), on ionic 
cross-linking of chitosan was investigated. Although ionic cross-linked chitosan has been 
previously investigated 
31
, the behavior of ionic liquid-chitosan composite as a drug carrier 
seems to be quite complex.  
Progesterone was selected as an (API) for the current study.  Progesterone is a poorly water 
soluble compound (water solubility = 3.79 * 10
-5 
M), therefore its encapsulation into micro- 
and nanoparticles has been widely investigated 
32
. Water immiscible ionic liquids have been 
investigated as an alternative strategy to control the release of poorly water soluble compounds, 
such as dexamethasone and progesterone 
33
.  
The present work was designed to prepare magnetic Fe3O4 nanorods for controlled delivery of 
progesterone. The samples were characterized using X-ray diffraction (XRD), Fourier 
transform infrared (FTIR), scanning electron microscope (SEM) and dynamic light scattering 
(DLS). Progesterone release from the magnetic nanorods was investigated and mathematically 
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modelled, in order to determine the drug release mechanism. A quantitative estimation of the 
amount of nanorods retained by a 0.1 Tesla external magnet was performed using a novel 
image processing analysis method. A relationship between the chemical composition of CS-
MIAA and physical properties of the composite, such as viscosity and swelling was 
established, with an insight in the thermodynamics of the system.   
 
 Materials and methods 6.2
6.2.1 Materials 
Chitosan (low molecular weight, inherent viscosity 30,000 cP, Sigma-Aldrich, USA), acrylic 
acid, N-methyl imidazole (Sigma-Aldrich, ON, CA), iron (II) sulfate heptahydrate 
(FeSO4·7H2O), ethanol, diethyl ether and sodium hydroxide (Na OH) (VWR, ON, CA) were 
used. 
6.2.2  Synthesis of CS-MIAA composite 
The ionic liquid (MIAA, Scheme 6-1) was synthesized according to the procedure reported by 
Ohno et al.
34
. CS-MIAA composites were prepared by mixing equal volumes of chitosan/acetic 
acid solution (0.2g/100ml) and MIAA (8, 15, 18, 22 and 30 mmol). The mixtures were then 
evaporated under vacuum to get the concentrated liquids. The chemical structures of CS and 
methyl imidazolium acrylic acid (MIAA) are presented in Scheme 6-1. 
6.2.3  Synthesis of uncoated magnetite in atmospheric 
conditions 
Uncoated magnetite (Fe3O4) was synthesized by chemical co-precipitation method using 
ferrous sulfate (1.39 g FeSO4.7H2O) as a precursor for iron. The iron salt was first dissolved in 
distilled water and then transferred to a preheated water bath (50 ºC). The pH of the medium 
was gradually increased by drop wise addition of ammonium hydroxide (NH4OH, pH = 13). 
The reaction temperature was elevated to 90 ºC and mixing was continued for 90 min. The 
obtained magnetite was then magnetically separated, washed with water and then dried in the 
oven at 60 ºC for 24 hours 
35
. 
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Scheme  6-1 Proposed chemical structure of chitosan-methyl imidazolium acrylic acid 
composite (CS-MIAA). 
6.2.4 Synthesis of magnetic nanorods coated with chitosan-
ionic liquid composite (CS-MIAA) 
CS-MIAA was added into a solution of iron precursor (FeSO4.7H2O), sonicated for 30 min in 
an ultrasonic bath and then the same procedure as in section 6.2.3. was repeated. The resulting 
nanorods were magnetically collected and washed and dried under vacuum for characterization 
and subsequent drug loading. The unused fraction of CS-MIAA composite liquid was collected 
and used for further synthesis. 
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6.2.5 Drug loading and calculation of encapsulation efficiency 
6.2.5.1  Drug loading 
Progesterone (5 and 10 mg) was dissolved in 5 ml aqueous dispersion of magnetite containing 
0.5 ml acetone and the mixture was mixed overnight at 800 rpm. 
6.2.5.2  Progesterone encapsulation efficiency 
Loaded magnetic nanorods were separated by centrifugation at 5000 rpm for 10 min. The 
collected samples were then dissolved in ethanol, filtered and the amount of dissolved 
progesterone was determined by UV-Vis spectrophotometry (Cary-100 UV-Vis 
spectrophotometer, Agilent Technologies, Mississauga, ON, Canada). For each sample, the 
encapsulation efficiency and the drug loading were calculated according to the following 
Equations 
36
. 
 
Equation 6-1 
 
 
 
 
Equation 6-2 
The solid mass collected after dissolution of progesterone in alcoholic solution was then used 
to assess the iron oxide content. 
6.2.6  Characterization of CS-MIAA functionalized magnetic 
nanorods 
Particles’ diameters were analyzed using dynamic light scattering (DLS) technique (Zeta sizer, 
300 HSA, Malvern, UK). The analysis was performed at a scattering angle of 90º and at a 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑟𝑜𝑔𝑒𝑠𝑡𝑒𝑟𝑜𝑛𝑒
 × 100 
𝐷𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =  
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑦 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
 × 100 
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temperature of 20º C. The surface morphology of nanorods was defined using scanning 
electron microscopy (SEM) (Hitachi High-Technologies GmbH, Germany). The samples were 
prepared on aluminum stabs, coated with gold and measured at an accelerating voltage of 20 
kV coupled with energy dispersive x-ray (EDX) for elemental analysis. The crystal diffraction 
patterns of both CS-MIAA coated and uncoated samples were examined using X-ray 
diffractometer (Rigaku Miniflex XRD, USA). The wavelength of the applied radiation was 
1.54 Å and the samples scanned over a 2-theta range between 15º to 70º and at a step size of 
0.02º. FT-IR spectra were measured on a Nicolet, Magna-550 spectrometer (Scientific 
Equipment Source, Ontario, CA). For sample preparation on FT-IR, magnetic powders were 
mixed with potassium bromide (K Br) and pressed for measurement. 
6.2.7  In-vitro drug release of progesterone from CS-MIAA 
coated magnetic nanorods 
For investigation of the drug release mechanisms, three different sets of experiments were 
performed. They included CS, MIAA and CS-MIAA coated samples. Each experiment 
contained 20 mg of progesterone loaded magnetic nanorods dispersed in 10 ml of phosphate 
buffer solution (pH = 7.4). The amount of progesterone released was quantified using UV-Vis 
spectrophotometer at 254 nm maximum wavelength. All drug release experiments were 
repeated at least three times. 
6.2.8 Statistical evaluation of drug release profiles 
6.2.8.1 ANOVA-based method  
One-way ANOVA testing was applied on the percentages drug released using Microsoft Excel 
2013. 
6.2.8.2  Model-independent method (pair-wise procedures) 
The difference factor (f1) and similarity factor (f2) were calculated based on Equations 6-3 and 
6-4, to compare two drug release profiles with a 90% confidence approach 
37
. 
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Equation 6-3 
 
Equation 6-4 
 
where n is the number of time points, Rt is the release value of the reference batch at time t and 
Tt is the dissolution value of the test at time t. 
6.2.8.3   Model dependent approaches 
Several mathematical models have been reported in the literature to fit the drug release profiles. 
A model with no more than three parameters is usually recommended (such as First order, 
Higuichi, Peppas, Hixon and Crowel and Lonsdale models) 
11, 37
 . In the present work we 
obtained the highest goodness of fit (the highest coefficient of correlation, R
2
) with Peppas 
model. 
6.2.9  Viscosity measurement and calculation of activation 
energy (EA) 
Viscosity measurements were carried out in a Brookfield DV-E viscometer (Brookfield 
Engineering Laboratories, Middleboro, MA, USA). The activation energy of CS-MIAA 
prepared with variable concentrations of ionic liquid was calculated from the linearization of 
Arrhenius Equation 
38
 (Equation 6-5).  
 
Equation 6-5 
ln 𝜂 = ln 𝜂0 −  
𝐸𝐴
𝑅𝑇
  
𝑓2 = 50 ∗ log
 
 
 
1
  1 + (1 𝑛⁄ )  𝑅𝑡 −  𝑇𝑡 
2𝑛
𝑡=1   
∗ 100
 
 
 
 
𝑓1 =   
   𝑅𝑡 −  𝑇𝑡 
𝑛
𝑡=1  
  𝑅𝑡
𝑛
𝑡=1  
  ∗ 100 
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where, η and η0 are the viscosity of CS-MIAA and pure CS, respectively. T is the temperature 
in Kelvin and R is the universal gas constant. The activation energy (EA) is calculated from the 
slope of (ln η) versus (1/T) curve.  
6.2.10 Swelling test 
The swelling behavior of CS- and CS-MIAA-coated magnetic nanorods was evaluated using 
gravimetric technique 
39
. A premeasured amount of nanorods (100 mg, W1) was first dispersed 
in 5 ml distilled water. Later on, magnetic nanorods were removed and dried by pressing 
between two filter papers and then weighed (W2). The swelling of different samples was 
determined at different time points (10, 20, 30, 40, 50 and 60 min). The percentage swelling 
(water uptake) was calculated based on Equation 6-6.  
 
Equation 6-6 
6.2.11 Quantitative analysis of magnetic localization of nanorods 
for potential biomedical applications 
The degree of magnetic retention of all magnetic samples was analyzed using the developed 
system illustrated in Scheme 6-2. This system consists of a digital camera, magnet and image 
processing software (Image-J). First typical RBG images were captured for aqueous magnetite 
dispersion, exposed to an external magnetic field (0.1 Tesla) at different time intervals. These 
images were then converted into 8-bit images using Image-J software. The images were 
presented in the Gray mode; which has 256 shades to represent the image (the black color is 
presented by the 0 shade, while the white color is presented by 255) 
40
. Thereafter, a specified 
selection area was determined for each image. In this selected area, analysis of the image was 
performed. The obtained profile was plotted by using Origin lab software. The same procedure 
was conducted for a blank sample. By using Origin lab software, the background curve was 
subtracted from each sample and the selected peak was integrated. In order to quantify the 
amounts of magnetite attracted to the magnet per each time interval, a calibration curve was 
constructed with known amounts of magnetite and the peak area was plotted versus the 
% 𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 =  
𝑊2 −  𝑊1
𝑊1
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magnetite concentration. In all image analysis tests the starting concentration of magnetite was 
2 mg/ml. 
 Results and discussion 6.3
6.3.1 Characterization of surface modified magnetic nanorods 
The primary objective for the current study was to develop CS-MIAA functionalized 
magnetic nanorods. A secondary objective was to investigate the effect of the concentration 
of MIAA on the kinetics of drug release. Understanding the type of interactions between 
Fe3O4 and MIAA as well as the interaction between CS and MIAA helped in elucidation of 
the dual functions of the ionic liquid.  
Scheme  6-2 An experimental setup for computing magnetic capturing using an image 
processing analysis technique. 
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First, ionic liquid acts as a template for nanorods formation. Cross-linking of CS could be the 
secondary role of the ionic liquid with consequences on the physical properties of the 
composite.   
The interaction between the ionic liquid and CS has previously been reported 
41
. CS and ionic 
liquid counter ions were primarily bonded through an electrostatic interactions; leading to the 
formation of CS-MIAA composite. Scheme 6-1 shows a proposed presentation of the 
composite structure, in which CS-imidazolium cations are countered by acrylic acid anions. 
The structure proposed is based on a previous study dealing with the synthesis of 1-butyl-
3.methylimidazolium octyl sulfate 
41
.  
6.3.1.1  Powder XRD and FTIR analysis 
FTIR and XRD patterns (Figures 6-1 & 6-2) were analyzed to understand the formation 
process of CS-MIAA composite and subsequent surface functionalization of magnetite. 
Scheme 6-1 explains that hydrogen bonding can occur between acrylate anions of ionic liquid 
and hydroxyl groups of CS; this is because of the high hydrogen bonding accepting 
functionality of MIAA. Figure 6-1 shows the XRD patterns of MIAA coated and CS-MIAA 
coated magnetic nanorods. The peak positions fitted well with the reported XRD patterns of 
magnetite nanoparticles 
42
, also the profile agree with the crystalline structure of magnetite 
(JCPCD card no. 01-072-8152). The characteristic peaks of magnetite (Fe3O4) were found at 2θ 
= 30.3º, 35.7°, 43.4°, 53.6°, 57.0° and 62.9°. The diffraction peaks in Figures 6-1A and 6-1B 
could be indexed to (220), (311), (400), (422), (511) and (440) planes, which indicated a face 
centered cubic structure. The obtained profiles revealed that MIAA or CS-MIAA surface 
coating did not cause any crystalline phase change for magnetite, except for two broad peaks 
observed at 2θ = 10.7º and 22.5º.  These peaks can be ascribed to the characteristic structure of 
chitosan, while the remaining peaks are superimposed with the crystalline structure of Fe3O4. 
The broad peak recorded at 2θ = 10.7º corresponds to the hydrated crystalline structure, while 
the peak at 2θ = 22.5º can be credited to the existence of an amorphous structure 43. The crystal 
structure of CS-MIAA functionalized magnetite was stabilized through π-π stacking 
interactions between imidazole rings, which were connected to CS chains. Increasing the ionic 
liquid concentration from 8 mmol to 30 mmol, diminished the two broad peaks of CS (2θ= 
10.7º and 22.5º), remarkably.  Further stabilization of CS-MIAA composite, particularly due to 
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the interconnected hydrogen bonding between COO
- 
group of ionic liquid and NH3
+
 group of 
CS, contributed to the observed increased crystallization (Figure 6-1C). 
 
Figure 6-1 X-ray diffraction profiles of MIAA functionalized nanorods (A), CS-MIAA 
functionalized nanorods prepared with different concentrations of MIAA: 8 mmol MIAA 
(B), 15 and 30 mmol (C). EDX pattern of CS-MIAA functionalized nanorods (D). 
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Figure 6-2 FTIR spectra for chitosan (A), MIAA-coated magnetic nanorods (B), uncoated 
magnetite (C) and chitosan-ionic liquid-coated magnetic nanorods (D). The peaks marked 
with asterisks correspond to π-π stacking of imidazole rings. 
Figure 6-1D presents the EDX pattern of the produced nanorods. The presence of iron (Fe) 
peak in the EDX of CS-MIAA functionalized nanorods showed successful incorporation and 
uniform distribution of Fe3O4 in the polymeric matrix. The assigned peaks demonstrated the 
3:4 ratio of iron to oxygen; which confirms the formation of magnetite.  
The FTIR spectra (Figure 6-2) of CS-MIAA coated magnetic nanorods revealed the interaction 
between CS and the imidazolium ring of the ionic liquid (MIAA). The appearance of peaks 
corresponding to the carboxylate stretching vibrations; indicates the presence of acrylic acid 
anion on the magnetic nanorods surface 
44
. The typical bending vibration for CS amine group 
(NH2), which is centered at 1545 cm 
-1
, moved to the peaks at 1593 and 1616 cm 
-1
. This shift 
was due to the asymmetric and symmetric vibrations of NH3
+
 group; which indicates the 
electrostatic interaction between the carboxylate group of acrylic acid moiety in MIAA ionic 
liquid and the amine group of CS (Scheme 6-1). The peak at 635 cm
-1 
is assigned for Fe-O 
group. The broad band observed at 3400 cm 
-1
 for the uncoated magnetite sample can be 
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referred to the –OH group. The symmetric CH2 stretch can be allocated at 2847 cm
-1
 for CS- 
and CS-MIAA coated MNPs. The absorption band at 1070 cm 
-1
 resulted from the stretching 
vibration of the C-O bond in the CH2-OH group for both CS- and CS-MIAA coated samples.  
In addition, the proposed π-π stack interaction of imidazolium ring demonstrated in Scheme 6-
1 was further confirmed by FTIR spectra. The change of the peak position assigned for the C-N 
stretching vibration of imidazolium ring (marked with an asterisk in Figure 6-2B) towards 
lower wavenumbers. The π-π stacking can also be examined by the change in the C-H 
stretching vibration of imidazolium ring at 2880-3160 cm
-1 
(Figures 6-2B & 2D). The peak 
broadening together with the shift in the absorption peaks towards lower wavenumbers 
probably originating from the π-π stack interactions of positively charged imidazole, which 
decreased the electron density of the C-H bond of the ring. The appearance of three strong 
absorption peaks in the spectrum (Figure 6-2D) additionally confirms the imidazolium packing 
proposed in Scheme 6-1.  
6.3.1.2  Morphology of magnetic nanorods 
FESEM images of magnetic nanorods coated with variable concentrations of MIAA are 
presented in Figure 6-3. The images indicate the formation of nanorods; with diameters < 30 
nm and a length of approximately 140 nm. Increasing the concentration of ionic liquid from 8 
to 30 mmol resulted in a remarkable capability of varying the size of magnetic nanorods. Table 
6-1 illustrates the effect of formulation variables on the particle size and polydispersity index 
of magnetic nanorods.  Increasing ionic liquid concentration from 8 to 30 mmol significantly 
increased the particle size from 23.2 ± 1.98 to 32.4 ± 2.95 and the polydispersity index from 
0.19 ± 0.25 to 0.46 ± 0.06, respectively. This agrees well with previous studies that 
demonstrate the effect of ionic liquid on changing the structural organization of nanomaterial 
surface as well as reshaping of nanoparticles 
45, 46
.  
6.3.1.3  Ionic liquid as a template for preparing magnetic nanorods 
Magnetic nanorods were synthesized by alkaline hydrolysis of iron precursor (FeSO4.7H2O) 
under atmospheric reaction condition. The proposed reaction mechanism for explaining the 
role of ionic liquid in the formation of magnetite nanorods is presented in Scheme 6-3. In this 
Scheme, the iron precursor (Fe
+2
) was first oxidized in air releasing Fe
+3
 into the reaction 
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medium. It is well known that Fe(OH)3 has smaller solubility than Fe(OH)2.With the gradual 
increase in the pH of the medium, Fe(OH)3 was first precipitated. Then Fe(OH)3 was 
transformed into FeOOH (goethite), which has a characteristic needle shape 
47
. Stabilizing the 
goethite nucleates could be considered as a key procedure of forming magnetite nanorods. 
Ionic liquid (methyl imidazolium acrylic acid) was functionalized on the surface of FeOOH 
needles by means of hydrogen bonding-co-π-π-stacking interactions 48. Later on, more 
hydroxyl ions were introduced into the reaction medium and it is time for Fe(OH)2 to reach its 
solubility product. At this points, Fe(OH)2 would grow on FeOOH-ionic liquid nucleates and 
finally converted into uniform magnetite (Fe3O4) nanorods 
47
.  
Figure 6-3 FESEM images of CS-MIAA-coated magnetic nanorods prepared with 5 
mmol MIAA (A), 15 mmol MIAA (B), 18 mmol MIAA (C) and 30 mmol MIAA (D). 
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Table 6-1 Effect of formulation parameters on the particle size, polydispersity index, 
drug loading and encapsulation efficiency of CS-MIAA magnetic nanorods.  
 Scheme  6-3 Diagram for illustrating the role of ionic liquid as a template for 
designing Fe3O4 nanords. 
 
Drug 
input 
(mg) 
Chitosan 
concentration 
(mg/ml) 
MIAA 
concentration 
(mmol) 
Particle 
size 
(nm) 
Polydispersity 
index 
Drug 
loading 
(%) 
Drug 
encapsulation 
efficiency 
(%) 
5 2 8 23.2 ± 1.98 0.19 ± 0.25 30 ± 2.75 60 ± 5.5 
10 2 8 23.2 ± 1.98 0.19 ± 0.25 34.5 ± 3.12 69 ± 5.42 
10 2 15 21.8 ± 2.09 0.17 ± 0.03 36 ± 2.95 72 ± 5.9 
10 2 18 25.5 ± 1.56 0.25 ± 0.03 32.5 ± 3.01 65 ± 6.02 
10 2 22 28.3 + 2.54 0.41 ± 0.04 35 ± 3.42 70 ± 6.84 
10 2 30 32.4 ±2.95 0.46 ± 0.06 37.5 ± 2.85 75 ± 5.7 
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6.3.2  In-vitro drug release study 
Based on preliminary experiments, 10 mg of progesterone was selected as the amount of drug 
input for all examined samples. Changing the concentration of ionic liquid in the composite 
resulted in increasing the drug encapsulation efficiencies from 69 ± 5.42 % to 75 ± 5.7 %. The 
highest percentages of drug loading and encapsulation efficiencies occurred for the sample 
functionalized with 30 mmol of MIAA (Table 6-1). Further increase in ionic liquid 
concentration decreased both the drug loading and encapsulation efficiency; because of the 
inability of progesterone to penetrate through the cross-linked network structure of CS. 
Analysis of progesterone release kinetics from CS-MIAA functionalized nanorods was 
performed using Peppas model 
49, 50
 (Equation 6-7). 
 
Equation 6-7 
where Mt / M∞ is the fraction of drug released at time (t), k is the release rate constant and n is 
the diffusional exponent; that depends on the mechanism of drug release and the shape of drug 
delivery system (Table 6-2). Investigating the mechanistic data based on mathematical 
modeling of different release profiles indicates that the release mechanism for the samples 
prepared with MIAA concentrations up to 30 mmol is Fickian diffusion. Increasing the 
concentration of MIAA produced drug delivery systems with an anomalous release mechanism 
(coupled transport). A more revealing understanding of the drug release from swelling matrices 
will be explained in the following sections.   
6.3.2.1 Release of progesterone from CS-MIAA functionalized 
nanorods 
We have previously reported the release of progesterone through poloxamer/beta cyclodextrin 
coated magnetic nanoparticles using two different techniques for drug loading 
11
. In the current 
study, we focus on investigating the effect of surface coating composition (CS-MIAA) on the 
diffusional release of progesterone from magnetic nanorods. 
 
 
𝑀𝑡
𝑀∞
⁄  = 𝑘 𝑡𝑛     
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Table 6-2 Prediction of the diffusion mechanism based on the calculated release exponent 
values. 
 
 
Drug release mechanism 
Release exponent (n) 
Case I transport (Fickian diffusion) n ≤ 0.5 
Anamolous diffusion 
(non Fickian or coupled diffusion) 
0.5 < n < 1.0 
Case II transport (Zero order) n = 1.0 
 
The release profiles of progesterone are shown in Figure 6-4. Uncoated magnetic samples 
showed a release of 51.33% ± 3.59 and 57.69 ± 5.19% of encapsulated progesterone within the 
first six hours for samples loaded with 5 and 10 mg of progesterone. The calculated T50 was 
approximately 11.23 ± 0.73 and 6.91± 0.42 hours (Figure 6-5). The calculated difference factor 
(f1) for these samples was 8.39 ± 1; which indicates significance of experiment. 
Primarily, the release of progesterone from magnetic nanorods showed significant dependency 
on the physical properties of the coating composite (CS-MIAA), such as viscosity and water 
uptake (swelling).  CS coated magnetic samples didn’t show significant enhancement in the 
release profile of progesterone; which can be referred to the increased swelling in the 
polymeric matrix. Stack packing arrangement of ionic liquid in CS-MIAA composite resulted 
in significant reduction in the initial burst effect of progesterone. For the sample coated with 8 
mmol of ionic liquid, only 32.51 ± 1.58 % of progesterone was released within the first six. 
However, the drug release profiles revealed that only 70.65 ± 3.43% of progesterone was 
released from CS-MIAA coated magnetic nanorods prepared with 8 mmol of MIAA at the end 
of release experiment. Increasing the concentration of MIAA resulted in enhancing the amount 
released to 95.38 ± 4.63 and 98.75 ± 6.38% at 15 and 18 mmol; which could be referred to the 
co-solvent properties of ionic liquid. 
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6.3.2.2 Effect of composite viscosity on progesterone release from 
magnetic nanorods 
Exploring the release data presented in Figure 6-4 revealed the dependence of progesterone 
release on the swelling of the composite (Figure 6A-1). However upon increasing the 
concentration of ionic liquid from 15 to 18 mmol, the initial release increased from 43.88 ± 
2.13 to 50.46 ± 2.45 %, within the first six hours. A prolonged T50 was also decreased with 
increasing the ionic liquid fraction on the surface of magnetic nanorods (Table 6-3); which 
indicates that the swelling kinetics is not the only parameter in controlling diffusion of 
progesterone from CS-MIAA polymeric matrix. In this context, the viscosity of the coating 
composite seems to have a remarkable effect on the release rate of progesterone. The viscosity 
profiles of variable CS-MIAA matrices are presented in Figure 6-5A. Rheological 
measurements of CS-MIAA composites indicated the shear thinning behavior, which is 
characteristic for worm like polymers. The observed release profiles could be originated from 
the reduced composite viscosity upon increasing MIAA concentration. The calculated release 
rate constants agreed well with previous literature; in which the change in the diffusional 
release rate could be related to the viscosity of the coating matrix due to the change in the film 
thickness surrounding the core nanoparticles 
51
.  
In case of composite based drug delivery systems, it is not only the physical properties of the 
composite controls the release of drugs, but also the type of bonds and cross-linking of the 
polymer were shown to greatly influence drug diffusion 
52
.  The combined diffusion and 
degradation might contribute to the increased release rate of progesterone as well 
53
.  
6.3.3 Effect of composite activation energy on kinetics of drug 
release 
One of the major drawbacks of chitosan is the increased water uptake, which limits its 
application in controlled drug delivery. The main objective of this work is to introduce ionic 
liquid (MIAA) as a drug delivery vehicle and to highlight its effect on the rheological 
properties of chitosan. Figure 6-5B shows the temperature dependence of CS-MIAA viscosity 
over a temperature range from 273-373 ºK. Based on the temperature dependence of the 
viscosity of CS-MIAA composites, the activation energy EA was calculated and presented in 
Table 6-4. Increasing MIAA concentration in the magnetite formulation resulted in higher 
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activation energy; which indicates the harder dissolution of chitosan (polysaccharide polymer) 
in the dissolution medium 
54
. This explanation was confirmed by the reduction in the initial 
burst effect as a result of the significant decrease in the swelling properties of CS (Figure 6A-
1). 
In this context, the dependence of progesterone diffusion coefficient on MIAA concentration 
could be related to the change in the EA of the coating composite. The diffusion of 
progesterone out of nanorods and the permeation of water molecules are actually two 
competitive processes that govern the drug release mechanism. In case of low concentrations of 
MIAA (from 8 to 15 mmol), the activation energy for the system is low (31.48 and 31.79 
kJ/mol. ºK, respectively); which facilitates both diffusion and permeation processes. However, 
increasing MIAA concentration more than 22 mmol resulted in significant reduction in the 
initial burst effect. This could be explained based on two facts: (1) Creation of smaller pores on 
the composite coating while being in contact with the release medium 
19, 55
. (2) The increased 
EA of the system (34.47 and 35.21 kJ/mol. ºK for 22 and 30 mmol MIAA); which results in 
decreased swelling and initial diffusion of progesterone. The increased EA for diffusion 
indicates the decrease in the molecular free volume; which is confirmed by the increase in 
crystallinity of the composite (Figure 6-1C). 
181 
 
 
 
 
Figure 6-4 Release profiles of progesterone from variable magnetic formulations. Effect 
of amount of progesterone input on the release profile from uncoated magnetite (A) and 
effect increasing concentrations of MIAA in CS-MIAA composites on the initial burst and 
release period of progesterone from magnetic nanorods (B), (C) and (D). 
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Figure 6-5 Viscosity profiles of CS-MIAA composites showing the increase in shear 
thinning upon increasing MIAA concentrations (A) and Arrhenius plots based on the 
measured viscosities at different temperatures (B). 
 
 
 
Table 6-3 Summary of release kinetics data obtained by mathematical curve fitting with 
Peppas-Sahlin model with a calculated goodness of model fit data (R
2
, WSS and AIC). 
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Table 6-4 Summary of calculated activation energy of CS-MIAA composites based on 
linearization of Arrhenius equation. 
 
6.3.4 Mathematical modeling of progesterone release from CS-
MIAA functionalized nanorods 
By fitting the drug release data to the model (Equation 6-8) proposed by Peppas and Sahlin 
56
, 
a quantitative understanding of the diffusion and relaxation mechanisms can be attained. 
 
Equation 6-8 
where, the term (k1t
m
) represents the Fickian diffusion contribution (FD) and the second term 
(k2t
2m
) represents the relaxation contribution (R) on the polymeric matrix. The ratio of the 
relaxation and diffusion can be presented as: 
 
Equation 6-9 
The release data were analyzed based on Equations 6-8 and 6-9. Figure 6-6A shows the 
calculated R/FD versus the fractions of progesterone released over the 14 days. With increasing 
𝑀𝑡
𝑀∞
⁄  = 𝑘1 𝑡
𝑚 + 𝑘2 𝑡
2𝑚  
𝑅
𝐹𝐷
⁄ =   
𝐾1
𝐾2
⁄  ∗  𝑡𝑚  
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the concentration of MIAA form 8 to 30 mmol, the ratio R/FD remains very low; indicating that 
the drug release mechanism is almost diffusion.  
Further increase in the weight fractions of MIAA is associated with an increase in the 
calculated R/FD as a result of the increased resistance of drug diffusion. The results presented 
revealed the possibility of shifting from Fickian to anomalous diffusion upon changing the 
polymeric composite structure (Figure 6-6B). The release data were plotted were 
mathematically modeled using the Peppas equations. The Akaike Information Criterion (AIC), 
presented in Equation 6-10, has been applied for selecting the optimum model of drug release.  
 
 
Equation 6-10 
where, n is the number of data points, WSS is the weighed sum of squares and p is the number 
of parameters in the model. From the definition described in Equation 6-10, the AIC depends 
on the magnitude of data as well as the number of data points. In this study, we compared 
different models for the best fit with progesterone release data from magnetic nanorods. Peppas 
model was assigned for the lowest AIC for our experimental release data; therefore, it is the 
best fitted for drug modeling. The presented data confirms that high concentrations of MIAA 
results in more entanglement of CS chains; decreasing the drug diffusion coefficient due to 
relaxation of the polymer 
57
. The release rate and diffusion exponent could be directly linked to 
the cross-link density of polymeric networks 
52
.  
𝐴𝐼𝐶 = 𝑛. ln 𝑊𝑆𝑆 + 2. 𝑝 
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Figure 6-6 Computed kinetics parameters based on mathematical modeling with Peppas-
Sahlin model: time dependent relaxation / diffusion ratios (R/FD) for different CS-MIAA 
magnetic nanorods prepared with an increasing concentration of ionic liquid up to 30 
mmol(A), curve fitting of experimental release data of CS-MIAA magnetic nanorods 
prepared with ionic liquid  concentration > 30 mmol (B) and its corresponding kinetics 
parameters (C). 
 
6.3.5  Magnetic performance study using image processing 
analysis technique 
In this study, we applied a simplified method for monitoring locally targeted drug delivery of 
progesterone. This could be accomplished through the application of an external magnet (0.1 
Tesla). Similar theoretical and experimental work has been reported 
10
 to support the 
application of magnetic implants in combination with externally applied magnetic field. On the 
other hand, the work performed in this work aims to highlight that surface functionalized 
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magnetic nanorods are not less magnetically responsive than uncoated magnetite, while being  
more suitable for clinical applications.  
Quantitative analysis, performed using image processing software (Image J), confirmed the 
feasibility of capturing particles with an external magnet (0.1 Tesla) and in the presence of 
other competing forces. Figures 6-7A & 6-7B showed the change in magnetic capturing upon 
changing the horizontal distance and the exposure time from the external magnet. After 2 min 
exposure, the percentage of magnetic capturing exceeds 30% for both uncoated magnetite and 
surface functionalized magnetic nanorods.  
In the presented experimental setup (Scheme 6-2), only horizontal magnetic force components 
were taken into consideration. Under this assumption, the magnetic to hydrodynamic force 
ratio was expected to be proportional to the square of nanorods’ diameters. The proposed setup 
neglects wall effects, but still represents a general idea of magnetic capturing of nanorods.  
It is predicted that larger magnetic nanorods can be magnetically captured more easily. 
However, administration of magnetic particles in the nanometer size range is more desirable 
from biomedical perspectives. Hence, an optimal diameter can be predicted to allow significant 
capturing, while minimizing the size of nanorods.  
The concentration profiles (gray value profiles) in horizontal directions were computed for 
three different starting positions and presented in Figure 6-7A. This Figure shows the change in 
the concentration profiles as the nanorods move horizontally towards the vial’s surface 
(Scheme 6-2).  
According to the results shown in Figure 6-7B, uncoated magnetite is most strongly attracted to 
the external magnet. Results also show that magnetic nanorods (diameter = 23.2 ± 1.98 nm) are 
weakly attracted to the magnet and in some cases even repelled. This agrees well with the 
previous expectations, concentration profiles confirm that larger magnetic nanorods are more 
easily captured with an external magnet, since the ratio of magnetic to hydrodynamic forces 
should scale with the square of nanorods’ diameter. Based on this assumption, significant 
capturing of 30 mmol MIAA functionalized nanorods was anticipated.  
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Figure 6-7 Typical concentration (gray value) profiles of magnetic nanorods capturing 
at different distances from the vial surface. The images taken at 0.5 cm (Image-1), 1 cm 
(Image-2) and 2 cm (Image-3) away from point A.  The images were taken after 2 min 
exposure to a 0.1 Tesla external magnet. Figure 7B- Computed percentages magnetic 
capturing for magnetic formulations with different surface compositions. 
 
 
 Conclusions 6.4
Magnetic nanorods, with diameter ranging from 21.8 to 32.4 nm, were successfully 
synthesized. The nanorods were surface coated with a novel ionic cross-linked CS composite. 
Control of progesterone initial burst effect was achieved by increasing the concentration of 
ionic liquid in the composite. Adjustment of the swelling kinetics of CS as well as its 
rheological properties helped in controlling the drug release rate. The drug release profile was 
mathematically modeled and the transport through magnetic nanorods was controlled by both 
diffusion and polymer relaxation processes. A relationship was constructed between the 
coating composition and the release mechanism of progesterone with an insight on the 
chemical configuration of the system. The presented method for monitoring magnetic retention 
demonstrates the effectiveness of our proposed nanorods in terms of magnetic localization of 
drug. 
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Appendix 6A 
 
Figure 6A-8 Swelling study for investigating the effect of ionic liquid on water uptake of 
chitosan coated magnetic nanoparticles. 
  
189 
 
 
 
 References 6.5
1. Hu FQ, Wei L, Zhou Z, Ran YL, Li Z, Gao MY 2006. Preparation of Biocompatible 
Magnetite Nanocrystals for In Vivo Magnetic Resonance Detection of Cancer. Adv  Mat 
18(19):2553-2556. 
2. Hongwei Gu, Keming Xu, Chenjie Xu and Bing Xu 2006. Biofunctional magnetic 
nanoparticles for protein separation and pathogen detection. Chem  Commun DOI: 
10.1039/b514130c:941 - 949. 
3. Roullin V, Deverre J, Lemaire L, Hindré F, Venier-Julienne M, Vienet R, Benoit J 2002. 
Anticancer drug diffusion within living rat brain tissue: an experimental study using [3H](6)-5-
fluorouracil-loaded PLGA microspheres. European Journal of Pharmaceutics and 
Biopharmaceutics 53:293-299. 
4. Dobrzański LA, Drak M, Ziębowicz B 2007. New possibilities of composite materials 
application—Materials of specific magnetic properties. J Mater Process Technol 191:352-355. 
5. Jia H, Zhu G, Ping W 2003. Catalytic behaviors of enzymes attached to nanoparticles: the 
effect of particle mobility. Biotechnology and Bioengineering 84(4):406 - 414. 
6. Nakayama H, Arakaki A, Maruyama K, Takeyama H , Matsunaga T 2003. Single-nucleotide 
polymorphism analysis using fluorescence resonance energy transfer between DNA-labeling 
fluorophore, fluorescein isothiocyanate, and DNA intercalator, POPO-3, on bacterial magnetic 
particles. Biotechnology and Bioengineering 84 (1):96 - 102. 
7. Ugelstad J, Berge A, Ellingsen T, Schmid R, Nilsen T-, Mørk PC, Stenstad P, Hornes E, 
Olsvik Ø 1992. Preparation and application of new monosized polymer particles. Progress in 
Polymer Science 17:87-161. 
190 
 
 
 
8. Billotey C, Wilhelm C, Devaud M, Bacri JC, Bittoun J, Gazeau F 2003. Cell internalization 
of anionic maghemite nanoparticles: Quantitative effect on magnetic resonance imaging. 
Magnetic Resonance in Medicine (MRM) 49 (4):646 - 654. 
9. Patil GV 2003. Biopolymer albumin for diagnosis and in drug delivery. Drug Development 
Research 58 (3):219 - 247. 
10. Alexiou C, Schmidt A, Klein R, Hulin P, Bergemann C, Arnold W 2002. Magnetic drug 
targeting:  biodistribution and dependency on magnetic field strength. J Magn Magn Mater 
252:363−366. 
11. Ragab DM, Rohani S, Consta S 2012. Controlled release of 5-fluorouracil and progesterone 
from magnetic nano-aggregates. Int J Nanomedicine 7:3167-3189. 
12. Fried T, Shemer G, Markovich G 2001. Ordered two-dimensional arrays of ferrite-br-
nanoparticles. Adv  Mater 13:1158–1161. 
13. Lin H, Watanabe Y, Kimura M, Hanabusa K, Shirai H 2003. Preparation of magnetic 
poly(vinyl alcohol) (PVA) materials by in-situ synthesis of magnetite in a PVA matrix. 
J  Appl  Polym  Sci 87:1239–1247. 
14. Lee DK, Kang YS, Lee CS, Stroeve P 2002. Structure and characterization of 
nanocomposite langmuir-blodgett films of poly(maleic monoester)/Fe3O4-br-nanoparticle 
complexes. J  Phys  Chem  B 106:7267–7271. 
15. Wan J, Cai W, Meng X, Liu E 2007. Monodisperse water-soluble magnetite nanoparticles 
prepared by polyol process for high-performance magnetic resonance imaging. 
Chem  Commun 47:5004–5006. 
16. Sun S ZH 2002. Size-controlled synthesis of magnetite nanoparticles. J  Am Chem  Soc 
124:8204–8205. 
191 
 
 
 
17. Yu WW, Falkner JC, Yavuz CT, Colvin VL 2004. Synthesis of monodisperse iron oxide 
nanocrystals by thermal decomposition of iron carboxylate salts. Chem Commun 20:2306–
2307. 
18. Jana NR, Chen Y, Peng X 2004. Size- and shape-controlled magnetic (Cr, Mn, Fe, Co, Ni) 
oxide nanocrystals via a simple and general approach, Chem  Mater 16:3931–3935. 
19. Xiong Y, Wang H, Wu C, Wang R 2012. Preparation and characterization of conductive 
chitosan-ionic liquid composite membranes. Polym Adv Technol 23:1429-1434. 
20. Zhuang P, Li Y, Fan L, Lin J, Hu Q 2012. Modification of chitosan membrane with 
poly(vinyl alcohol) and biocompatibility evaluation. Int J Biol Macromol 50:658-663. 
21. Panyam J, Labhasetwar V 2012. Biodegradable nanoparticles for drug and gene delivery to 
cells and tissue. Adv Drug Deliv Rev 64, Supplement:61-71. 
22. Bhattarai N, Gunn J, Zhang M 2010. Chitosan-based hydrogels for controlled, localized 
drug delivery. Adv Drug Deliv Rev 62:83-99. 
23. Park JH, Saravanakumar G, Kim K, Kwon IC 2010. Targeted delivery of low molecular 
drugs using chitosan and its derivatives. Adv Drug Deliv Rev 62:28-41. 
24. Dobler D, Schmidts T, Klingenhöfer I, Runkel F 2013. Ionic liquids as ingredients in 
topical drug delivery systems. Int J Pharm 441:620-627. 
25. Bica K, Rijksen C, Nieuwenhuyzen M, Rogers RD 2010. In search of pure liquid salt forms 
of aspirin: ionic liquid approaches with acetylsalicylic acid and salicylic acid. Phys Chem 
Chem Phys 12:2011-2017. 
26. Moniruzzaman M, Tamura M, Tahara Y, Kamiya N, Goto M 2010. Ionic liquid-in-oil 
microemulsion as a potential carrier of sparingly soluble drug: Characterization and 
cytotoxicity evaluation. Int J Pharm 400:243-250. 
192 
 
 
 
27. Moniruzzaman M, Tahara Y, Tamura M, Kamiya N, Goto M 2010. Ionic liquid-assisted 
transdermal delivery of sparingly soluble drugs. Chemical Communications 46:1452-1454. 
28. Shamshina JL, Barber PS, Rogers RD 2013. Ionic liquids in drug delivery. Expert Opinion 
on Drug Delivery 10:1367-1381. 
29. Tokuda H, Ishii K, Susan MABH, Tsuzuki S, Hayamizu K, Watanabe M 2006. 
Physicochemical properties and structures of room-temperature ionic liquids. 3. Variation of 
cationic structures. J Phys Chem B 110:2833-2839. 
30. Tokuda H, Hayamizu K, Ishii K, Susan MABH, Watanabe M 2005. Physicochemical 
properties and structures of room temperature ionic liquids. 2. variation of alkyl chain length in 
imidazolium cation. J Phys Chem B 109:6103-6110. 
31. Zeng W, Huang J, Hu X, Xiao W, Rong M, Yuan Z, Luo Z 2011. Ionically cross-linked 
chitosan microspheres for controlled release of bioactive nerve growth factor. Int J Pharm 
421:283-290. 
32. Jameela SR, Kumary TV, Lal AV, Jayakrishnan A 1998. Progesterone-loaded chitosan 
microspheres: a long acting biodegradable controlled delivery system. J Controlled Release 
52:17-24. 
33. Jaitely V, Karatas A, Florence AT 2008. Water-immiscible room temperature ionic liquids 
(RTILs) as drug reservoirs for controlled release. Int J Pharm 354:168-173. 
34. Ohno H, Yoshizawa M, Ogihara W 2004. Development of newclass of ion conductive 
polymers based on ionic liquids. Electrochim  Acta 50:255–261. 
35. Kim DK, Mikhaylova M, Zhang Y, Muhammed M 2003. Protective coating of 
superparamagnetic iron oxide nanoparticles. Chem  Mater 15:1617–1627. 
193 
 
 
 
36. Sonvico F, Cagnani A, Rossi A, Motta S, Di Bari MT, Cavatorta F, Alonso MJ, Deriu A, 
Colombo P 2006. Formation of self-organized nanoparticles by lecithin/chitosan ionic 
interaction. Int J Pharm 324:67-73. 
37. Salama RO, Traini D, Chan H, Young PM 2008. Preparation and characterisation of 
controlled release co-spray dried drug-polymer microparticles for inhalation 2: Evaluation of 
in-vitro release profiling methodologies for controlled release respiratory aerosols. European 
Journal of Pharmaceutics and Biopharmaceutics 70:145-152. 
38. de Vasconcelos CL, de Azevedo FG, Pereira MR, Fonseca JLC 2000. Viscosity-
temperature-concentration relationship for starch-DMSO-water solutions. Carbohydr Polym 
41:181-184. 
39. Huanbutta K, Cheewatanakornkool K, Terada K, Nunthanid J, Sriamornsak P 2013. Impact 
of salt form and molecular weight of chitosan on swelling and drug release from chitosan 
matrix tablets. Carbohydr Polym 97:26-33. 
40. Behin J, Farhadian N 2013. Residence time distribution measurements in a two 
dimensional rectangular airlift reactor by digital image processing. Exp Therm Fluid Sci 
51:244-250. 
41. Bharmoria P, Singh T, Kumar A 2013. Complexation of chitosan with surfactant like ionic 
liquids: molecular interactions and preparation of chitosan nanoparticles. J Colloid Interface 
Sci 407:361-369. 
42. Harris LA, Goff JD, Carmichael AY, Riffle JS, Harburn JJ, St. Pierre TG, Saunders M 
2003. Magnetite Nanoparticle Dispersions Stabilized with Triblock Copolymers. Chem Mater 
15:1367-1377. 
194 
 
 
 
43. Wang SF, Shen L, Zhang WD, Tong YJ 2005. Preparation and mechanical properties of 
chitosan/carbon nanotubes composites. Biomacromolecules 6:3067-3072. 
44. Rocchiccioli-Deltcheff C, Franck R, Cabuil V, Massart R 1987. Surfacted 
ferrofluids:interactions at the surfactant-magnetic iron oxide interface. J  Chem  Res 5:126–
127. 
45. Li Z, Jia Z, Luan Y, Mu T 2008. Ionic liquids for synthesis of inorganic nanomaterials. 
Current Opinion in Solid State and Materials Science 12:1-8. 
46. Dupont J, Scholten JD 2010. On the structural and surface properties of transition-metal 
nanoparticles in ionic liquids. Chem Soc Rev 39:1780-1804. 
47. Lian S, Wang E, Kang Z, Bai Y, Gao L, Jiang M, Hu C, Xu L 2004. Synthesis of magnetite 
nanorods and porous hematite nanorods. Solid State Commun 129:485-490. 
48. Park H, Lee Y, Choi BG, Choi YS, Yang J, Hong WH 2010. Energy Transfer in Ionic-
Liquid-Functionalized Inorganic Nanorods for Highly Efficient Photocatalytic Applications. 
Small 6:290-295. 
49. Ritger PL, Peppas NA 1987. A simple equation for description of solute release I. Fickian 
and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or 
discs. J Controlled Release 5:23-36. 
50. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA 1983. Mechanisms of solute 
release from porous hydrophilic polymers. Int J Pharm 15:25-35. 
51. S.-H. Chiou, W.-T. Wu, Y.-Y. Huang, T.-W. Chung 2001. Effects of the characteristics of 
chitosan on controlling drug release of chitosan coated PLLA microspheres. J Microencapsul 
18:613-625. 
195 
 
 
 
52. Singh B, Sharma V 2014. Influence of polymer network parameters of tragacanth gum-
based pH responsive hydrogels on drug delivery. Carbohydr Polym 101:928-940. 
53. Jameela SR, Jayakrishnan A 1995. Glutaraldehyde cross-linked chitosan microspheres as a 
long acting biodegradable drug delivery vehicle: studies on the in-vitro release of mitoxantrone 
and in vivo degradation of microspheres in rat muscle. Biomaterials 16:769-775. 
54. Gericke M, Liebert T, Seoud OAE, Heinze T 2011. Tailored Media for Homogeneous 
Cellulose Chemistry: Ionic Liquid/Co-Solvent Mixtures. Macromolecular Materials and 
Engineering 296:483-493. 
55. Ramya CS, Selvasekarapandian S, Savitha T, Hirankumar G, Angelo PC 2007. Vibrational 
and impedance spectroscopic study on PVPâ€“NH4SCN based polymer electrolytes. Physica 
B: Condensed Matter 393:11-17. 
56. Peppas NA, Sahlin JJ 1989. A simple equation for the description of solute release. III. 
Coupling of diffusion and relaxation. Int J Pharm 57:169-172. 
57. Karatas A, Baykara T 2001. Studies on indomethacin inserts prepared by water-soluble 
polymers. II. The relation between dissolution rate and swelling behaviour. Farmaco 56:197-
202. 
  
 
 
 
 
 
 
 
 
196 
 
 
 
CHAPTER 7 
7 CONCLUSIONS AND RECOMMENDATIONS 
 Conclusions 7.1
 The current thesis described two different strategies of formulating dry 
powders for drug delivery to the respiratory tract. The first approach involved a 
controlled crystallization technique for the development of progesterone microcrystals 
suitable for pulmonary inhalation purposes. Different solid-state and surface 
characterization techniques were applied in order to provide a valuable insight on the 
powder dispersion and flow properties. A significant correlation between the 
crystallization operating conditions, such as the antisolvent addition rate, initial drug 
concentration and dynamic solvent composition, and the aerodynamic characteristics 
of progesterone microcrystals was obtained.  
The second approach proposed in this thesis is the drug encapsulation in a nano-carrier 
system in order to control its release profile and prolong the duration of its action. In 
this perspective, two model drugs were investigated; progesterone and 5-fluorouracil. 
The proposed carrier system is prepared with a great potential for localized magnetic 
targeting of therapeutic agents. The rate and extent of drug release can be modulated 
by controlling different formulation parameters. In addition, the drug release 
mechanism was analyzed by mathematical curve fitting to different drug release 
kinetics models. In most cases, the drug release profile was significantly correlated to 
Peppas model; which indicates that both drugs are released by diffusion through the 
polymeric matrix.  
In addition, this study highlights the amount of drug loaded as a basic determinant for 
the drug release rate. It is worthy to point out that the proposed aggregates of 
nanoparticles demonstrated a sustained release profile of chemotherapeutic agent (5-
fluorouarcil) for 14 days with a considerable amount of drug released within the first 
few hours.  
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Based on detailed investigations, magnetic samples loaded with progesterone or 
formulated with high polymer concentrations exhibited a high initial burst effect. A 
modified Peppas model is introduced to assess drug release parameters in this initial 
stage.  The burst effect could be beneficial, in this case, to account for the prolonged 
lag period between the dose administration, propagation of magnetic field and 
therapeutic effectiveness.  
Further examinations were performed on the loaded magnetic particles in terms of 
their effectiveness on the viability of A549 lung cancer cells. The conclusions of the 
in-vitro cytotoxicity study can be summarized as follows: 
1) Drug loading showed significant effect on the viability of A549 cells.   
2) The two suggested methods of drug loading; in-situ and post-synthetic 
techniques inhibited the proliferation of lung cancer cells. 
3) Significant effect of polymer concentration on the cytotoxicity of 5-
fluorouarcil is displayed in a dose dependent profile. 
The previous observations demonstrate the potential applicability of our 
synthesized aggregates as a carrier of anticancer drugs. Further examination of the 
possibility of targeted aerosol drug delivery to the respiratory tract was illustrated. 
The in-vitro aerosol deposition was assessed with the application of an external 
magnetic field, with a field strength if 1 Tesla. The major findings in this section 
are:  
1) The change in the particle size along with the particle shape showed 
prominent effect on the dispersion behavior of aggregated particles. 
2) The observed morphological transformation of individual magnetic 
nanoparticles from spherical to cubic structure could be referred to 
different polymeric composition; which affects the rate of thermal 
decomposition of iron precursor. 
3) The in-vitro aerosol deposition in magnetic next generation impinger 
(mNGI) seemed to be a complicated process and depends on various 
interactive factors. 
4) Different formulation parameters have to be modulated in order to optimize 
the aerosolization performance of magnetic nano-carriers. A deaggregation 
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index is proposed and being calculated as a function of the inhalation 
airflow rate. Mathematical curve fitting of the obtained deaggregation-
airflow rate titration is performed; leading to a comprehensive selection of 
the ideal dry powder formulation. 
 Recommendations and future directions 7.2
The first part of this thesis describes the modulation of aerodynamic and flow properties of 
progesterone as a function of different crystallization variables. It is suggested to examine the 
influence of polymorphic transformation on the aerosolization characteristics of progesterone 
particles. Further enhancement on the prepared microcrystals particle size distribution is 
suggested here for the aim of deeper lung deposition. Building on the results obtained on 
chapter three, it is very likely that a narrower particle size distribution can be attained by the 
addition of a crystallization growth retarding agent (i.e., viscosity imparting agent).  
On the controlled drug delivery issue, control of the initial burst effect observed in some 
formulations should be an interesting research area for many therapeutic agents. We tried to 
benefit from the high initial release of drug to counter over the prolonged lag time between 
propagation of magnetic field and therapeutic effectiveness. Yet, in other therapeutic agents 
this burst effect is unfavorable and has to be controlled.  
It is also suggested to examine the possibility of surface modification of our proposed magnetic 
nano-carrier with a cell targeting molecule, i.e., Folic acid in order to achieve more specific 
localization in the cancer cells.  
In the current study we demonstrated the effect of individual particles morphology on the 
aerosol deposition in mNGI. However, the shape of the aggregates has an impact on the 
aerodynamic drag forces of particles and considerably affects their entrainment in air stream. 
Herein, we assumed that the aggregates morphology is the same in all examined samples. 
However, evaluation of the aggregates geometries is needed for the development of geometric 
shape factor that can be applied in the calculation of drag force coefficient and can be 
suggested as an interesting point for future investigation.  
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 Future perspectives for manufacturing pulmonary dry 7.3
powders 
Pharmaceutical manufacturing of dry powder inhalation systems involves a combination of a 
device and a formulation process. The fraction of fine particles deposited in the respiratory 
system varies significantly between the different products. Enhancing the deposition of 
respiratory particles to the deeper part of the lung will directly reduce the required drug load 
per delivery, and hence decrease the total costs for active pharmaceutical ingredients (APIs). 
Due to the prohibition of propellant systems, dry powder inhaler systems are increasingly 
leading the pulmonary drug delivery market. Current research has created a good 
understanding on the characterization and dynamic interaction between fine drug particles and 
carrier particles as well as the interaction with the inhaler device in airstream. Particle 
engineering of the drug crystals alone or in combination with excipients have led to new 
approaches in drug delivery to the respiratory tract, in order to enhance safety and efficacy. In 
addition, technology enhancements in processing, manufacturing and control of dry powder 
inhaler devices have solved the major challenges of manufacturing dry powders for pulmonary 
inhalation. The costs -of -goods-sold for inhalation products are determined in the early stages 
for product development. Assuming that the powder formulation and the preparation costs are 
the same, the package, filling and device costs become the predominant factors. In the case of 
dry powder inhaler devices, the device costs mainly originate from the number of high 
precision parts needed and the assembly costs. Currently there are two types of inhaler devices 
available for dry powder systems; reservoir-based and capsule-based devices. The reservoir-
based devices require more than 20 plastic and metal parts that are assembled into a functional 
device. However, the capsule-based devices are composed of six parts including the plastic and 
needles parts. The complexity of inhaler device has been confirmed to influence the costs-of-
goods-sold; which directly affect the introduction of new products in emerging market due to 
the high costs. Compared to pressurized metered dose inhalers, dry powder inhaler platform 
technologies are more cost effective than others as they provide good opportunities for the re-
formulation into more affordable versions suitable for the economic conditions in emerging 
markets. 
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